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Abstract 
 
Marine flora and fauna have provided numerous alluring natural products, some 
of which contribute to treating diseases. The genus Clavelina is the source of a variety of 
tricyclic alkaloids, including the lepadiformine and cylindricine families. Novel 
approaches to synthesizing these molecules are sought after to increase their accessibility 
and for analogue development. In this dissertation, reaction sequences involving an 
intramolecular Schmidt transformation, which can quickly build up the molecular 
architecture associated with these targets is described. In one approach, the Lewis acid 
promoted intramolecular Schmidt reaction is combined in series with a Prins reaction to 
afford an interesting tricyclic lactam. This methodology culminates in a formal synthesis 
of lepadiformine A and a total synthesis of lepadiformine C. In another project, a tandem 
Diels–Alder/Schmidt reaction is utilized to prepare a similar tricyclic lactam. This 
process is applied toward an asymmetric total synthesis of (–)-cylindricine C. The 
preparation for the optically active starting material for the synthesis of (–)-cylindricine C 
is also discussed, as it is a prominent figure in the preparation of prostaglandins. 
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Chapter 1 
 
Introduction to the Lepadiformine and Cylindricine Families of Natural Products 
 
1.1. History for the Lepadiformines and Cylindricines 
 
1.1.1. The Source 
 
The ocean is full of all forms of life, from large, complex animals to microscopic, 
single-celled bacteria. The copious amounts of biodiversity in the ocean provide novel 
natural products, many of which are biologically active and some with important 
therapeutic activities including anti-cancer and anti-microbial effects. Numerous species 
of marine life have been probed for new molecules with hopes of finding cures for 
diseases that plague mankind.1 
Ascidians, also known as sea squirts, are marine organisms and plentiful sources 
of novel natural products. These filter feeders reside on inanimate oceanic terrain and 
feed by extracting edible particles from the water flowing through their bodies. The 
extrusion of water from their siphon was how these fascinating creatures got their name. 
These marine-dwelling invertebrates are known to be rich sources of natural products.2 
Currently, researchers are investigating the origin of marine natural products and whether 
or not they result from symbiotic relationships between ascidians and microorganisms or 
are products of individual species.1,3,4  
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1.1.2. Cylindricine Family 
 
One genus of ascidians known as Clavelina is made up of a wide variety of 
brilliantly colored sea squirts that have contributed a plethora of natural products, 
including the cylindricine and lepadiformine families. Clavelina cylindrica is the source 
of the cylindricine family of alkaloids, which contains 11 tricyclic alkaloids (Figure 1), 
isolated off the coast of Tasmania. The natural products were isolated by extraction of 
freeze-dried Clavelina cylindrica and obtained in small yields between 0.0002-0.01%. 
How these natural products are biosynthesized or their natural functions are currently 
unknown. The only biological testing done in this family, carried out on the equilibrium 
mixture of cylindricines A and B only, was a brine shrimp assay (Artemia salina), which 
indicated in modest cytotoxicity (93% mortality after 24 hr at a 3 mM concentration).5-7 
The equilibrium between 1 and 2 was shown when each pure compound in solution 
converted to a 3:2 mixture after six days at room temperature. Despite the modest 
biological activity of this family of molecules, the structures pose a synthetic challenge 
and therefore have made the cylindricines a much sought-after family of molecules for 
total synthesis.8 
The common numbering of these molecules is depicted in Figure 1. Atom 1 is the 
nitrogen and proceeds in a clockwise fashion around the molecule as depicted. The 
significant structural features include alkyl substitution at C-2, oxidation at C-4, the 
azadecalin fusion at C-5 and C-10, and a functionalized methylene group at C-13. Also, 
each ring is associated a specific letter of the tricyclic system such that the A ring is the 
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cyclohexane ring, the B ring is the piperidine ring, and the C ring represents the 
pyrrolidine ring. This nomenclature is used throughout this account. 
The tricyclic pyrrolidine and tricyclic piperidine scaffolds were the first of their 
kind to be isolated. Some interesting structural motifs in the cylindricine family include 
the aza-spirocenter that fuses a cis-azadecalin with a pyrrolidine or piperidine ring. This 
complex center creates an interesting synthetic challenge, as there is no easy, 
straightforward procedure for preparing it. Features that differ among the cylindricine 
members include the oxidation state at C-4, either a carbonyl or an acetate, and the 
substitution at C-2, either a hexyl or butyl group. The major variation in the molecules 
exists at the C-14 where a multitude of functional groups appear, including a halogen, 
alcohol, methoxy, acetoxy, or thiocyanate functionality. The absolute configuration of the 
natural enantiomer remains unknown as no optical rotation was taken after isolation of 
these molecules, perhaps due to the isolation of an insufficient amount of the compounds. 
 
Cylindricine A: R = Cl (1)
Cylindricine C: R = OH (3)
Cylindricine D: R = OMe (4)
Cylindricine E: R = OAc (5)
Cylindricine F: R = SCN (6)
R = Cl
Cylindricine B (2)
Cylindricine G (7) Cylindricine H: R = SCN (8)
Cylindricine I: R = NCS (9)
Cylindricine J (10)
proposed intermediate
Cylindricine K (11)
N
C6H13
R
O
N
C4H9
NCS
O
N
C4H9
R
OAc
N
C6H13
Cl
O
N
C6H13
O
Cl
N
C6H13
O
Cl
N
C4H9
OAc
NCS
10
2
5
13
14
4
A
BC
 
Figure 1. The cylindricine family  
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1.1.3. Lepadiformine Family 
 
Another family of natural products structurally related to the cylindricines is the 
lepadiformine family, which contains three tricyclic alkaloids (Figure 2). The 
lepadiformines have been isolated from Clavelina lepadiformis off the coast of Tunisia 
and Clavelina moluccensis off the coast of Djibouti.9,10 Similar to the cylindricines, the 
biosynthetic details and evolutionary purpose for these molecules remains unknown; 
however, they demonstrate interesting biological activity. Lepadiformines A and B have 
inhibitory effects on the inward rectifying potassium current which causes bradycardia, 
an effect seen in antiarrhythmic agents.10,11 This activity, along with the interesting 
synthetic architecture, has made the lepadiformine family a hot target for total synthesis. 
Disagreement in the literature about the originally reported structure of 
lepadiformine A sparked significant synthetic interest. Biard and coworkers originally 
assigned the structure of lepadiformine A. Weinreb and coworkers prepared the proposed 
structure, which yielded inequivalent spectral data.12-14 A short time later, Kibayashi and 
coworkers prepared the newly proposed version of lepadiformine A (12), the spectral 
data of which coincided with that of the isolated natural product.15 Weinreb and 
Kibayashi, separately, also determined the absolute configuration of the natural 
enantiomer by preparing both enantiomers and comparing the optical rotations.16,17 The 
pioneering efforts of both Weinreb and Kibayashi paved the way for an illustrious 
portfolio of synthetic achievements for these families of molecules.  
Although the structures of the lepadiformines are strikingly similar to the 
cylindricine family, the relative stereochemistry at C-10 represents one major difference. 
 5 
The inverted stereochemistry at the aza-spirocenter generates a trans-azadecalin core in 
the lepadiformine series in contrast to the cis-azadecalin core of the cylindricines. In 
addition, the lepadiformines lack oxidation at the C-4 position. 
 
N
C6H13
HO
Lepadiformine A (12)
N
C4H9
Lepadiformine C (14)
N
C4H9
HO
Lepadiformine B (13)
10
2
5
13
4
 
Figure 2. The lepadiformine family 
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1.1.4. Similar Natural Products 
 
Other molecules with similar architectures to the cylindricines and lepadiformines 
include fasicularin18 and polycitorols A and B,19 all isolated from marine ascidians 
(Figure 3). Fasicularin was isolated from Nephteis fasicularin and has been shown to 
alkylate DNA through an intermediate similar to the proposed aziridinium intermediate in 
Figure 1.20 The polycitorols were isolated from an unknown tunicate species and possess 
no known biological activity, most likely due to lack of biological testing.  
 
N
C6H13
NCS
N
C4H9
HO
N
C4H9
HO
Fasicularin (15) Polycitorol B (17)Polycitorol A (16)  
Figure 3. Natural products related to the cylindricines and lepadiformines 
 
 7 
1.1.5. Previously Reviewed Syntheses 
 
The lepadiformine and cylindricine families of natural products, as well as 
fasicularin, have all been the targets of numerous total and formal syntheses, most of 
which have been reviewed.8,21-23 Some interesting and innovative methodologies have 
emerged en route to these classes of molecules. Of the reviews, the one by Weinreb is the 
most comprehensive and encompasses all of the synthetic achievements pertaining to 
these families of natural products through 2006. For comparison purposes, Table 1 
includes a summary of the syntheses contained in the Weinreb review, which focuses on 
construction of the aza-spirocenter, other significant ring closure techniques, the source 
of asymmetry (if applicable), the number of steps, and the overall yield. 
The construction of the aza-spirocenter has been carried out in different ways 
including double conjugate additions, Diels–Alder reactions and other cycloadditions, as 
well as radical-mediated reaction sequences (Table 1). Also, the chiral pool serves as a 
major source for chirality. Figure 4 demonstrates several examples to construct the aza-
spirocenter. 
 
Table 1. Weinreb review summary8 
Principle 
Investigator 
Molecule Construction of the 
Aza-spirocenter  
Significant 
Cyclizations  
Origin of 
Asymmetry  
Steps 
(Yield) 
Snider24 (±)-Cylindricine 
A 
Intermolecular double 
conjugate addition 
Radical cyclization NA 7 
(13%)a 
Heathcock25 (±)-Cylindricine 
A 
Intermolecular double 
conjugate addition 
Radical cyclization NA 11 
(19%)a 
Molander26 (–)-Cylindricine 
C 
Intramolecular double 
conjugate addition 
NA (S)-1,2,4-
Butanetriol 
11 
(12%)b 
Trost27 (+)-Cylindricine 
C, D, E 
Intramolecular conjugate 
addition 
Hydrative diyne 
cyclization 
L-Serine 9 
(12%)b,c 
Kibayashi28 (+)-Cylindricine 
C 
Grignard addition to 
imine 
Enamine addition, 
conjugate addition 
(S)-Pyroglutamic 
acid 
14 
(9%)a 
 8 
Kibayashi15 (±)-Fasicularin Acylnitroso Diels–Alder 
reaction 
SN2 Displacement NA 29 
(<1%)a 
Kibayashi29 Putative 
lepadiformine 
Acylnitroso Diels–Alder 
reaction 
Reductive 
amination 
NA 23 
(<1%)a 
Kibayashi15 (±)-
Lepadiformine A 
Acylnitroso Diels–Alder 
reaction 
SN2 Displacement NA 21 
(5%)a 
Kibayashi30 (–)-Fasicularin Intramolecular conjugate 
azaspirocyclization 
SN2 Displacement (S)-Pyroglutamic 
acid, (R)-Binal 
11 
(28%)a 
Kibayashi30 (–)-
Lepadiformine A 
Intramolecular conjugate 
azaspirocyclization 
SN2 Displacement (S)-Pyroglutamic 
acid, (S)-Binal 
9 
(31%)a 
Kibayashi30 (+)-Cylindricine 
C 
Intramolecular conjugate 
azaspirocyclization 
SN2 Displacement (S)-Pyroglutamic 
acid, (S)-Binal 
12 
(12%)a 
Hsung31 (+)-Cylindricine 
C 
Aza-Prins reaction Aza-conjugate 
addition 
(S)-Pyroglutamic 
acid 
9 
(11%)a 
Hsung32 (–)-
Lepadiformine A 
Aza-Prins reaction Aza-conjugate 
addition 
(S)-Pyroglutamic 
acid 
12 
(7%)a 
Hsung33 (–)-Cylindricine 
C 
Intramolecular aza-[3+3] 
cycloaddition 
NA L-Serine 22 
(5%)b 
Ciufolini34 (–)-Cylindricine 
C 
Oxidative 
spirocyclization 
Reductive 
amination 
D-Homotyrosine 18 
(15%)b 
Ishibashi35 Core approach Radical cascade NA NA NA 
Hunter36 Core approach Alkylation of 
silyloxypyrrole 
RCM, SN2 
displacement 
NA NA 
Funk37 (±)-Fasicularin 2-Amidoacrolein Diels–
Alder reaction 
Aldol condensation NA 18 
(<1%)b 
Funk38 (±)-
Lepadiformine A 
2-Amidoacrolein Diels–
Alder reaction 
SN2 Displacement, 
aziridination 
NA 16 
(13%)b 
Dake39 (+)-Fasicularin 
(formal) 
Silylepoxy semipinacol 
rearrangement 
SN2 Displacement L-Glutamic acid 24 
(<1%)b 
Oppolzer40 Core approach Nitroso/olefin dipolar 
cycloaddition 
NA (2R)-bornane-
10,2-sultam 
NA 
Pearson41 Putative 
lepadiformine 
Azaallyl dipolar 
cycloaddition 
Reductive 
amination 
NA NA 
Weinreb13 Putative 
lepadiformine 
Nitrone/olefin dipolar 
cycloaddition 
Intramolecular 
conjugate addition 
NA 17 
(3%)a 
Weinreb42 (±)-
Lepadiformine A 
N-Acyliminium 
spirocyclization 
Condensation NA 15 
(11%)a 
Weinreb17 (–)-
Lepadiformine A 
N-Acyliminium 
spirocyclization 
Condensation (S)-Pyroglutamic 
acid 
15 
(13%)a 
Kim43 (–)-
Lepadiformine A 
(formal) 
Amino acid ester-enolate 
Claisen reaction 
RCM, 
condensation 
(S)-Pyroglutamic 
acid 
15b,d 
Renaud44 (±)-
Lepadiformine A 
Radical carboazidation Reductive 
amination, 
lactonization 
NA 10 
(15%)b,c 
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Figure 4. Examples of aza-spirocenter construction from Table 1 
 
Since the Weinreb review, substantial synthetic efforts have been made to 
synthesize the lepadiformines and cylindricines.8 The following section will seek to 
examine the recent synthetic strategies with an emphasis on the construction of the aza-
spirocenter. 
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1.2. Total Syntheses of the Lepadiformines 
 
The following section will discuss the eight syntheses of the lepadiformines that 
have been published since the release of the 2006 Weinreb review. A variety of 
transformations were applied to achieve the aza-quaternary center, including radical-
mediated transformations and well-known reactions such as the Diels–Alder or Michael 
reactions. 
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1.2.1. Radical Reactions  
 
The formation of a fully substituted carbon can require crafty innovation or 
skilled ingenuity. Radical generation can be manipulated to accomplish this task. 
However, radical generation at the desired location is not always easy, particularly when 
sterically crowded. One alternative is to generate the radical at a remote location of the 
molecule and transfer the radical to the desired location intramolecularly, a task achieved 
by H. Tokuyama and coworkers in their total synthesis of (±)-lepadiformine A (12).45 
H. Tokuyama and coworkers began with succinimide (18) and quickly 
constructed the key intermediate (20) by N-alkylation, reduction, and sulfonation to get 
19 (Scheme 1). Two more steps afforded 20, the key step precursor. To initiate the key 
step, azabisisobutyronitrile (AIBN) and tributyltinhydride (Bu3SnH) were used to 
accomplish the deiodination to phenyl radical 21, which was translocated through a 6-
membered transition state to generate a stabilized radical alpha to the amide (22). The 
radical added to the double bond before being terminated by picking up a hydrogen atom 
to complete the formation of the aza-spirocenter in excellent diastereoselectivity (>95:5 
by NMR) due to the preferred pseudo-equatorial conformation of the alkene to avoid a 
steric interaction between the sulfone and the PMB group, thus forming 23.  
The total synthesis was continued by oxidation with cerium ammonium nitrate 
(CAN) that removed the PMB protecting group to achieve 24. The benzyl protected 
hydroxy methylene was introduced through a series of transformations to yield 25. Six 
more steps were required to complete the total synthesis of (±)-lepadiformine A (12), 
including a reductive amination reaction between the deprotected amine and aldehyde 
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groups in 26 to close the third ring. Although this synthesis was low yielding, 19 steps 
and 1% overall yield, the translocation strategy effectively permitted the generation of a 
radical at an otherwise difficultly-accessible α-amido carbon. The methodology 
presented here was a novel and useful way to stereoselectively set aza-spirocenters from 
substituted lactams. 
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Scheme 1. Tokuyama synthesis of (±)-lepadiformine A (12)45 
 
In 2010, Rychnovsky and coworkers completed the first asymmetric total 
synthesis of (+)-lepadiformine C (14) using a nitrile-mediated lithiation methodology 
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developed in their laboratory.46 As shown in Scheme 2, the synthesis began with 
enantiomerically pure propargyl alcohol 27, which was transformed to 28 in seven steps. 
With 28 and 29 in hand, the A ring (the cyclohexane ring) was closed by a double 
displacement reaction initiated by LDA. The first displacement connected the α-cyano 
carbon of 29 to 28 by an SN2 reaction on the primary bromide to form intermediate 30. 
Subsequent treatment of 30 with more LDA (3.0 equiv total) allowed for the second SN2 
displacement on the secondary bromide to occur to afford 31. From 31, the silyl ether 
was converted to phosphate 32, the necessary substrate for the key cyclization step to 
form the pyrrolidine ring. The second cyclization, the aza-spirocenter formation, was 
initiated by combining lithium di-tert-butylbiphenylide (LIDBB) with 32, which 
underwent two sequential single-electron transfers. The ring closure occurred through 
anion 33 to form spirocycle 34. The total synthesis of (+)-lepadiformine C (14) was 
completed by conversion of 34 to mesylate 35, followed by SN2 displacement by the 
deprotected nitrogen to close the remaining B ring.  
This total synthesis of (+)-lepadiformine C (14) was completed in 14 linear steps 
from the known 27 in 7% yield. During the course of this synthesis, all three rings were 
constructed separately and two of the three stereocenters set via asymmetric reactions, 
both in 28. The aza-quaternary center was set using their reductive lithiation 
methodology in diastereoselective fashion controlled by the cyclohexane ring 
conformational preference. 
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Scheme 2. Rychnovsky synthesis of (+)-lepadiformine C (14)46 
 
Azides are a useful source of nitrogen in synthesis. As shown in Scheme 3, the 
Renaud group has devised a way to transfer azide through a radical process to generate an 
aza-spirocenter en route to a total synthesis of (±)-lepadiformine C (14).47 Enamine 36 
was converted in four simple steps to the precursor for the key transformation, 37. 
Sulfonylazide 38 was irradiated with di-tert-butyldiazene, a radical initiator, to form 
radical 39 and the azide radical after extruding SO2. Alkene 37 propagated the sequence 
by combining with 39 to form radical 40, which reacted with the azide radical generated 
from the breakdown of the sulfonylazide, allowing for continuation of the radical cycle 
by regenerating 39. The resulting azide 41 (dr = 3:2) was taken on as a mixture of 
inseparable diastereomers and was reduced to the amine followed by reductive amination 
to yield decahydroquinoline 42 as the major diastereomer. Treatment of 42 with a strong 
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Lewis acid, Me2AlCl, closed the lactam and subsequent treatment with lithium aluminum 
hydride (LAH) reduced the amide to the amine to conclude the total synthesis of (±)-
lepadiformine C (14).  
The carboazidation process developed by Renaud and coworkers was an efficient 
way to generate sterically-congested amines. This process was especially effective in 
forming aza-spirocenters because the radical generated from a 1,1-disubstituted double 
bond favored the tertiary radical formation (Scheme 3). This total synthesis of (±)-
lepadiformine C (14) was accomplished in seven steps and 23% overall yield from 
commercially available material. 
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Scheme 3. Renaud synthesis of (±)-lepadiformine C (14)47  
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1.2.2. Sulfone-Assisted Transformations 
 
Sulfones are useful functional groups in organic chemistry as they allow for 
functionalization of carbon atoms without leaving a footprint. The electron-withdrawing 
nature of the sulfonyl group decreases the pKa of the hydrogens on the adjacent carbon 
allowing for easy functionalization. The sulfone can then be cleaved by reductive 
conditions, leaving only the newly functionalized carbon. This process is an excellent 
way to achieve carbon-carbon bond formation.  
In a total synthesis of (±)-lepadiformine A (12) by Craig and coworkers, the 
sulfone group was used in a 5-endo-trig cyclization to achieve the pyrrolidine ring 
formation.48 As depicted in Scheme 4, Craig’s total synthesis of (±)-lepadiformine A (12) 
began with the formation of the aza-spirocenter. Substituted cyclohexanone 44 was 
converted to epoxide 45 with the desired relative stereochemical configuration using a 
substrate-controlled epoxidation. In this reaction, the methylene was delivered from the 
axial face, with the acetal-containing sidechain in the equatorial position, affording 
excellent diastereoselectivity. Next, the epoxide in 45 was opened with 2-
(trimethylsilyl)ethylsulfonamide (SESNH2) to give an N-protected amino alcohol, 46. 
Using Mitsunobu conditions, the aza-spirocenter configuration was set by displacement 
of the activated alcohol with complete inversion of configuration. Next, the sulfone was 
installed to form 48, the substrate for the key cyclization step. 
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Scheme 4. Craig synthesis of (±)-lepadiformine A (12)48 
 
 With 48 in hand, the sulfone-mediated 5-endo-trig cyclization was investigated. 
The 5-endo-trig ring closure is typically disfavored according to Baldwin’s rules.49 As 
shown in Scheme 5, 48 was treated with n-BuLi to form an anion adjacent to the sulfone, 
which added to the 2-benzyloxyethanal. Activation of the resulting alkoxide with benzoyl 
chloride and elimination of the resulting ester produced intermediate 49, which 
underwent a disfavored 5-endo-trig cyclization by the amine to close the C ring, 50. To 
continue the total synthesis, 50 was treated first with tetrabutylammonium fluoride 
(TBAF) to deprotect the amine and secondly with boron tribromide (BBr3), which 
unveiled the aldehyde as well as debenzylated the alcohol to form intermediate 51. 
Subsequent in situ condensation of the amine onto the aldehyde and addition of the 
hydroxymethylene resulted in the desired B ring closure seen in aminal 52. The aminal 
was opened with an alkynyl Grignard to provide 53, which was converted to (±)-
lepadiformine A (12) in seven more steps.  
 Although lengthy, the total synthesis of (±)-lepadiformine A (12) by Craig and 
coworkers included a number of interesting and useful chemical transformations. The 
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epoxidation-aziridination strategy to install the aza-spirocenter was high yielding, 
effective, and stereoselective. Also, the sulfone strategy to close the pyrrolidine ring was 
a nice showcase of the disfavored ring-closure. Despite a lengthy end game sequence the 
total synthesis of (±)-lepadiformine A (12) was accomplished in 16 total steps and 19% 
overall yield.  
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Scheme 5. Craig synthesis of (±)-lepadiformine A (12) (continued)48 
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1.2.3. Intramolecular Diels–Alder Approach  
 
The Diels–Alder reaction is a useful and effective way to generate six-membered 
rings. The intramolecular variation of the Diels–Alder reaction (IMDA) has been used in 
a plethora of total syntheses and has the potential for quickly generating elevated 
complexity.50,51 In an account by Lygo et. al., the power of the aza-IMDA reaction is 
highlighted in a short, protecting group-free synthesis of (±)-lepadiformine A (12).52 
As shown in Scheme 6, the Lygo synthesis begins with commercially-available 
trans-nonenal (54), which was converted to 55 in three steps. Subsequent conjugate 
addition to 55 by glycine imine 56 followed by acid mediated condensation delivers 57, 
the aza-IMDA precursor, in good yield. With 57 in hand, a myriad of standard IMDA 
conditions were investigated. The aza-IMDA product 58 was ultimately obtained a 5:1 
mixture of diastereomers, the major component of which had the relative stereochemistry 
desired for the synthesis of (±)-lepadiformine A (12). During this step, two rings were 
formed and the aza-spirocenter was set along with two other stereocenters 
simultaneously. That reaction represents the ability of the IMDA reaction to create high 
levels of complexity with relative ease in a single step. The total synthesis was completed 
by olefin hydrogenation and acid reduction.  
The Lygo approach to (±)-lepadiformine A (12) was achieved in eight linear steps 
and 14% overall yield. This synthesis was protecting group free and used the powerful 
IMDA reaction to set the aza-spirocenter and two other stereocenters. The endo-adduct, 
the major Diels–Alder product, set the correct relative stereochemistry of all four 
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stereocenters in the molecule. This total synthesis represents an excellent example of the 
utility of the Diels–Alder reaction in natural product synthesis. 
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Scheme 6. Lygo synthesis of (±)-lepadiformine A (12)52 
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1.2.4. Organocatalyzed Conjugate Addition 
 
Organocatalysis, reactions catalyzed by organic molecules rather than metals, is 
of increasing interest in the synthetic community due to the lack of often highly toxic 
metals.53 In total syntheses of (–)-lepadiformine A (14) and (+)-cylindricine C (3), an 
asymmetric conjugate addition was used by the Shibasaki group with an organic catalyst 
system they developed.54 The organocatalytic conjugate addition set only one 
stereocenter but had a dramatic effect over the outcome of the other three stereocenters 
formed.  
The Shibasaki route to the Clavelina natural products began with pimelic acid 
(59), which was converted to dienedione 60 in three steps. The asymmetric conjugate 
addition mediated by an organocatalyst commenced by combining 60 with 61. After 
optimization, the catalyst, (S,S)-TaDiAS (TaDiAS; tartrate-derived diammonium salt), 
was chosen to achieve 62 in 91% es. With 62 in hand, mildly acidic conditions initiated a 
tandem Mannich/aza-Michael reaction sequence to afford the tricycles 63a, 63b, and a 
third diastereomer. Many conditions and additives were investigated to improve 
diastereoselectivity. Without the additives, 63a and 63b were formed in a 1:2 ratio, with a 
third diastereomer formed in trace amounts. The addition of additives (MgCl2, LiCl, 
AlCl3, or La(OTf)3) dramatically increased the amount of 63a formed over the other two 
diastereomers; however, in all cases and conditions tried, mixtures of three diastereomers 
were formed. Interestingly, 63b was converted to 63a following subjection to simple 
basic conditions of K2CO3/MeOH or TBAF.  
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Scheme 7. Shibasaki synthesis of (–)-lepadiformine A (14) and (+)-cylindricine C (3)54 
 
 The mechanism for the triple cyclization is shown in Scheme 8. Compound 62 
first underwent nitrogen transimination by loss of H2O and benzophenone onto the 
nearest carbonyl, forming intermediate 62a. Next, an intramolecular Mannich reaction to 
intermediate 62b, where the second ring was closed to form the aza-spirocenter. From 
bicycle 62b, multiple convergent pathways to close the third ring were possible. The first 
pathway was an aza-Michael addition to afford 63b, which possessed the trans-
azadecalin moiety of the lepadiformines. Alternatively, 62b could undergo enolization 
through enol 62c, which can return to the keto form with the adjacent stereocenter 
inverted, 62d. From there, an aza-Michael addition formed 63a, which possessed the cis-
azadecalin moiety as seen in the cylindricines. As mentioned previously, the additive 
addition had a dramatic stereochemical outcome. The authors propose that the Lewis 
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acidity of the additives increase the enol formation and an increased amount of 63a by 
chelating the free hydroxyl and amine groups of 62c. Without the additive, the 
lepadiformine precursor, 63b, was the major product and taken on to a total synthesis of 
(–)-lepadiformine A (14). With the additive, the major product formed was 63a, which 
was used in a total synthesis of (+)-cylindricine C (3). Although conjugate addition has 
been frequently used in other syntheses for these molecules (Table 1),8 the cascade of 
cyclizations shown in Scheme 8 was most impressive as all three rings were formed in a 
single step including the formation of three new stereocenters and the challenging aza-
spirocenter. 
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Scheme 8. Shibasaki proposed mechanism54 
 
 As shown in Scheme 9, a formal synthesis of (–)-lepadiformine A (12) was 
accomplished by reducing the ester and ketone followed by selective protection of the 
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primary alcohol to afford 64, an intermediate in a total synthesis by Hsung and 
coworkers.32 (–)-Lepadiformine A (12) was completed by dehydroxylation of 64 under 
Barton–McCombie conditions55 followed by TBAF to unveil the primary alcohol. With 
those results, Shibasaki accomplished a formal total synthesis of (–)-lepadiformine A in 
ten steps and 4% overall yield. Starting from pimelic acid, the total synthesis of (+)-
cylindricine C (3) was completed in six linear steps and 6% overall yield, the shortest 
asymmetric synthesis to date. 
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Scheme 9. Shibasaki synthesis of (–)-lepadiformine A (14) and (+)-cylindricine C (3) 
(continued)54 
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1.2.5. Sulfinamide-Mediated Synthesis  
 
Chiral sulfinamides are effective chiral transfer reagents.56 Following the 
pioneering work by Davis et. al.57 and Ellman et. al.,58 a myriad of synthetic examples 
utilizing sulfinamide chemistry surfaced including natural product syntheses and 
preparations of pharmaceutical agents.56 Much work has focused on preparation and 
utilization of sulfinamides in both academia and industry in recent years.59,60 To add to 
the list of total syntheses using chiral sulfinamides, a total synthesis of (–)-lepadiformine 
A (12) was accomplished by Mei and Zhao.61 
 Zhao and coworkers established the stereochemistry of the aza-spirocenter using 
zinc allylation chemistry.62 The total synthesis began with ethyl 2-(2-
oxocyclohexyl)acetate (65), which was converted in four steps to 66 in 97% es, where the 
stereocenter alpha to the imine was set through a Corey-Bakshi-Shibata (CBS) reduction 
of 65 and separation of the resulting diastereomers (Scheme 10). With 66 in hand, the key 
step to prepare the aza-spirocenter involving addition of allyl group into the sulfinimide 
via Zn allylation provided 67 in 89% yield and 12:1 dr. Six steps were needed to 
deprotect the sulfinamide and homologate the double bond in 68. Subsequently, the C 
ring was closed and the third stereocenter set with Sharpless dihydroxylation conditions 
and displacement of a tosylate over five steps to afford 69. The acyclic tether was 
homologated and converted to 70 in three steps.  
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Scheme 10. Zhao syntheses of (–)-lepadiformine A (12) and (–)-fasicularin (15)61 
 
 Compound 70 was used to produce (–)-fasicularin (15) and (–)-lepadiformine A 
(12) as shown in Scheme 11. First, 70 was converted to 71, or 2-epi-lepadiformine A, by 
deprotection of the nitrogen atom, which led to cyclization onto the carbonyl to close the 
third ring, reduction of the enamine intermediate, and deprotection of the TBDPS group. 
(–)-Fasicularin (15) was formed from 71 using Mitsunobu-type conditions to form an 
aziridinium intermediate (see Figure 1) and was opened with the thiocyanate. The total 
synthesis of (–)-fasicularin (15) was thus completed in 23 steps and 3% overall yield 
from commercially-available starting material. 
 In the total synthesis of (–)-lepadiformine A (12), 70 was reduced with L-
Selectride to alcohol 72 (Scheme 11). The subsequent steps included deprotection of the 
amine and Mitsunobu-type displacement of the alcohol with the free amine to close the 
third ring. A TBAF-mediated deprotection of the TBDPS group afforded  (–)-
lepadiformine A 12, which completed the total synthesis in 23 steps and 5% overall yield 
from commercially-available starting material. Both syntheses of (–)-lepadiformine A 
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(12) and (–)-fasicularin (15) provided nice examples of the utility of sulfinamides in 
natural product synthesis as well as effective approaches to generate aza-spirocenters. 
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Scheme 11. Zhao syntheses of (–)-lepadiformine A (12) and (–)-fasicularin (15) 
(continued)61 
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1.3. Total Syntheses of Cylindricines  
 
Since the last major review of the cylindricines,8 a number of additional total 
syntheses have been published. Three total syntheses of cylindricine C are included here. 
A fourth total synthesis, the shortest to date and only asymmetric synthesis of 
cylindricine C covered here was already discussed in Section 1.2.4 as it was 
accomplished in conjunction with a total synthesis of (–)-lepadiformine A (12).54   
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1.3.1. Why Cylindricine C 
 
Cylindricine C is the most commonly synthesized target of all the cylindricines 
(Table 1). Synthetic chemists often synthesize molecules that display interesting 
biological activity. Within the cylindricine family, only A and B have been biologically 
evaluated to date. No biological data has been reported for cylindricine C; therefore, there 
is no compelling biological reason to synthesize this particular member over the others. 
In solution, cylindricine A undergoes interconversion with cylindricine B (in 
equilibrium as a 3:2 ratio of A:B)5 through the aziridinium intermediate shown in Figure 
1.24,25 In contrast, the picrates of A and B are stable and do not interconvert. The 
aziridinium intermediate formation occurs with the cylindricines D and E as it was 
demonstrated in Blackman’s isolation experiments that addition of sodium methoxide or 
sodium acetate resulted in interconversion between cylindricine A and both D and E.6 
During the isolation, cylindricine C was not interconvertible with cylindricine A.  
Cylindricines F-K have not been synthesized to date. The cylindricines G-J 
contain a butyl sidechain at C-2 rather than the hexyl group, which is a minor difference 
and could easily be incorporated into many of the known syntheses. In contrast, 
cylindricines H-J contain an extra stereocenter in the form of an acetoxy group at C-4 
rather than a carbonyl, which would pose an additional synthetic challenge.  Also 
noteworthy, cylindricines F-I contain either thiocyanate or isothiocyanate substitutions on 
methylene C-14, a substitution pattern that has only been prepared synthetically by 
converting cylindricine A/B to cylindricine F using sodium thiocyanate, as described in 
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the isolation paper, and by Kibayashi and coworkers in their total synthesis of 
fasicularin.30  
The cylindricines are synthetic targets due to their interesting architecture but 
have little structural diversity within the family. There seems to be no clear reason why 
there is such a high frequency of cylindricine C syntheses relative to the rest of the 
cylindricine family. One speculation could be that most other family members could be 
derived from an accomplished synthesis of cylindricine C and until a biological driving 
force for their synthesis is discovered, this trend will continue. 
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1.3.2. Total Syntheses 
 
Using an approach similar to that shown in Scheme 3, Renaud and coworkers 
synthesized (±)-cylindricine C (3) using carboazidation chemistry.63 As shown in Scheme 
12, their synthetic strategy began with 1-octyne. The precursor to the key step, 73, was 
prepared in six steps from 1-octyne and used cyclohexanone to incorporate the 
cyclohexane ring moiety. The carboazidation reaction took place in good yield using 
similar conditions as shown in Scheme 3, however, the authors also report the reaction 
occurs in 57% yield under air and triethylborane. Both sets of reaction conditions 
produced the desired product, 74, as a mixture of diastereomeric azides, separable by 
column chromatography, where the major compound 74 was obtained in a 7:3 ratio. The 
subsequent transformation, reduction of the azide to the amine, was accomplished with 
SnCl2 and the amine was immediately taken on to the bis-reductive amination step 
without purification. Both pyrrolidine and piperidine rings B and C were formed in a 
single step under sodium triacetoxyborohydride (NaBH(OAc)3)-mediated conditions as a 
single diastereomer, 75. Unfortunately, the stereocenters at C-13 and C-5 where not set 
correctly and needed to be epimerized. After six steps, 75 was converted to 76, the 
epimer at C-13. The final steps involved oxidizing the hydroxymethylene substituent to 
the carboxylic acid and epimerizing C-13, which completely converted to the desired 
stereochemistry. From 76, oxidation of the free hydroxyl group provided an opportunity 
for the epimerization of C-5. Under TBAF conditions, the C-5 epimerization was 
precedented,48 and accomplished in excellent yield to afford (±)-cylindricine C, 3.  
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 Overall, the total synthesis was completed in 17 steps and 11% overall yield from 
commercially-available 1-octyne. The key attributes included the effective carboazidation 
strategy that prepared the aza-spirocenter in good diastereoselectivity and the double 
reductive amination that closed both of the remaining rings and afforded the product as a 
single diastereomer. Although it was undesirable to require two epimerization steps, the 
ability to overcome those issues was another impressive feature of the total synthesis. 
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Scheme 12. Renaud synthesis of (±)-cylindricine C (3)63 
 
 In the next synthesis, Donohoe et. al. completed a formal and total synthesis of 
(±)-cylindricine A (1) and (±)-cylindricine C (3), respectively, to showcase their 
developed methodology of ispo-selective addition of alkyl Grignard reagents to C-2 
substituted pyridinium salts.64 Beginning with picolinic acid, the key pyridinium salt, 77, 
was prepared by esterification and o-dimethoxybenzyl (DMB) salt formation as shown in 
Scheme 13. The subsequent key step was a regioselective Grignard addition ipso to the 
 33 
ester to afford 78, thus establishing the aza-spirocenter. An intriguing aspect of this aza-
spirocenter formation was that it occurred via regioselective addition to the most 
sterically-congested carbon. The authors noted the use of the DMB protecting group was 
necessary to achieve the desired regioselectivity. The cyclohexane ring was then closed 
to the exclusively cis-fused bicycle, 79, with sodium amide (NaNH2) and then 
transformed to 80 in three more steps.  Next, the nitrogen was reprotected with a 2-
(trimethylsilyl)ethoxycarbonyl (Teoc) group, necessary for the completion of the 
syntheses. The protection allowed for the homologation of the aldehyde to 81 through 
olefination, hydrogenation, and reduction to the saturated aldehyde. The construction of 
81 provided a divergent intermediate for the syntheses of both cylindricine A and C.  
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Scheme 13. Donohoe synthesis of (±)-cylindricine A (1) and (±)-cylindricine C (3)64 
 
 As shown in Scheme 14, 81 was converted in two steps to 82 by olefination and 
deprotection, which was the same intermediate used in the total syntheses of (±)-
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cylindricine A (1) by Snider24 and Heathcock.25 Incorporating the two known, final steps, 
Donohoe and coworkers accomplished the formal total synthesis of (±)-cylindricine A in 
15 total steps and 3% overall yield. Separately, 81 was converted to epoxide 83 using the 
Corey-Chaykovsky ylide,65 trimethylsulfonium iodide (TMSI), as a 1:1 mixture of 
diastereomers. Epoxide 83 was converted in a 99% yield to a 1:1 mixture of (±)-
cylindricine C (3) and 13-epi-cylindricine C through a simple deprotection of the 
nitrogen, which opened the epoxide to unveil the hydroxymethylene group and complete 
the total synthesis in 13 total steps and 2% overall yield.  
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Scheme 14. Donohoe synthesis of (±)-cylindricine A (1) and (±)-cylindricine C (3) 
(continued)64 
 
 A third total synthesis of (±)-cylindricine C (3) by Padwa and coworkers 
showcases a conjugate addition/dipolar-cycloaddition cascade developed in their 
laboratory.66 Their synthesis, shown in Scheme 15, begins with δ-valerolactone, which 
was converted to hydroxylimine 85 by hydrolysis with methyoxymethylamine to form 
the Weinreb amide, alcohol protection, Grignard addition to the amide, and condensation 
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with hydroxylamine. The key transformation was then accomplished between 84, readily 
available in two steps from 2-butyne-1,4-diol, and 85. The formation of 87 commenced 
with a conjugate addition of nitrogen to afford intermediate 86a, followed by a [3+2]-
dipolar cycloaddition, 86b, of the activated hydroxylamine and the remaining double 
bond by heating in a sealed tube. The [2.2.1] bicycle 87 was synthesized in good yield 
but as a 1:1 mixture of diastereomers. This mixture was submitted to Mn-mediated 
epoxidation conditions to afford epoxide 88 as a single diastereomer albeit in low yield.  
The subsequent transformation was the second of two cascades in this total 
synthesis.  Epoxide 88 was submitted to Zn dust and aqueous ammonium chloride, which 
began the cascade by cleavage of the N-O bond, followed by extrusion of phenylsulfenic 
acid to unveiled the carbonyl of the 4-piperidone shown as intermediate 89. Next, the 
pyrrolidine ring, ring C, was formed by nitrogen addition to the proximal carbon of the 
epoxide which gave rise to the necessary hydroxymethylene in compound 90. The last 
event that occurred in this sequence was the reductive removal of the second 
phenylsulfonyl group to afford 90 in 90% yield and high dr of 9:1. The synthesis 
continued with a benzoyl protection of the hydroxymethylene while the silyl ether was 
deprotected and tosylated to give 91. Potassium tert-butoxide was used to initiate the enol 
displacement of the tosyl group to close the A ring of the tricyclic system and mercury 
acetate was used for the oxidation to enaminone 92. The total synthesis was completed by 
a copper-mediated Grignard addition to establish the hexyl group and a basic 
deprotection of the benzoyl group.  
The highlights for this synthesis include two impressive cascades that led to the B 
ring formation and then the A ring formation. This synthesis further demonstrated 
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another excellent use of the sulfonyl group and its importance as a synthetic tool in 
natural product synthesis. The yield for the total synthesis of (±)-cylindricine C (3) was 
4% over 14 linear steps.  
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Scheme 15. Padwa synthesis of (±)-cylindricine C (3)66 
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1.4. Approaches to the Tricyclic Core  
 
As discussed above, multiple methodologies have been developed for the total 
syntheses of the lepadiformines and cylindricines. In addition, multiple noteworthy 
methodologies and strategies have been developed to quickly construct the tricyclic cores 
of these families of molecules. The core structures that are targeted include the [5.6.6] 
tricycle containing either the cis- or trans-azadecalin moieties as in most of the 
cylindricines and lepadiformines, respectively, as well as the [6.6.6] tricycle found in 
cylindricine B (2) and fasicularin (15) containing the cis- and trans-azadecalin moieties, 
respectively.  
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1.4.1. [5.6.6] Tricyclic Core Approaches 
 
Construction of the [5.6.6] tricyclic core quickly and efficiently is an ideal 
strategy for the synthesis of these families of molecules. Even more ideal is obtaining 
stereochemical control over the decalin fusion. The following two synthetic approaches 
to the cylindricine C core, the cis-azadecalin containing [5.6.6] tricycle, maintain 
complete control over the decalin fusion. 
 The well-known Hajos–Parrish reaction uses L-proline to accomplish a Robinson 
annulation.67 Shown in Scheme 16, Tu and coworkers constructed 93 from 1,3-
cyclopentadione using adapted Hajos–Parrish conditions en route to the core structure of 
(±)-cylindricine C (3).68 The catalyst, D-Prolinamide, shown in Scheme 16, was used to 
prepare 93 in 94% es to begin the asymmetric approach to tricyclic lactam 95. From 93, 
functional group manipulations were done to reduce the enone to the alkene and to 
convert the mono-substituted alkene to azide 94. After submission to Lewis acid 
conditions, in this case boron trifluoride diethyletherate (BF3), azide 94 underwent an 
intramolecular Schmidt reaction69,70 to unveil a tricyclic lactam, which was 
stereoselectively hydrogenated to give 95. This approach was an effective asymmetric 
route to the tricyclic ring system of the cylindricines utilizing the power of the Hajos–
Parrish cyclization as well as the intramolecular Schmidt reaction.  
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Scheme 16. Tu approach to the core structure of (±)-cylindricine C (3)68 
 
 In Scheme 17, another approach to the cis-azadecalin [5.6.6] tricycle was 
prepared using a novel transannular Mannich reaction, accomplished by Tanner and 
coworkers.71 Starting with cycloheptanone, compound 96 was prepared in four steps 
including an initial homologation, Wittig reaction, hydroboration/oxidation, and Suzuki 
coupling. The key macrocyclic intermediate, 97, was prepared in three further steps of 
tosylation, bicyclic formation, and ozonolysis of the double bond to form the diketone. 
Trifluoroacetic acid (TFA) was used to initiate the transannular Mannich reaction by first 
removing the tert-butoxycarbonyl (Boc) group, forming an iminium bicycle, and finally, 
an intramolecular enol addition to quench the iminium ion to achieve tricycle 98. This 
method prepared the racemic tricycle 98 as a single diastereomer in few steps and 
incorporates the C-4 oxidation state.  
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Scheme 17. Tanner approach to the core structure of the cylindricines71  
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1.4.2. [6.6.6] Tricyclic Core Approach. 
 
The [6.6.6] tricycle of (±)-cylindricine B (2) and (±)-fasicularin (15) was 
accomplished by Martin and coworkers using a novel iminium cascade reaction.72 The 
core construction of the [6.6.6] tricycle began with δ-ketoacetal 99 and aminoallylsilane 
100, shown in Scheme 18. Initiation of the cascade began with condensation of the amine 
in 100 onto the ketone in 99 in the presence of molecular sieves. TFA was then added to 
the reaction to convert the acetal to an oxonium ion, to which the imine added to form 
intermediate 101. From there, the allyl silane added into the iminium to form the aza-
spirocenter as well as set the stereochemistry of the azadecalin moiety. Subsequent 
submission to sodium cyanide (NaCN) replaced the methoxy ether with a cyano group 
and ultimately achieve 102 in a 66% overall yield as a mixture of four diastereomers in 
relatively equal proportions. Although this route did not maintain stereocontrol over 
construction of the tricycle, the methodology was effective in quickly building a complex 
structure from simple starting materials through seemingly simple transformations. This 
methodology was applied to a myriad of natural products and core structures.  
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1.5. Conclusion 
 
Although the cylindricine and lepadiformine families currently demonstrate little 
known biological activity, the congested aza-spirocenter contained within these 
molecules provides a fascinating challenge for synthetic chemists and has the potential to 
bring about exquisite methodologies to be used in syntheses of other molecules that 
present medicinally relevant properties. Many examples for the quick and elegant 
construction of the congested aza-spirocenter were reviewed. No doubt, these strategies 
will be utilized in the future for the construction of other medicinally important 
compounds and natural products. These syntheses have provided useful methodology for 
organic chemists; however, there is still room for novel approaches to prepare these 
molecules and their architectures. In the body of this dissertation, our contributions to the 
methodology development and synthetic approaches to these molecules are reported. 
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Chapter 2 
 
Tandem Prins/Schmidt Reaction Development: Formal and Total Syntheses of 
Lepadiformines A and C 
 
2.1. Introduction to the Schmidt Reaction 
 
In 1991, our laboratory discovered a reaction involving the intramolecular 
nucleophilic attack of a tethered azide to a cyclic ketone followed by a ring expansion to 
form a bicyclic lactam.69 As shown in Scheme 19a, the ketone in 104 underwent an 
intramolecular addition from the proximal nitrogen of the azide under acidic conditions to 
form intermediate 105. Upon collapse of the tetrahedral intermediate, bond migration and 
extrusion of N2 afforded bicyclic lactam 106. That reaction was thoroughly investigated 
with a variety of tether lengths, ring sizes, and Lewis acids.70 
Another application of the intramolecular Schmidt reaction is shown in Scheme 
19b. Treatment of azidoketone 104 with the cyclopropyldiphenylsulfonium ylide, 
developed by Trost and coworkers,73 afforded [5.3]spirocyclic ketone 107. Exposure of 
107 to the strong Lewis acid TiCl4 induced an intramolecular Schmidt reaction to form 
the [5.6.6] tricycle 108 that contained a cis-azadecalin moiety around an aza-spirocenter. 
As demonstrated by the two examples in Scheme 19, the intramolecular Schmidt reaction 
provided an effective way to prepare not only tertiary lactams, which could be easily 
reduced to tertiary amines, but also for synthesizing synthetically challenging aza-
spirocenters. 
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In the decades to follow, the intramolecular Schmidt reaction was utilized in 
numerous total syntheses and was employed in tandem reaction sequences incorporating 
other Lewis-acid-mediated reactions.74 More specifically, the Schmidt reaction has been 
conducted in tandem with a Diels–Alder reaction75,76 as well as in domino sequences with 
aldol and Sakurai reactions.77 Because of the similarities of the cores of 108 and 3, we 
envisaged preparing (±)-cylindricine C (3) utilizing a route similar to that in Scheme 19b.  
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2.2. Retrosynthetic Analysis 
 
Our retrosynthetic approach, shown in Scheme 20, began with a late-stage 
functional group conversion of the lactam carbonyl in 109 to the C-13 hydroxy 
methylene, similar to that reported by Renaud and coworkers in their total synthesis of 
(±)-lepadiformine A (12).44 Also, a deprotection and oxidation of the C-4 protected 
alcohol would complete the conversion of 109 to (±)-cylindricine C (3). We envisioned 
109 coming from an intramolecular Schmidt reaction of 110. Since the intramolecular 
Schmidt reaction occurs with retention of configuration,70 the necessary stereochemistry 
of the spirocyclobutanone is depicted in 110, as that would achieve the cis-azadecalin 
ring fusion. The stereochemistry of the protected alcohol would be irrelevant for the 
completed total synthesis but we needed to control the stereochemistry at the azide so we 
envisaged a 1,3-syn-selective reaction to construct 110. Investigation into the literature 
revealed a potential solution to the synthesis of [5.3]spirocyclic ketone 110 by combining 
vinylcyclopropylsilyl ether 112 with 3-azidoaldehyde 111, or the acetal equivalent, two 
relatively simple starting materials.78,79 This literature example is discussed in detail 
below. Also, since the Prins reaction was Lewis-acid mediated, we hoped we could 
achieve a one-pot Prins/Schmidt sequence to achieve 109 directly from 112 and 111. 
However, at the time, there was no literature precedent for a 1,3-syn-selective addition 
involving azides. 
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Scheme 20. Retrosynthetic analysis 
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2.3. Precedent for the Prins Addition Reaction 
 
Trost and coworkers developed an interesting vinylogous cyclopropanol reaction 
as shown in Scheme 21.78 The vinylogous cyclopropanol is referred to as a composite 
functional group because it functions similar to an enol, although the oxygen is not 
directly attached to the alkene, by transforming through the cyclopropane.78 The example 
in Scheme 21 illustrates that, when combined with an acetal under Lewis acid conditions, 
the alkene of 113 adds into the oxonium species formed by the breakdown of the acetal to 
form the carbocation in 114. In this type of Prins reaction, the carbocation is quenched by 
a ring expansion of the cyclopropane, whereas in a typical Prins reaction, the carbocation 
is quenched directly by an oxygen; hence the composite functionality of the vinylogous 
cyclopropanol. The resulting product from the ring expansion is cyclobutanone 115. 
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Scheme 21. Trost vinylogous cyclopropanol chemistry 
 
A similar example of vinylogous cyclopropanol addition to acetals was later 
developed by Cha and coworkers using 112 is shown in Scheme 22.79,80 The reaction is 
mechanistically equivalent to the Trost example seen in Scheme 21. Starting with 112, 
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the Prins-type reaction generated spirocyclobutanones 117 and 118 and a third 
diastereomer with undefined stereochemistry. The diastereochemical difference at the 
spirocenter results from the competing ring expansion processes of the two diastereotopic 
cyclopropane C-C bonds of intermediate 116. In this case, the ring expansion was only 
slightly selective and gave a diastereomeric mixture. Nonetheless, the reaction produced 
spirocyclobutanones with a similar oxygen substitution pattern that we would require for 
the synthesis of cylindricine C. Shown later, we completed this reaction where an azide 
replaced the bromine and afforded similar results. 
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Scheme 22. Cha vinylogous cyclopropanol chemistry 
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2.4. Starting Materials 
 
Our work began by preparation of compound 112 using the Kulinkovich reaction 
as shown in Scheme 23, which converts an ester to a cyclopropanol.79 There is some 
debate in the literature over the mechanistic details.81 However, it is proposed that 
titanium tetraisopropoxide initially combines with ethylmagnesium bromide to generate a 
diethyl-diisopropoxide titanium species, which undergoes β-hydride elimination to 
extrude ethane and form a titanocyclopropane. The titanocene can be thought of as an 
ethyl group that is nucleophilic at both carbons. Upon addition of the ester, the titanocene 
undergoes a migratory insertion to incorporate the ester. Collapse of the tetrahedral 
intermediate generates a ketone, which then undergoes an intramolecular migratory 
insertion to form the cyclopropanol. At that point, the ethylmagnesium bromide displaces 
the newly formed cyclopropoxide to regenerate the titanium. 
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Thus, the Kulinkovich reaction of commercially-available methyl-1-cyclohexene-
1-carboxylate provided cyclopropanol 119, which was treated with trimethylsilyl triflate 
(TMSOTf) to afford 112 in quantitative yield (Scheme 24a). With 112 in hand, we 
required a reaction partner to initiate our investigation of a potential tandem 
Prins/Schmidt reaction. 
Various reports of Prins reactions encouraged us to initially investigate the use of 
an acetal coupling partner. Further, acetals are more reactive than aldehydes due to the 
activated oxonium species generated upon submission to acid. Therefore, acetal 121, 
lacking an additional complicating stereocenter, was initially evaluated. Acetal 121 was 
prepared in two steps from acrolein, which was treated with sodium azide and acetic acid 
in water (Scheme 24b).82 These conditions generated hydrazoic acid (HN3), which 
underwent conjugate addition with the acrolein to form 3-azidopropanal, 120. Treatment 
of 120 with trimethylorthoformate in methanol with a catalytic amount of p-
toluenesulfonic acid (TsOH) afforded the dimethoxyacetal 121. With compounds 112 and 
121 in hand, we began our investigation of a Prins/Schmidt methodology toward a total 
synthesis of (±)-cylindricine C (3). 
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Scheme 24. Initial starting material preparation 
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2.5. Methodology Overview 
 
The desired tandem transformation is shown in Scheme 25a. For this example we 
followed the example by Cha and coworkers shown in Scheme 22.80 Exposure of 112 
with 121 to Lewis acidic conditions could afford spirocyclobutanone 124. The 
stereochemistry of the methoxy group represents what we expect.80 The stereochemistry 
of the spirocyclobutanone 122 represents the desired stereochemistry that would afford 
the cis-decalin configuration of 123. Since the reaction mixture was already under Lewis 
acidic conditions, we envisioned that an intramolecular Schmidt reaction could occur in 
situ on 122 similar to Scheme 1b9, resulting in the formation of tricyclic lactam 123. 
Alternately, we could form 122 by the same Prins reaction in Scheme 22 followed by 
azide displacement of the bromide with NaN3 and then attempt the intramolecular 
Schmidt reaction independently. 
Our proposed mechanism for this transformation is shown in Scheme 25b. We 
envisaged combining 112 with in situ generated oxocarbenium ion 124 to form 
intermediate 125. Two stereocenters were set during the Prins addition. For the total 
synthesis, the stereochemistry of the carbon-oxygen bond was irrelevant because it would 
be stereoablated in the latter stages of the synthesis. 
The next stereochemical issue arises from the ring expansion of the cyclopropanol 
during the conversion of 125 to 122. We anticipated the ring expansion would occur 
placing the carbonyl on the same side as the OMe, the opposite of what we wanted.80 
From there, the tethered azide could add to the carbonyl of the cyclobutanone that would 
be activated by the presence of the Lewis acid, depicted in Scheme 25b as TiCl4. The 
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intramolecular Schmidt reaction to convert 122 to 123 would proceed through 126, a 
seven-membered ring intermediate, with retention of configuration at the spirocenter. 
Although not an ideal arrangement, similar transformations have been previously 
observed.69 
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Scheme 25. Desired transformation and proposed mechanism for 112 with 121 
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2.6. Acetal Approach 
 
We began our investigation by treating cyclopropane 112 with 3-azidopropanal 
dimethoxyacetal (121) under TiCl4-promoted conditions as shown in Scheme 26.80 Under 
these conditions, three diastereomers of the spirocyclobutanones were obtained in a ratio 
of 10:4:1 (122a:122b:122c) in an 83% yield. The stereochemistry of 122a was 
determined by comparison to the product obtained by repeating the Cha reaction and 
displacing the bromide of 117 with azide using NaN3. The other two structures, as with 
most other structures in this chapter, were cyclized to the tricyclic lactam and analyzed 
by 2-D NMR techniques. The rigid tricyclic structures, like 123b, provided strong NOE 
correlations, which facilitated stereochemical elucidation. The structure elucidation 
information for 123b is detailed in the experimental section (Chapter 5). The structure of 
123c was determined by comparison of 1H and 13C NMR to a structure determined by 
single crystal diffraction, the details of which are in Appendix 1. 
Attempted optimizations were unsuccessful. We investigated other Lewis acids 
under similar conditions: Sc(OTf)3, Cu(OTf)2, Zn(OTf)2, Yb(OTf)3, ZnCl2, TFA, Triflic 
acid, SnCl4, and AlCl3. Various temperatures were investigated from –78 °C to room 
temperature (rt), and only TiCl4 gave the Prins adduct in greater than trace amounts. We 
then moved forward to investigate the intramolecular Schmidt reaction on azides 122a-c. 
As shown in Scheme 26, each of the diastereomers was independently submitted 
to TiCl4 at rt overnight. Diastereomers 122b and 122c were quantitatively converted to 
the corresponding lactams 123b and 123c, respectively. In those two cases, a single 
diastereomer was used and a single diastereomer was afforded. In contrast, when the 
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major isomer, 122a, was submitted to the same conditions, a mixture of lactam 
diastereomers was observed. The observed complex mixture from 122a was significant 
because it indicated that the major product of the Prins reaction did not map to a 
productive Schmidt pathway. 
In an attempt to achieve a one-pot Prins/Schmidt reaction sequence, we treated 
112 and 121 with TiCl4 at –78 °C for 2 hr, then treated the reaction with more TiCl4 at 0 
°C, and allowed the reaction to warm to rt for 12 hr (Scheme 27). We isolated the tandem 
Prins/Schmidt product, the lactam, albeit in a significantly diminished yield of 35% as a 
mixture of three diastereomers. Interestingly, the major diastereomer of the tandem 
reaction corresponded to the minor diastereomer of the independent Prins 
addition/Schmidt reaction sequence in Scheme 26. 
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 55 
N
O
OMe
a. TiCl4, DCM
    -78 oC, 2 h
b. TiCl4
    0 oC to rt, 12 h
35%
dr = 3:1:1
OMe
MeO N3
OTMS
112
121
123c  
Scheme 27. Tandem Prins/Schmidt reaction 
 
Although the reaction sequence was not fully developed, we explored the use of 
123c in a synthesis of (±)-cylindricine C (3). We anticipated that we could achieve a 
more convergent reaction sequence by incorporating the hexyl side chain at C-2 into the 
acetal by using 3-azidononenal dimethoxyacetal, 127. Substrate 127 was prepared the 
same way as 121 in Scheme 24 starting with trans-2-nonenal. Scheme 28 shows the 
results when we combined 112 with 127 under the previously used conditions. The Prins 
reaction between 112 and 127 occurred in good yield as a mixture of five inseparable 
diastereomers of 128. With hope that perhaps the lactams would be separable, the 
mixtures of diastereomers of 128 were submitted to the intramolecular Schmidt 
conditions. This afforded a high yield of lactam (129) as a mixture of diastereomers that 
remained inseparable. The complex diastereomeric mixtures of 128 and 129 made it 
difficult to determine any stereochemical information from the reaction. Since we were 
seeking a specific diastereochemical outcome, the mixture was not useful. If the 
diastereomers were separable or if a major diastereomer existed over the others, this route 
might have been more useful, but as it stood, we chose not to pursue it.  
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Scheme 28. Prins and Schmidt reactions with 3-azidononenal dimethoxyacetal 
 
Since the direct incorporation of the hexyl group into 128 proved problematic, we 
briefly explored a way of installation of the hexyl group at a later stage of the synthesis. 
We considered electrochemical techniques developed in the Moeller lab at Washington 
University,83 as shown in Scheme 29a. In that work, lactam 130 was oxidized to 131 
using simple conditions of graphite anodes and platinum wire in methanol, the source of 
the methoxy group. From 131, allyltrimethyl silane and TiCl4 were used to replace the 
methoxy group with an allyl group in 133 through the iminium ion 132. We envisioned 
being able to apply this chemistry to achieve the correct C-2 substitution in the tricyclic 
lactam. We attempted to apply that chemistry to our tricyclic lactam 134 in Scheme 29b, 
to first afford 135, but the two-step yield of 136 from 134 was low, <16%. We concluded 
it was unproductive to pursue the electrochemistry route further. 
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Scheme 29. Electrochemistry of amides 
 
In another effort to assess the acetal version of the Prins/Schmidt approach, we 
examined deprotecting the methyl ether at C-4 with BBr3 (Scheme 30). Unfortunately, 
when 123c was treated with boron tribromide (BBr3) under standard conditions, we did 
not achieve the desired deprotection but instead isolated a combination of the migrated 
hydroxy compound 137 and the eliminated product 138 (Scheme 30). The structures of 
137 and 138 were determined by 13C DEPT analysis.  
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Scheme 30. Deprotection of methyl ether 
 
Our mechanistic hypothesis for this transformation is depicted in Scheme 31. We 
figured the oxygen displaced a bromine on the boron but instead of the bromine returning 
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to remove the methyl as expected, a secondary carbocation was formed in place of the 
oxygen. The cation intermediate could undergo elimination to form 138, or undergo a 
1,2-hydride shift to form the more stable tertiary carbocation. After water adds to the 
tertiary carbocation, the resulting product is 137, the major product seen in the reaction. 
Regardless, at this point, we opted for an alternative pathway. 
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Scheme 31. Mechanistic hypothesis for BBr3 reaction 
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2.7. Aldehyde Approach 
 
All of the precedent regarding the Prins reaction with the vinylogous 
cyclopropanols involved an acetal as a coupling partner. Based on the results described 
above, we decided to embark on an investigation using aldehydes as coupling partners in 
the same type of reaction. One potential problem for that route included the decreased 
reactivity of the aldehyde relative to the oxonium species afforded by the acetal. 
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2.7.1. Non-Substituted 3-Azidoaldehyde 
 
Early efforts toward this project were carried out by Christopher Katz84 and Sze-
Wan Li85 and I began by reexamining their results as described in this section. To begin, 
an extensive reaction screen of appropriate conditions for the reaction between 112 and 
3-azidopropanal (120) was done. Temperatures from –78 °C to 100 °C were examined as 
well as a variety of Lewis acids (AlCl3, MeAlCl2, BF3•Et2O, TMSOTf, Ti(Oi-Pr)4, 
Sc(OTf)3, Triflic acid, SnCl4, TiCl4/ Ti(Oi-Pr)4, and TiCl4). Different equivalent ratios of 
cyclopropanol to aldehyde were examined as well. Most reactions were done in 
dichloromethane (DCM) as THF is known to polymerize under Lewis acid conditions. 
Under most conditions, the resulting product was [5.3]spirocyclic ketone 139, the product 
of ring expansion and protonation of 112 accomplished by submission to acid (Scheme 
32). However, some hope was found using TiCl4 at elevated temperatures. 
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Scheme 32. Unsuccessful attempts at Prins/Schmidt reaction 
 
After an extensive trial of the Prins/Schmidt reaction with TiCl4, we arrived at the 
optimal conditions. The reaction was initiated by addition of 1.5 equiv of TiCl4 at 0 °C to 
the mixture of 112 and 120 and then a second addition of TiCl4 two hours later and 
heating to 40 °C for another two hours (Scheme 33). This led to an interesting result: two 
different compounds ultimately identified as 140 and 141 were observed as single 
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diastereomers as shown in Scheme 33, as identified by 13C NMR analysis of the crude 
reaction mixture. 
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Scheme 33. Prins/Schmidt reaction with 3-azidopropanal 
 
At the time, we were unsure of the stereochemical relationship of 140 and 141, 
and so initially concentrated on converting the latter to a lactam. Numerous conditions 
were attempted, but all failed. Eventually, we decided to protect the hydroxyl group of 
141 as an acetate group by treatment with acetic anhydride (Ac2O) to form 142 (Scheme 
34). The protection reaction was high yielding for 142 (89%) and was mass balanced by 
the isolation of byproduct 143 (11%). Azide 142 was submitted to TiCl4 and quickly 
underwent ring expansion to tricyclic lactam 144 in excellent yield. 
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Scheme 34. Tricycle formation from 141 
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With tricycles 140 and 144 in hand, we wanted to compare the molecules to see if 
they were in the same stereochemical series or not. In order to directly compare the two, 
140 was converted to the acetate ester 145 (Scheme 35). Comparison of the NMR spectra 
determined that these compounds were not identical. Eventually we were able to obtain a 
crystal structure of 140 (See Appendix 1), but we needed to find out the stereochemical 
differences between 144 and 145. The details to the structure elucidation are in Chapter 5. 
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Scheme 35. Conversion of 140 to the acetate 
 
Lactams 144 and 145 were epimeric at the aza-spirocenter. Accordingly, tricycle 
145, modified from 140, the compound that underwent the tandem Prins/Schmidt 
reaction shown in Scheme 33, contained a cis-azadecalin ring fusion, similar to that seen 
in the cylindricine family of molecules. In contrast, 144, derived from the 
spirocyclobutanone 141 from Scheme 33 and Scheme 34, contained the trans-azadecalin 
ring fusion as present in the lepadiformines. Interestingly, the relative stereochemistry 
between C-4 and C-5 were the same. 
Having determined the structural differences between the two lactams, we were 
still curious as to why one of the diastereomers of the spirocyclobutanone underwent the 
intramolecular Schmidt reaction in situ while the other diastereomer did not. Scheme 36 
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shows the divergent pathways of the two spirocyclobutanone diastereomers formed. First, 
the Prins reaction occurs to form carbocation 146. From there, the ring expansion can 
occur two ways, forming 147 and 141. Diastereomer 141 remained, while the other 
diastereomer, 147, was able to undergo azide addition and ring expansion to form 140. 
The only difference was the spirocenter stereochemistry. 
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Scheme 36. Divergent pathways 
 
One possible theory to give some insight into the stereochemical divergence was 
formed after the isolation of ketal 143 shown in Scheme 34. Since the ketal could be 
protected as the acetate, 141 must be in equilibrium with the corresponding hemiketal. 
Illustrated in Scheme 37, when 112 was reacted with 120, two spirocyclobutanones were 
formed. As also shown in Scheme 36, 147 proceeded to undergo an intramolecular 
Schmidt reaction to form 140. However, to the extent that the equilibrium of 141 with 
148 favors the hemiketal, it cannot undergo the intramolecular Schmidt reaction. 
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Scheme 37. Hypothesis for stereochemical divergence 
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2.7.2. Alkyl-Substituted 3-Azidoaldehydes 
 
Since the original idea of the tandem Prins/Schmidt methodology was for the total 
synthesis of (±)-cylindricine C (3), we then investigated the incorporation of an alkyl 
substitution at the geminal position of the azide in the 3-azidoaldehydes. Using 3-
azidononanal, 111, as the coupling partner, the titanium-promoted reaction with 112 
produced four products as shown in Scheme 38. The products isolated from the reaction 
included a single diastereomer of a spirocyclobutanone 149 in 30% yield, which 
contained four stereocenters, and three diastereomeric lactams, 150a-c. The latter each 
contain four stereocenters and were obtained in 22% yield in a ratio of 3:1:1. The 
structure of 150a was determined by first acetylation and then structure elucidation with 
2-D NMR techniques. Lactam diastereomer 150b was assigned based on a crystal 
structure.84 The configuration of 150c was determined by comparison to the equivalent 
molecule derived from 149, converted in Scheme 39. 
The structures of 150a and 150b both contained the cis-azadecalin configuration 
found in the cylindricines; however, only 150b contained the correct configuration of the 
hexyl group at C-2. The low yield of 150b did not bode well for its use in a total 
synthesis of (±)-cylindricine C (3). Interestingly, diastereomer 150c contained the trans-
azadecalin moiety and had the configuration for the C-2 hexyl group needed for 
conversion to (±)-lepadiformine A (12). 
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Scheme 38. Prins/Schmidt reaction with 3-azidononanal 
 
In order to determine the stereochemistry of spirocyclobutanone 149, we 
converted it to the tricyclic lactam. That was accomplished by protection of the hydroxyl 
group with an acetate and submission to Lewis acid conditions (Scheme 39). The yield 
for the conversion of 149 to 151 was slightly diminished (74%) because the 
corresponding acetoxy ketal 152, similar to 143, was also isolated in 19% yield. 
Submission of 151 to TiCl4 quickly afforded tricyclic lactam 153 in high yield. Structure 
elucidation of 153 was shown to have the same stereochemistry as 150c by comparing the 
1D NMR spectra, which included the trans-azadecalin system and the same hexyl 
configuration as (±)-lepadiformine A (12). 
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Scheme 39. Cyclization of 149 
 
We opted to prepare a butyl-substituted analogue as that substitution is found in 
other cylindricines and lepadiformines. We applied the tandem Prins/Schmidt reaction 
conditions to 112 and 154, prepared the same way as other 3-azidoaldehydes except 
starting with trans-2-heptenal, and obtained results similar to those shown in Scheme 38 
(Scheme 40). The yield of 155 was decreased to 22% relative to 149 because the 
corresponding hemiketal was isolated from this reaction mixture. Three diastereomers of 
the lactam, 156a-c, were also isolated in 33% yield and dr = 3:1:1, similar to Scheme 38 
and also corresponding to the same stereochemistry. The structures of 156a-c were 
determined by 2-D NMR structure elucidation (Chapter 5).  
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Scheme 40. Prins/Schmidt reaction with 3-azidoheptanal 
 
Spirocyclobutanone 155 was converted to the tricyclic lactam, as was the hexyl-
containing 149 (Scheme 41). Thus, the hydroxyl group in 155 was protected as an acetate 
and the compound was subjected to the intramolecular Schmidt reaction affording 
tricyclic lactam 158. The stereochemistry of 158 was deactylated (Scheme 45) and the 
structure was equivalent to 156c. 
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Scheme 41. Cyclization of 155 
 
In the interest of looking into the stereochemistry a little more, we also chose to 
examine a 2-alkyl-3-azidoaldehyde. To that end, we began with methacrolein to prepare 
3-azido-2-methylpropanal, 159, in the same way as previous azidoaldehydes, and applied 
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the tandem Prins/Schmidt conditions (Scheme 42). We expected increased selectivity as a 
result of the α-substitution but saw not only decreased selectivity, but decreased 
reactivity as well. Spirocyclobutanone 160 was the major spirocyclobutanone formed, 
however there was an unknown minor diastereomer of spirocyclobutanone formed also. 
13C NMR analysis of the crude reaction mixture indicated the spirocyclobutanones were 
formed with a dr = 4:1. The minor diastereomer was inseparable and gradually 
diminished over the course of the next couple reactions before the structure elucidation 
could occur and we were unable to determine the stereochemistry. Spirocyclobutanone 
160 was converted to acetate 162 and then cyclized to 163 in the same way as the 
previous spirocyclobutanones for structure elucidation. The tricyclic lactams were formed 
in a slightly different profile than the previous examples. First, four diastereomers of 161 
were formed in dr = 4:2:2:1. Second, the lactams were mostly inseparable; a 2:1 mixture 
of 161a to 161b was isolated and their structures were able to be determined. The 
configurations of the two remaining diastereomers were undetermined. 
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Scheme 42. Prins/Schmidt reaction with 2-methyl-3-azidoaldehyde 
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2.8. Formal Synthesis of (±)-Lepadiformine A 
 
In the tandem Prins/Schmidt reaction with 3-azidononanal, one of the three 
diastereomers of the lactams formed, 150b, contained the required stereochemistry for 
(±)-cylindricine C (3) and was obtained in approximately 4% yield. However, the major 
product of the reaction mixture, spirocyclobutanone 149, contained the correct azadecalin 
configuration and correct relative stereochemistry of the hexyl group as (±)-
lepadiformine A (12). So instead of continuing to pursue the cylindricine route, we 
decided to pursue a formal synthesis of (±)-lepadiformine A (12) through a common 
intermediate used by Renaud and coworkers in their total synthesis.44 
As shown in Scheme 39, 149 was converted in two steps to the tricyclic lactam 
153. Shown in Scheme 43 is the completion of the formal synthesis. Compound 153 was 
treated with basic conditions to deprotect the alcohol, which afforded 150c, one of the 
lactams formed in the tandem Prins/Schmidt reaction shown in Scheme 38. Although 
150c was formed in the tandem reaction, it was produced in such a small amount (ca. 
4%) making the completion of the synthesis difficult from that stage despite the fact that 
the sequence would have been three steps shorter. From 150c, the hydroxyl group was 
removed using Barton-McCombie conditions: forming xanthate 164 followed by radical 
C-O bond cleavage to afford 165.55 
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Scheme 43. Formal synthesis of (±)-lepadiformine A (12) 
 
From 165, Renaud and coworkers installed the hydroxymethylene in three steps. 
First, lactam 165 was converted to the thioamide 166 with Lawesson’s reagent (Scheme 
44). The thioamide was activated with methyl iodide (MeI) and the alkynyl lithiate was 
added and then reduced with LAH to afford 167. The final step for their total synthesis 
was ozonolysis of 167 with a reductive workup to complete (±)-lepadiformine A (12). 
The Renaud group accomplished the total synthesis in ten linear steps from commercially 
available starting material in 15% overall yield. 
Incorporating the Renaud end game, our formal total synthesis of (±)-
Lepadiformine A (12) corresponds to 12 total steps and 8% overall yield using the 
spirocyclobutanone 149 as an intermediate. Going through 150c would shorten the 
synthesis to nine total steps but would correspond to only 2% overall yield. 
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Scheme 44. Renaud end game for their total synthesis of (±)-lepadiformine A (12)44 
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2.9. First Total Synthesis of (±)-Lepadiformine C 
 
The tandem Prins/Schmidt reaction with 3-azidoheptanal yielded a slightly higher 
amount of lactam that corresponded to the cylindricine natural products than did 3-
azidononanal; lactam 156b was formed in a 6% yield, shown in Scheme 40. That lactam 
could have been used to synthesize any of the cylindricines G-J (7-10). Instead, we chose 
to pursue a total synthesis of (±)-lepadiformine C (14) from spirocyclobutanone 155 in 
the same way we moved forward with the formal synthesis of (±)-lepadiformine A (12) 
shown in Scheme 43. 
For the total synthesis of  (±)-lepadiformine C (14), we began with lactam 158 as 
formed from spirocyclobutanone 155 (Scheme 41). As shown in Scheme 45, lactam 158 
was treated with base to form 156c, the same lactam formed in the tandem Prins/Schmidt 
reaction in Scheme 40. Treating 156c with Barton-McCombie dehydroxylation 
conditions, we first formed xanthate 168 and then lactam 169 through a radical 
transformation. To reduce the amide in 169 to the amine, LAH was used. The resulting 
amine was protonated with HCl and purified to complete the first total synthesis of (±)-
lepadiformine C (14). 
The total synthesis of (±)-lepadiformine C (14) was accomplished in nine total 
steps and 10% overall yield proceeding through spirocyclobutanone 155. Using lactam 
156c from the tandem Prins/Schmidt reaction accomplished the total synthesis in seven 
total steps and an overall yield of 3%. 
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Scheme 45. Total synthesis of (±)-lepadiformine C (14) 
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2.10. Conclusion 
 
The tandem Prins/Schmidt reaction has provided a useful pathway to prepare 
complex tricyclic lactams from simple starting materials. Although the yields are not 
outstanding, the complexity and diastereochemical outcome of these sequences remains 
impressive as, in most cases, four stereocenters were set and two rings were formed in a 
single-pot reaction. This methodology allowed for the completion of a formal synthesis 
of (±)-lepadiformine A (12) and a total synthesis of (±)-lepadiformine C (14). Since this 
methodology did not furnish the total synthesis of (±)-cylindricine C (3), a second-
generation approach was needed. 
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Chapter 3 
 
Efficient Process for the Preparation of Enantiomerically Pure 4-Hydroxy-2-
cyclopenten-1-ones 
 
3.1. Importance of 4-Hydroxy-2-cyclopenten-1-ones 
 
4-Hydroxy-2-cyclopenten-1-one (HCP), shown in Figure 5 as a silyl-protected 
variant, has historically been an important intermediate in prostaglandin synthesis. Many 
synthetic methods have been developed both to prepare this molecule and to study its 
reactions.86-88 A number of naturally-occurring prostaglandin drugs are currently on the 
US and world pharmaceutical markets, including dinoprostone (PGE2, used to induce 
labor), PGE (peptic ulcer treatment), and PGE1 (treatment of patent ductus arteriosus in 
newborns). Because HCP is a common intermediate to these important drugs, producing 
it on large scale is necessary. Efficient processes are required for molecules being made 
in batch. Although there are many routes to HCP, we developed our own synthesis that 
was shorter than all previous routes. We have devised a concise, asymmetric approach 
that is adaptable to large-scale synthesis. Although useful in the area of prostaglandin 
research and therapeutics, we developed this process for the use of a starting material in a 
total synthesis approach that will be described in Chapter 4. 
 
 
 77 
R3SiO
O
4-Hydroxy-2-cyclopenten-1-one
Prostaglandin Intermediate
R
CO2H
OH
PGE2
O
HO
 
Figure 5. Core of prostaglandins  
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3.1.1. Prostaglandins 
 
In the 1930’s, gynecologists discovered prostaglandins when they observed 
muscle contraction and relaxation of the uterus when exposed to semen.89 The active 
compounds were later named prostaglandins because they were identified to exist in the 
prostate gland. In the 1960’s, further investigation led to the discovery of the biosynthesis 
of some prostaglandins from arachidonic acid (AA) which was followed by reports of 
biosynthetic inhibition by aspirin and other non-steroidal anti-inflammatory drugs 
(NSAIDS), culminating in a Nobel prize awarded to Sune Bergström, Bengt Samuelsson, 
and John Vane in 1982 for their discoveries concerning prostaglandins and related 
biologically active substances. 
 Scheme 46 diagrams the biosynthesis of some of the prostaglandins. When a cell 
detects chemical or physical stress, acyl hydrolases, commonly phospholipase A (PLA2) 
are activated. PLA2 hydrolyses the ester bond of the phospholipids of the cell membrane 
and releases arachidonic acid (AA). AA is acted on by cyclooxygenase actions of COX-1 
or COX-2 to form the cyclic endoperoxide prostaglandin G2 (PGG2), which contains an 
acyclic peroxide in addition to the endoperoxide.90 PGG2 is converted to prostaglandin H2 
(PGH2) by hydroperoxidase action of either COX-1 or COX-2. For clarification, both 
isoforms of COX enzymes, 1 and 2, perform the cyclooxygenase and hydroperoxidase 
activities, however, they usually exist in cells such that one isoform is dominant over the 
other. COX-1 is considered the main source for prostaglandins involved in regulatory 
functions that occur under conditions of low stress. COX-2 is induced in times of stress 
and provides prostaglandins for inflammation and cancer.  
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 A variety of synthases convert PGH2 to different prostaglandins, depending on 
physiological need. The key structural feature in these prostaglandins that is relevant to 
the work herein is the cyclopentane rings bearing the stereodefined hydroxyl groups seen 
in PGE2, PGF2α, PGD2, and PGI2.  
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Scheme 46. Prostaglandin biosynthesis 
 
 The prostaglandin structures possess vast biological activity profiles. In some 
cases, it is therapeutically desirable to inhibit prostaglandin actions, such as in the 
induction of inflammation. For example, COX inhibitors, like aspirin, are widely used 
anti-inflammatory agents. Obtaining a selectivity profile of COX-2 inhibition over COX-
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1 has brought to market some popular drugs for the treatment of rheumatoid arthritis like 
celecoxib, a current drug on the market developed by Pfizer. 
 In other cases, the increase of prostaglandin levels is desired. The prostaglandins 
are agents of autocrine or paracrine signaling, so they are synthesized for use in a specific 
location. Unfortunately, the half-life of prostaglandins is short, around 30 minutes. 
Moreover, up-regulation of prostaglandin biosynthetic enzymes might not be 
advantageous because it would lead to effects in numerous tissues, as this biosynthetic 
machinery is quite ubiquitous. A solution to this problem involves external synthesis of 
the prostaglandins and administration as needed in the desired location. 
 There are many desirable biological effects of the prostaglandins.91 Some 
examples of these effects include PGI2 inhibiting platelet aggregation and breaking up 
aggregates that have already formed, which has major implications in myocardial 
infarction and stroke prevention or treatment. PGE2 maintains the ductus arteriosus, 
which connects the pulmonary artery to the aortic arch in fetuses to bypass fluid-filled 
lungs. PGE2 also has bronchodilating effects, while PGF2α has bronchoconstricting 
effects. PGE2 and PGI2 both play a critical role in maintaining renal blood flow and salt 
excretion as well as protect cardiac tissue from oxidative injury.  
 Because of the many biological effects of prostaglandins, they have many 
therapeutic uses. Because PGEs and PGFs cause uterine contractions, they are used in 
pregnancy terminations. Dinoprostone, synthetic PGE2, is approved for inducing labor by 
ripening the cervix and inducing abortion in the second trimester. PGE2 in combination 
with Mifepristone (RU486) is highly effective in terminating early pregnancies. 
Misoprostol, an analog of PGE1 (similar to PGE2 with the cis-double bond 
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hydrogenated), is an approved drug for the treatment of gastric ulcers that were caused by 
NSAIDS. The effectiveness is similar to that of a proton-pump inhibitor. PGE1, 
alprostadil, is used as an injectible therapeutic for the treatment of erectile dysfunction as 
a result of the vasodilation effects. 89 
 Clearly, the vast array of biological targets for the prostaglandins exists. Efficient 
processes to synthesize enantiomerically pure advanced intermediates to the 
prostaglandins are desirable to not only recreate the natural prostaglandins, but also to 
prepare libraries of analogs to further probe their biological portfolio. 
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3.1.2. Prostaglandin Synthesis from HCP’s 
 
Two comprehensive reviews on prostaglandin synthesis have been published, one 
in 1993 and another in 2007.87,88 All prostaglandins contain a cyclopentane ring, while 
only some of them contain a 4-hydroxy-2-cyclopenten-1-one substructure, as in PGE2 
and PGD2. Two convenient ways to prepare the HCP containing prostaglandins include a 
two-component coupling and a three-component coupling strategy.  
 The two-component process has been employed to prepare PGE1 (Scheme 47).92 
A Suzuki-Miyaura reaction was used to couple iodoenone 170 to an alkylborane to form 
171. The second component involved a cuprate-mediated conjugate addition of vinyl 
stannane 172 to form the 2,3-substituted cyclopentanone 173. The stereochemistry of 173 
resulted from the conjugate addition adding to the opposite face as the silyl ether. The 
protonation of the enolate formed after the cuprate addition occurred to orient the alkyl 
substituents trans to each other. Compound 173 was taken on to PGE1 methyl ester. 
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Scheme 47. Two-component coupling process 
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 The other common procedure for the preparation of prostaglandins from HCP’s 
involves a three-component coupling shown in Scheme 48.93 Starting with 174, the 
conjugate addition of 175 to 174 forms enolate 176. Treatment of enolate 176 with a 
propargyl iodide, forms 177. These two steps occur in one-pot. 
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Scheme 48. Three-component coupling process 
 
 The two-component and three-component coupling processes are just two simple 
examples of the utility of the HCP’s in the synthesis of prostaglandins. Based on the 
biological profile of prostaglandins and the facile accessibility from HCP’s, a quick and 
easy approach to prepare HCP’s could positively impact this area of therapeutics.
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3.2. Previous Synthetic Approaches 
 
We sought to prepare a silyl-protected HCP, a common intermediate for the 
synthesis of prostaglandins. Current methods for making this intermediate require a 
multi-step route that entails a number of non-optimal steps, including strong oxidizing 
conditions for making the initial starting material, the use of an enzymatic reaction to 
induce stereochemistry, and the possibility that a later key intermediate has the potential 
for racemization due to a latent plane of symmetry in the molecule. Nonetheless, this 
route has been used due to the lack of more efficient alternatives.  
 Scheme 49 outlines the initial steps of the most common approach that has been 
adapted by many but was originated by Deardorff and coworkers.94,95 The process began 
with cyclopentadiene, which was cracked and then treated with peracetic acid in DCM 
with sodium acetate (NaOAc) and sodium carbonate (NaCO3) to form epoxide 178. In 
our hands, this reaction worked well to form a volatile epoxide. The epoxide-opening 
reaction was less friendly. The reported procedure for the conversion of 178 to (±)-179 
reported a 72-76% yield, however in our hands, that was never the case. The palladium-
mediated SN2' addition of the acetate to 178 was sensitive and not reproducible in our 
hands. Racemate (±)-179 required multiple recrystallizations for sufficient purity as high 
purity was required for the enzymatic hydrolysis reaction and the diacetate 180 was an oil 
and accordingly could not be recrystallized. Once in hand, racemic monoacetate (±)-179 
was converted to diacetate 180 with ease and enantiomerically pure (1R,4S)-179, was 
prepared via enzymatic hydrolysis with electric eel acetylcholine esterase.   
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Scheme 49. Initial steps for enantiomerically pure cyclopentene (1R,4S)-179 
 
 From (1R,4S)-179, multiple steps were required to obtain the two the silyl-
protected HCP enantiomers. As shown in Scheme 50, three more steps were needed to 
synthesize (S)-181 following a procedure by Danishefsky and coworkers.96 If the R 
enantiomer was required, one extra protecting group strategy was needed; so five extra 
steps were required.97 The extra steps are because the enzyme only hydrolyzed one 
enantiomer of acetate and that was not interchangeable for the other enantiomer. 
Therefore, the total steps required to synthesize (S)-181 was seven and nine steps for the 
(R)-181.  
 
OAcHO OTIPSO
(1R,4S)-179 (S)-181
3 Steps
OAcHO O OTIPS
(1R,4S)-179 (R)-181
5 Steps
 
Scheme 50. Literature routes to (R)-181 and (S)-181 
 
 Other routes to HCP included drawing the chirality from the chiral pool, namely 
sugars. As shown in Scheme 51, (4S)-HCP was synthesized from D-arabinose or in two 
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fewer steps from 2-deoxy-D-ribose.98 In that approach, the sugars were converted to 182 
in eleven or nine steps, respectively. From there, ring-closing metathesis (RCM) formed 
183 and subsequent Dess-Martin periodinane (DMP) oxidation afforded (S)-174. The 
target was obtained in >98% es with an overall step count of 11 from commercially 
available 2-deoxy-D-ribose. Also, both enantiomers can be made using this method 
because L-arabinose is also commercially available. 
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Scheme 51. Sugar approach to HCP 
 
 Shown here are just a few of numerous approaches the HCP’s. Although there are 
many other approaches, we sought to develop a route that was short, highly 
enantiomerically selective, user friendly, and scalable.  
 
 87 
3.3. Our Synthetic Strategy 
 
Our initial idea involved a RCM approach similar to that shown in Scheme 51, 
where the key chiral intermediate could be prepared in enantiomerically pure form from a 
Noyori reduction (Scheme 52). In an Organic Syntheses preparation, 185 was synthesized 
starting with acetyl acetone, which was converted to 184. From 184, a Noyori reduction 
resulted in 185 in >98% es.99 From there, a Corey-Chaykovsky reaction converted 185 to 
186, as demonstrated by Hanson and coworkers.100 The conversion of 186 to 187 would 
require RCM and a monoprotection step to form 187, which could be oxidized to 188, the 
target molecule. One advantage of this route was that either enantiomer would be 
accessible by the same route depending on which enantiomer of the chiral catalyst was 
used. Also, the two alcohols in 186 are equivalent because the molecule is C2-symmetric.  
Our proposed route in Scheme 52 differed from the standard processes in several 
ways. First, the starting materials are readily available on large scale as was the case with 
the common route shown in Scheme 49, but that didn’t translate well in our lab. Next, the 
stereochemistry is derived from a non-enzymatic catalyst, which has several advantages 
over an enzyme; both enantiomers of the target molecule could be made with equal ease 
using simple reaction conditions. Moreover, the Noyori reduction has considerable 
precedent on an industrial scale. Third, the key cyclic intermediate en route to the HCP is 
simply converted to the target HCP molecule in a minimal number of steps. 
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Scheme 52. Proposed route to HCP 
 
 We began with acetylacetone and followed the Organic Synthesis preparation to 
synthesize 1,5-dichloro-2,4-pentanedione 184 (Scheme 53).99 The resulting mixture was 
purified by distillation. Due to its instability, compound 184 was stored as the copper salt 
complex, 189. Complexation was accomplished by stirring with cuprous acetate 
(Cu(OAc)2), which formed a grey powder that was easy to handle and store. Prior to the 
subsequent Noyori reduction, 184 was unveiled by stirring the grey powder in a biphasic 
mixture of sulfuric acid (H2SO4) and ether.  
The Noyori reduction was performed in a large Par bomb apparatus under a 
pressure of 1250 psi of H2 gas. We used the S-BINAP version of the ruthenium catalyst 
because we desired the R stereochemistry at the alcohols. The resulting solution of the 
Noyori reduction was recrystallized from hexanes and DCM and produced 185 as 
beautiful white needle crystals. The literature value99 for the enantiomeric purity of 185 is 
>98% es for this process so we analyzed our solid by melting point and optical rotation to 
ensure our purity. The reported melting point is 85-86 °C, and we obtained a melting 
point of 83.6-85.5 °C. The reported optical rotation is [α]D = +21.1 (c 1.125, CHCl3), and 
we obtained an optical rotation of [α]D = +20.8 (c 1.125, CHCl3). With these data, we felt 
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confident in a high degree of enantiopurity and moved forward. The white crystals were 
stable and stored at room temperature until they were needed. 
 
OO OO
Cl Cl
OHOH
Cl Cl
184
OO
Cl Cl
189
Cu
2
AlCl3, PhNO2
ClCH2C(O)Cl
Cu(OAc)2
(S)-BINAP-Ru(II)Cl2
H2, MeOH
H2SO4, Et2O
185
60%
40%
 
Scheme 53. Preparation of (2R, 4R)-1,5-dichloro-2,4-pentanediol 
 
 The next step of the reaction sequence toward HCP was a Corey-Chaykovsky 
homologation reaction that converted the terminal chloro- to a terminal alkene (Scheme 
54).65 In that reaction, the trimethylsulfonium iodide (Me3SI) was freshly prepared from 
dimethylsulfide (DMS) and methyl iodide (MeI) followed by recrystallization from 
ethanol. The other key to preparing Me3SI was mixing the DMS and MeI in a plastic 
container because if glassware was used, the product had to be removed by breaking the 
glass flask and chipping away the glassware from the outside of the hard solid formed on 
the inside. The plastic container allowed for bending and flexing of the sides to loosen up 
the hard solid inside. 
 The freshly prepared Me3SI was deprotonated by n-BuLi at –40 °C to prepare the 
sulfonium ylide. After addition of 185, presumably an intermediate similar to 190 was 
formed. Elimination of DMS from each end of 190 formed 186. Aqueous workup of the 
reaction removed byproducts and salts. This was followed by the removal of DMS and 
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solvent by rotary evaporation to afford 186 in 95% yield. This material was usually pure 
by NMR without further purification but sometimes required column chromatography. 
The enantiopurity of 186 was analyzed by optical rotation; the literature value is [α]D =   
–29.9 (c 0.33, DCM) and we obtained a value of [α]
! 
23.6
D
 = –26.4 (c 0.33, DCM). 
 
OHOHOHOH
Cl Cl
OO
SMe2Me2S
Me3SI, n-BuLi
THF, -40 °C
95%
185 186190  
Scheme 54. Corey-Chaykovsky homologation 
 
 Initially we envisioned cyclizing 186 and then monoprotecting the resulting diol. 
Table 2 shows the results of the RCM conversion of 186 to 191. Three different 
ruthenium catalysts were tried: Grubbs I,101 Grubbs II,102 and Hoveyda–Grubbs II103 
(Figure 6). The reaction concentration for these reactions was 0.0075 M to promote an 
intramolecular ring closure because higher concentrations resulted in some cross 
metathesis i.e. polymerization or oligomerization. We achieved a yield of ca. 70% using 
Grubbs II under the conditions shown in entry 7 of Table 2 so we chose to move forward 
to the protection step. 
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Figure 6. Ring-closing metathesis catalysts 
 
Table 2. RCM of 186 
HO OHOHOH
186 191
conditions
 
Entry Catalyst Solvent Time/Temp Yield of 191 
1 Grubbs I DCM 48 h/rt 0% 
2 Grubbs II DCM 24 h/rt 71% 
3 Grubbs II MeOH:H2O (9:1) 24 h/rt 64% 
4 Grubbs II DCE 2 h/ 80 °C 10% 
5 Hoveyda-Grubbs II DCM 12 h/rt 50% 
6 Grubbs II MeOH:DCM (1:1) 12 h/rt 70% 
 
  
The next step in the sequence involved monoprotection of 191. At the outset, we 
expected that with dilute conditions and careful addition of one equivalent of the 
silylating agent, we could achieve a monoprotected product. However, this step proved 
more problematic than expected. Table 3 shows the results of the various monoprotection 
attempts. Initially we targeted a triisopropylsilyl ether as the protecting group, but some 
other silanes were tried also because all of the results were disappointing. 
As evident from Table 3, it became clear that monoprotection of 191 was not a 
tenable route for the production of cyclopentene 187. In all cases examined, the 
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monoprotection of one alcohol seemed to have little if any inhibitory effect on the second 
hydroxyl protection and led to the mixture of 187, 192 and starting material 191. At that 
point we decided to reformulate the protection strategy to increase the amount of 
monoprotection over the other two possible products.  
 
Table 3. Monoprotection attempts of 191 
HO OH
191
OSiR3HO
187
conditions OSiR3R3SiO
192
+
 
Entry Silane 
(equiv) Base 
Solvent 
(conc) Temp 
Yield 
of 187 
Yield of 
191 
Yield of 
192 
1 TIPSCl (1) Imidazole DMF  (0.5 M) rt 41% 47% 12% 
2 TIPSCl (1) Imidazole DCM  (0.1 M) 0 °C 23% NC 16% 
3 TIPSCl (1) Imidazole, DMAP 
DMF 
(0.05 M) 0 °C 39% NC NC 
4 TIPSCl (1) Imidazole, DMAP 
DMF 
 (1.0 M) 65 °C 44% NC 10% 
5 TIPSCl (2) Imidazole DMF  (1.0 M) 65 °C NO NO 99%* 
6 TIPSCl (2) DMAP DMF  (1.0 M) rt NO NO 99%* 
7 TBDPSCl (1.5) TEA 
THF  
(0.5 M) 60 °C NO 99%* NO 
8 TBDPSCl (1) DIPEA 
DMF 
(0.25 M) rt NO 99%* NO 
9 TBSCl (2) Imidazole DMF  (1.0 M) rt NO NO 85% 
10 TIPSOTf (1.5) 
2,6-
Lutidine 
THF  
(0.5 M) 0 °C 21% NC 10% 
11 TIPSCl (1) n-BuLi THF  (0.1 M) –78 °C 42% NC NC 
* Conversion by NMR 
NC = not calculated 
NO = not observed by crude NMR 
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 One observation we noticed was the large difference between 186 and 191 on 
TLC (ΔRf ca. 0.3), with 191 being more polar. The solubility was also different as 191 
was water soluble. That was likely due to the lack of intramolecular hydrogen bonding 
between the two alcohols in the cyclic diol as opposed to the ready formation of some in 
186. We decided to attempt the protection reaction on 186. 
 Table 4 shows the results of the attempts to monoprotect 186. Thermodynamic 
conditions with imidazole and DMAP were unproductive but kinetic deprotonation with 
n-BuLi provided a nearly quantitative conversion of 186 to the desired monoprotected 
product 193. With the success of monoprotecting diol 186, we reinvestigated the RCM 
reaction. 
 
Table 4. Monoprotection of 186 
OHOH
186
conditions
OTIPSOH
193
OTIPSTIPSO
194
+
 
Entry Silane 
(equiv) 
Base Solvent Temp Yield of 
193 
Yield of 
194 
1 TIPSCl (1) Imidazole DMF 80 °C 0% 0% 
2 TIPSCl (3) Imidazole, DMAP DCM rt 0% 99%* 
3 TIPSCl (1.2) 
Imidazole, 
DMAP DCM rt 50%* 50%* 
4 TIPSOTf 2,6-Lutidine DCM 0 °C 99%** - 
5 TIPSCl n-BuLi THF –78 °C 99% - 
* Conversion by NMR 
** Conversion by NMR but not able to be purified 
 
 The RCM reaction of 193 to 195 was successful although it occurred in moderate 
yield. Scheme 55 shows the endgame for the completion of the desired cyclopentenone 
 94 
(R)-181. For the RCM, either Grubbs I or Grubbs II worked equally well. An exhaustive 
screen of conditions was not conducted. The final step to synthesize the desired 
prostaglandin intermediate was an oxidation and we chose pyridinium dichromate (PDC), 
which worked well and was simple to run. The workup for the oxidation reaction 
required a series of filtrations.  Purification by column chromatography was utilized to 
remove any residual chromium. MnO2 has also been shown to achieve this oxidation.96,104 
The enantiomeric purity was determined to be >98% es by chiral GC analysis. Chiral GC 
separation: Astec Chiraldex B-DM fused silica capillary column, 30 m x 0.25 mm x 0.12 
µm, temperature gradient from 120 ºC→140 ºC ramping up at 0.25 ºC/min, tR = 44.13 
min, tS = 45.26 min. Also the optical rotation was measured of (R)-181 to be [α]
! 
25.2
D
 +53.3 
(c 1.05, MeOH), compared to a literature value of [α]D –58.8 (c 1.05, MeOH) for the 
enantiomer.104 
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Scheme 55. RCM and oxidation end game 
 
 We chose to form the TIPS-protected HCP (R)-181 because we needed the large 
steric bulk and stability under Lewis acid conditions for a reaction sequence presented in 
Chapter 4. We expect that the sequence could be extended to related protecting groups by 
a straight forward modification of the route. 
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3.4. Conclusion 
 
Herein, we described the novel route to the preparation of (R)-181. We generated 
the chirality from a Noyori reduction, which in principle allows synthesis of either the R 
or S enantiomer of the product. It was found that first monosilyation and subsequent 
cyclization gave (R)-181. The reaction sequence is scalable as most purification can be 
conducted by distillation or recrystallization. HCP, (R)-181, could be produced in six 
steps starting from acetylacetone. This sequence represents the shortest route to the 
enantiopure material. We utilized this cyclopentenone in an approach toward the total 
synthesis of (–)-cylindricine C (3) as described in Chapter 4. 
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Chapter 4 
 
Total Synthesis of (–)-Cylindricine C via a Tandem Diels–Alder/Schmidt Reaction 
 
4.1. Diels–Alder/Schmidt Reaction History 
 
As discussed in Chapter 2, the intramolecular Schmidt reaction takes place under 
Lewis or Brønsted acid conditions. The pairing of the intramolecular Schmidt reaction 
with other acid-mediated processes, like the Prins reaction was also outlined. In this 
chapter, the intramolecular Schmidt reaction was performed in tandem with a Diels–
Alder reaction to quickly construct a complex tricyclic lactam.  
The first example of a tandem Diels–Alder/Schmidt reaction was accomplished in 
2002 during a formal synthesis of (±)-stenine (Scheme 56).76 Scheme 56 outlines the key 
transformation that converted the triene 196 to the tricyclic lactam 198. In this sequence, 
the first step involved a Diels–Alder reaction between the diene and the enone to form 
bicyclic ketone 197. The second step involved the intramolecular Schmidt reaction 
between the ketone and the tethered azide. The order of reactivity was important in these 
tandem reactions since azides rarely add to the carbonyl of an enone.105 In this case, the 
yield represents a single diastereomer; one other diastereomer as well as a regioisomer 
were also isolated.  
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Scheme 56. First tandem Diels–Alder/Schmidt reaction toward the synthesis of stenine 
 
 Another variant of this reaction is depicted in Scheme 57. Here, three examples of 
an intermolecular Diels–Alder reaction in tandem with an intramolecular Schmidt 
reaction were demonstrated, with variation at the location of the azide tether.75 In Scheme 
57a, the azide was tethered to the β-position of enone 199. When 199 was combined with 
1,3-butadiene under Lewis acid conditions, Diels–Alder adduct 200 was formed, which 
then underwent an intramolecular Schmidt reaction to form bicycle 201. In Scheme 57b, 
where the azide was tethered to the α-position of enone 202, the Diels–Alder reaction 
formed intermediate 203, which underwent the intramolecular Schmidt reaction to form 
tricycle 204 in 85% yield. This example shows that simple starting materials like 202 and 
substituted butadienes can quickly form complex structures, like the aza-spirocenter in 
204.  
 In a third example, the azide tether resides on the diene rather than the enone 
(Scheme 57c). Diene 205 was combined with 2-cyclopenten-1-one under Lewis acidic 
conditions to form the Diels–Alder adduct 206, which underwent an intramolecular 
Schmidt reaction exclusively on the cyclopentane carbonyl to afford complex tricycle 
207. This type of Diels–Alder/Schmidt reaction was applied to another total synthesis of 
(±)-stenine106 and other Stemona alkaloids.107 The Diels–Alder/Schmidt chemistry was 
further utilized in the synthesis of chemical libraries based on the Stemona alkaloids.108  
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Scheme 57. Examples of intermolecular Diels–Alder/Schmidt reactions 
 
 The tandem Diels–Alder/Schmidt reaction has the ability to expeditiously 
construct a variety of complex bi- and tricyclic lactams. We chose to pursue a total 
synthesis of (–)-cylindricine C (3) using this methodology. 
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4.2. Retrosynthetic Analysis 
 
Our retrosynthetic analysis is depicted in Scheme 58. We envisioned the final 
steps of the total synthesis to involve functional group manipulations of 208 that would 
include reduction and alkylation of the lactam, conversion of the OTIPS group to a 
ketone, and a hydrogenation to accomplish both reduction of the cyclohexene and 
hydrogenolysis of the benzyl group. We anticipated 208 to arise from our key reaction, a 
tandem Diels–Alder/Schmidt reaction, between 210 and 1,3-butadiene that reacts through 
209. Since we planned to conduct an asymmetric synthesis, we intended to construct 210 
in enantiomerically pure form.  
 When considering the construction of 210, we sought to unite (R)-181 with either 
(S)-211 or (R)-212. We knew (R)-181 could be prepared in enantiomerically pure form 
from the methodology discussed in Chapter 3 and we chose the TIPS-protected variant to 
provide the maximum steric effect during the Diels–Alder reaction. In addition, we 
thought that a robust, bulky protecting group would have the best chance of surviving 
treatment with strong Lewis acid treatment. We wanted a convergent route to append the 
alkyl portion to the silyl-protected 4-hydroxy-2-cyclopenten-1-one (HCP). This would 
involve uniting an azide coupling partner (R)-181 with (R)-212 using either a Mukaiyama 
aldol or a Baylis–Hillman reaction. Alternatively, we could combine (R)-181 with (S)-
211 through a Suzuki-Miyaura coupling. The azide could not be used in the Suzuki-
Miyaura coupling because an allylic azide continuously undergoes a [3,3]-sigmatropic 
rearrangement at room temperature and therefore the preinstalled stereochemistry at that 
center would be stereoablated. The most convergent route would involve adding in a 
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synthon with the azide installed. Therefore, we began our investigation by attempting to 
combine (R)-181 with (R)-212. 
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Scheme 58. Retrosynthesis of (–)-cylindricine C (3) 
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4.3. Preparing the Azide for the Key Reaction 
 
4.3.1. Racemic Starting Materials 
 
 Our initial methodology development was conducted on racemic compounds, as 
they were easier and cheaper to make. We prepared racemic 181 from furfuryl alcohol 
following a procedure by Curran and coworkers as shown in Scheme 59.109 Furfuryl 
alcohol was treated with aqueous potassium dihydrogen phophate (KH2PO4) in a buffered 
solution with a pH of 4.1, which isomerized the furfuryl alcohol to 213 after heating. 
Also included in the Curran paper were results on the hydroxyl protection by a variety of 
protecting groups; TIPS was not one of the protecting groups discussed. Since we desired 
the TIPS-protected HCP, we tried multiple conditions using either TIPSCl or TIPSOTf 
and in both cases, the yields were between 0-20%. Although 213 could be made in 10 g 
batches, the disappointing yield of the TIPS protection led us to look elsewhere for a 
preparation of racemic 181.  
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Scheme 59. Furfuryl alcohol approach to racemic HCP 
 
 Since we wanted to prepare 181 in large quantities, we opted for the well-known 
procedure of Deardorff et. al. to prepare 179 (Scheme 60).94 From there, using 
procedures from Gracias and coworkers developed in our lab, we formed racemic 180.104 
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Treatment of 180 with K2CO3 and methanol formed 214. Subsequent oxidation with 
PDC, as done in Chapter 3, provided 181 in good overall yield and sufficient quantities.   
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Scheme 60. Preparation of (±)-181 
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4.3.2. Mukaiyama Aldol Approach 
 
 With 181 in hand, we set out to investigate a Mukaiyama aldol approach to 
prepare 210. We intended to follow a similar procedure to that used in a formal synthesis 
of (–)-lasubine accomplished in our lab.104 We sought to convert 215 to 218 according to 
the reaction sequence shown in Scheme 61. Mukaiyama aldol addition to 212 should 
afford 216 and subsequent dehydration would result in 217. We strongly desired the aldol 
addition and dehydration to occur in one pot for step economy, but we planned on 
investigating both one- and two-step processes. Finally, we anticipated isomerizing the 
double bond in 217 inside the cyclopentane ring to ultimately generate 218, our targeted 
intermediate for our key reaction. 
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Scheme 61. Desired Mukaiyama aldol approach 
 
Before we could begin our investigation, we needed to regioselectively prepare 
the silyl enol ether. As depicted in Scheme 62, we used Karstedt’s catalyst to achieve the 
silyl enol ether formation to make 215.104 Karstedt’s catalyst is a divinyltetramethyl-
disiloxane complex that, in the presence of triethylsilane (TES), converts an enone to a 
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silyl enol ether by delivering a hydride to the β-carbon of the enone and trapping the 
resulting enolate in a regioselective manner.  
We then attempted to adjoin 215 to 3-azidopropanal. To our disappointment, the 
best result obtained was 28% (Scheme 62). We tried a one-pot aldol addition/dehydration 
reaction, but under all conditions tried, including TiCl4, TMSOTf, and TsOH, we never 
observed any trace of the desired product. One potential problem could have been the 
instability of azides to high temperature required for dehydration reactions. Without any 
promising results, we opted to change our strategy. 
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Scheme 62. Mukaiyama aldol attempts 
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4.3.3. Baylis–Hillman Approach 
 
 The next reaction type we investigated involved the Baylis–Hillman reaction 
approach (Scheme 63). We envisioned 181 adding into aldehyde 212 to form 221. Two 
benefits of this process over the Mukaiyama aldol approach included (1) directly using 
181 instead of requiring an oxidation state adjustment like 215, and (2) forming the 
double bond in the desired location directly without requiring isomerization. However, 
the hydroxyl group formed in 221 would need to be removed in order to form 218. Since 
the azide could be installed prior to the Baylis–Hillman reaction, this route was still 
convergent and could theoretically afford the desired intermediate 218 quickly. 
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Scheme 63. Baylis–Hillman approach 
 
 We began our investigation of the Baylis–Hillman with a simple model study 
involving the reaction of 2-cyclopenten-1-one with 3-azidopropanal. Table 5 lists the 
results of the model study. Initially, we attempted the reaction only on 2-cyclopenten-1-
one and 3-azidopropanal and obtained no positive results. As a control, we repeated the 
results on benzaldehyde, a non-enolizable aldehyde known to undergo Baylis–Hillman 
reactions. Under some of the conditions investigated, the benzaldehyde reaction partner 
produced positive results, but we did not observe formation of an adduct between 2-
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cyclopenten-1-one and 3-azidopropanal under any conditions investigated. A variety of 
bases and solvent systems were investigated, but nothing worked as desired. At that 
point, we opted to change strategies again.  
 
Table 5. Baylis–Hillman reaction results 
O
O N3
+ or
O
base, solvent
O
R
OH
Aldehyde Base Solvent Desired product
azide PBu3 3:1 CHCl3/MeOH No
azide PBu3 7:3 THF/H2O No
benzaldehyde PBu3 3:1 CHCl3/MeOH No
benzaldehyde PBu3 7:3 THF/H2O Yes
azide DBU 7:3 THF/H2O No
benzaldehyde DBU 7:3 THF/H2O Yes
azide TMEDA 7:3 THF/H2O No
benzaldehyde TMEDA 7:3 THF/H2O No
azide DABCO 3:1 CHCl3/MeOH No
benzaldehyde DABCO 3:1 CHCl3/MeOH No
azide imidazole 7:3 THF/H2O No
benzaldehyde imidazole 7:3 THF/H2O Yes
azide DMAP 3:1 CHCl3/MeOH No
benzaldehyde DMAP 3:1 CHCl3/MeOH No  
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4.3.4. Suzuki–Miyaura Approach 
 
 We next investigated an approach based on the Suzuki–Miyaura reaction. Similar 
reactions have been published by Johnson and coworkers in syntheses of prostaglandins 
that involved 2-iodo-2-cyclopenten-1-ones (Scheme 64).92,110 In one example, 4-
benzyloxy-1-butene (223) was treated with 9-borabicyclo(3.3.1)nonane (9-BBN) to 
hydroborate the alkene and form the borane needed for the coupling reaction. Separately, 
222 was combined with the palladium catalyst followed by the borane solution and then 
an aqueous base solution of potassium phosphate. The Suzuki–Miyaura reaction 
produced 224, resulting from an sp2-sp3 coupling that was similar to our desired 
transformation. 
 
O
TBSO
OBn
I
+
a. 9-BBN
b. PdCl2(dppf)
    K3PO4, DMF/
    H2O/THF OBn
O
TBSO
72%
222
223
224  
Scheme 64. Johnson precedent92 
 
 The coupling reaction we hoped to achieve is outlined in Scheme 65. Beginning 
with (S)-211, hydroboration with 9-BBN would form borane 227. In parallel, the 
palladium(II) catalyst would be reduced to Pd(0) in situ, and would then undergo 
oxidative addition into the carbon-iodide bond of (R)-225 to form intermediate 226. 
Then, the borane would react with water to form the borate 227, which would undergo 
transmetallation with the palladium species 226 to form 228. Reductive elimination of the 
palladium should regenerate the Pd(0) catalyst and form the desired product, 229. From 
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229, we figured a simple deprotection of the hydroxyl group and conversion to the azide 
would form 210, given an appropriate protecting group for the alcohol. Before we began 
work on the completely functionalized system, we investigated a model system. 
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Scheme 65. Catalytic cycle for desired Suzuki-Miyaura coupling 
 
 The initial step was investigated as shown in Scheme 66. We first wanted to 
develop conditions for the hydroboration reaction because the borane would be prepared 
in situ for the coupling reaction. We first treated allyl alcohol with 1.2 equiv of 9-BBN in 
a 0.5 M solution of THF, Scheme 66a. The reaction was stirred at room temperature for 
12 h and then heated to 60 °C for three hours, but only starting material was recovered. 
We then attempted the reaction on commercially available allyl tert-butyldimethylsilyl 
ether under the same conditions, Scheme 66b, and again, no hydroboration was observed. 
The reaction concentration was increased, Scheme 66c, and still no reaction was 
observed. Finally, the 9-BBN solution was added to the neat alkene, Scheme 66d, and 
 109 
after 12 h at rt all of the alkene was consumed as determined by NMR analysis of the 
crude reaction mixture. The neat conditions were also tried on commercially available 
allyl acetate with successful hydroboration reactivity. From this set of experiments, we 
determined it was necessary to carry out the hydroboration without adding solvent 
beyond that already present in the 9-BBN reagent.  
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1.2eq 9-BBN/THF
0.5 M THF, 60 °C No reaction
OTBS
1.2 eq 9-BBN/THF
0.5 M THF, 60 °C No reaction
OTBS
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1.1eq 9-BBN/THF
neat, rt, 12 h
All alkene used
OAc
1.2eq 9-BBN/THF
neat, rt, 12 h All alkene used
(a)
(b)
(c)
(d)
(e)
 
Scheme 66. Hydroboration investigation 
 
 Next, we attempted incorporating the hydroboration step using 2-iodo-2-
cyclopenten-1-one, 230, prepared from iodination of 2-cyclopenten-1-one following a 
procedure from Krafft and coworkers.111 Scheme 67 depicts the initial attempts at the 
Suzuki–Miyaura reaction using allyl tert-butyldimethylsilyl ether and 230. Having 
figured out the hydroboration step, we could do a controlled study of the actual coupling 
conditions. We chose [1,1’-bis(diphenylphosphino)ferrocene]dichloropalladium(II) 
(PdCl2(dppf)) as the catalyst as this is the catalyst used by Johnson and coworkers for a  
similar type of sp2-sp3 coupling.92 Different bases were tried, including NaOH, Cs2CO3, 
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and K3PO4. A variety of different solvents and solvent mixtures of water, DCM, DMF, 
and THF were investigated. A range of temperatures was tried, including rt, 40 °C, 60 °C 
and 75 °C. The reaction was ran with and without triphenylarsine as an additive. All of 
these reactions were attempted with 230 as the limiting reagent with the alkene 
equivalents ranging from 1.1 to 5. For all the reactions tried, no more than a trace amount 
of the coupled product was observed.  
 
+
O
I
OTBS
a. 9-BBN/THF
    neat, rt, o/n
b. PdCl2(dppf)
    base, additive
    DMF, temp Little to no coupling 
product detected
230  
Scheme 67. Unsatisfactory coupling results 
 
 Next tried was to switch the limiting reagent to the alkene in the presence of 1.5 
equiv of 230 (Scheme 68). This was not a desirable change because in the functionalized 
system the cyclopentenone component was the most difficult to make. However, we 
obtained the desired product 231 in 60% yield using 3 M K3PO4 as the base and with no 
additive. We also attempted the reaction on allyl acetate for comparison of the protecting 
groups and formed 232, albeit at a lesser yield of 33%.  
 
 111 
O
+
O
I
OTBS
60% OTBS
OAc +
O
I
O
33%
same
OAc
a. 9-BBN/THF
    neat, rt
b. PdCl2(dppf)
    3M K3PO4
    DMF, rt
230
230
231
232
 
Scheme 68. Successful coupling results 
 
 With the success of the Suzuki–Miyaura reaction on a model system, we sought to 
incorporate more functionalization and work up to the fully-functionalized reaction in a 
systematic manner. Shown in Scheme 69 is the coupling reaction with the functionalized 
cyclopentenone, 225, which was prepared from 181 with iodine and pyridine (pyr) in 
ether. The coupling of 225 with allyl tert-butyldimethylsilyl ether achieved the desired 
product 233 in 55% yield. This was significant because the TIPS group is large and it was 
reassuring to know that steric hindrance did not decrease the reactivity.  
 
O
I2, pyr
Et2O
O
I
85%
9-BBN
PdCl2(dppf),
3M K3PO4,
DMF, rt
55%
TIPSO TIPSO
O
OTBS
TIPSO
OTBS
181 225 233  
Scheme 69. Suzuki–Miyaura reaction with 225 
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 Before attempting to prepare the completely functionalized system, we did one 
more model study, in which 2-cyclopenten-1-one was treated with the 3,4-dihydroxy-1-
butene synthon. Scheme 70 shows the preparation of racemic 4-benzyloxy-3-hydroxy-1-
butene, 234, from benzyloxyacetaldehyde using vinylmagnesium bromide, a reaction 
developed by Ghosh and coworkers.112 With 234 in hand, we began to investigate the 
Suzuki–Miyaura coupling reaction with 2-cyclopenten-1-one. 
 
O
H
OBn
MgBr
OH
OBn
234
88%
THF, 0 °C
 
Scheme 70. Formation of 4-benzyloxy-3-hydroxy-1-butene 
 
 As depicted in Scheme 71, we used a variety of different protecting groups on the 
secondary hydroxyl group on 234. We initially attempted to couple 234 with 230, but no 
coupling product was detected using 1.2 equiv of 9-BBN. This was a slight obstacle 
because in order to accomplish the coupling, a third protecting group (TIPS and Bn being 
the other two) was going to be needed. Ideally we wanted an easily removed protecting 
group to ensure that the TIPS group remained in place. The first group we tried was a 
TMS protecting group, shown in Scheme 71, because it is labile and could be easily 
removed in a workup step and would not add steps to the linear sequence. We converted 
234 to 235 by treatment with TMSCl and TEA in THF. We submitted the TMS-protected 
allylic alcohol with 2-cyclopenten-1-one to Suzuki–Miyaura conditions to determine if 
coupling could be achieved. NMR analysis of the crude reaction mixture indicated no 
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coupling had occurred and the TMS group was removed. Obviously, this was not going 
to be a productive pathway, so we moved on to a different protecting group.  
The next protecting group we tried was a triethylsilane (TES) group (Scheme 71). 
The TES group is slightly more stable than the TMS group but can still be easily removed 
under mild acidic conditions. The conversion of 234 to 236 was performed using TESCl 
and pyridine in DCM. Silyl alcohol 236 was treated with the same coupling conditions as 
described in schemes 68, 69 and 71. Crude reaction analysis by NMR also indicated no 
coupling product and the TES group was again removed.  
Continuing on, we moved away from a silyl protecting group and tried an acetate. 
Scheme 71c shows the protection of 234 under standard conditions of Ac2O, pyridine and 
catalytic dimethylaminopyridine (DMAP) in DCM to form 237. Under the same reaction 
conditions, we combined 237 with 230 and unfortunately the same results as in (a) and 
(b) were observed: no coupling product was observed and the acetate group was 
removed. Clearly, the basic conditions required for the Suzuki–Miyaura reaction were 
removing the protecting groups tried. Our strategy needed to be modified to use a much 
more robust protecting group that could survive the basic conditions. 
Shown in Scheme 71, we opted for a TBS group because we knew it worked in 
the previous examples done on simpler systems (Schemes 68 and 69), despite the 
likelihood that removing it would a step instead of just using a workup. Also, we were 
not confident about the selective deprotection of the secondary acyclic OTBS in the 
presence of the secondary cyclic OTIPS group. Nonetheless, we moved forward anyway 
because we were most concerned with accomplishing the coupling reaction. We prepared 
238 from 234 using TBSCl and imidazole in DMF following a procedure from Yadav 
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and coworkers.113 With 238 in hand, we proceeded with the Suzuki–Miyaura reaction 
using the conditions developed and isolated the coupled product 239. With this coupling 
result accomplished, the next step was to attempt the coupling on the fully-functionalized 
system. However, before we committed to the idea of needing the third protecting group, 
we tried one more option. 
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Scheme 71. Suzuki–Miyaura reaction with functionalized alkene 
 
 Perhaps instead of protecting the two alcohols of the alkene synthon separately, 
we could protect them as one. We looked into the possibility of using a benzylidene 
protecting group on the 3,4-dihydroxybutene (Scheme 72). 3,4-Dihydroxybutene could 
be protected with benzaldehyde to form 240 following a procedure by Buono and 
coworkers.114 Suzuki–Miyaura coupling with 225 would afford 241 and a single hydride-
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mediated reduction would unveil 242. The alcohol in 242 could then be converted to the 
desired azide 218 in one or two steps. Another attribute of 242 is the terminal benzyloxy 
group, which we desired because it could be removed in the last step along with the 
hydrogenation of an alkene and would not require a separate step to be removed (Section 
4.2). 
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Scheme 72. Benzylidene protecting group idea 
 
 Accordingly, we prepared 240 following literature precedent, albeit at a dismal 
yield that moreover seemed to be irreproducible (Scheme 73).114 However, with some 
240 to work with, we attempted the coupling reaction under the standard conditions with 
230, which afforded 243 in good yield. However, when we took this reaction one step 
further to attempt the monodeprotection with diisobutylaluminum hydride (DIBAL),114 
the carbonyl was reduced rather than the benzylidene to form 244. With the disappointing 
reduction result and the difficulty to reproduce 240, we abandoned this approach and 
returned to the TBS protection strategy. 
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Scheme 73. Benzylidene protecting group attempt 
 
Since other protecting groups were unpromising, a TBS protecting group was 
examined. Pleasingly, when we combined 238 and 225, we not only achieved the desired 
coupling product 245, but also in a high yield of 70%, in a 1:1 a mixture of diastereomers 
(Scheme 74). We were not concerned with the diastereomeric mixture at this point 
because for the total synthesis, we would be coupling together enantiomerically pure 
materials. With the coupling step worked out, we could move forward with the total 
synthesis. 
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Scheme 74. Suzuki–Miyaura reaction for functionalized system 
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4.3.5. Conversion to Desired Azide 
 
In order to begin investigation on the tandem Diels–Alder/Schmidt reaction, we 
first needed to deprotect the silyl ether of 245 to afford alcohol 242. We felt this should 
be a straightforward deprotection as a TBS is known to be deprotected faster than a TIPS 
group under acidic, basic and fluoride conditions.115 As depicted in Scheme 75, we first 
tried deprotection using 1% HCl in ethanol. We achieved the selective deprotection in a 
70% yield to afford 242 as a 1:1 mixture of diastereomers but we were hoping for a better 
result. When we tried the deprotection under basic conditions of 5% NaOH in EtOH 
(Scheme 75), the result was a messy mixture of products. We finally tried deprotection 
with TBAF (Scheme 75) and observed solely the selective deprotection of the TIPS 
group, 246. Therefore we returned to acidic conditions; when pyridinium p-
toluenesulfonate (PPTS) was used, we received similar yields to the HCl conditions, 
however, they were much more reproducible. A byproduct we noticed from these 
reactions resulted from conjugate addition of the alcohol onto the cyclopentenone. 
Accepting these conditions and yields as sufficient, we moved on to conversion of the 
alcohol to the azide. 
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Scheme 75. Removal of TBS protecting group 
 
 With 242 in hand, we next sought to convert the free hydroxyl group to the azide 
functionality. Initially we wanted to achieve this transformation in a one-step procedure 
for step economy, which can be accomplished with diphenylphosphoryl azide (DPPA). 
However, under a variety of conditions, using DPPA, a 44% yield was the maximum 
achieved. Although one step is good for step economy, a 44% yield would be a large 
material depletion at this stage in the synthesis. 
 To improve the yield, we tried a two-step sequence to convert the alcohol to the 
azide (Scheme 76). First, 242 was treated with methanesulfonyl chloride (MsCl) and 
TEA to mesylate the hydroxyl group, 247. In the second step, we treated the mesylate 
with sodium azide (NaN3) and DMSO. Both steps in Scheme 76 followed a procedure 
from Molander and coworkers.26 Mesylate 247 was converted with ease to 218 in a two-
step yield of 98%. Therefore, although there are two steps to convert the alcohol to the 
azide, the yield is almost quantitative. Also, no purification was needed between the two 
steps as both of the reactions were clean.  
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Scheme 76. Conversion to the desired azide 
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4.4. Diels–Alder/Schmidt Reaction 
 
Prior to accessing 218, we were able to synthesize tethered azides on the model 
systems. Shown in Scheme 77, compound 231 was deprotected to alcohol 248 with 
TBAF although the yield was poor. The spectral data for 248 matched that in the 
literature.116 We subsequently converted the alcohol 248 to azide 249 using DPPA; the 
spectral data matched the literature values.77 With 249 in hand, we were able to attempt 
the Diels–Alder/Schmidt reaction. Using a procedure previously published by this group, 
this involved bubbling gaseous 1,3-butadiene through a solution of the azide in 0.1 M 
DCM at 0 °C.75 The solution was then treated with methylaluminum dichloride. After the 
reaction was stirred at 0 °C and allowed to warm up to room temperature, most of the 
solution became a solid mass as the butadiene polymerized. In order to attempt extracting 
the reaction, the solid gelatinous mass was ground up in a mortar and pestle with sand. 
This allowed for some release of any non-polymeric molecules from the solid matrix. The 
ground up solid was extracted with DCM and filtered. We tried the reaction again using a 
much more dilute concentration of 0.025 M and we were able to avoid the gelatinous 
mass and isolate the desired product, 250, in 63% yield. 
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Scheme 77. Diels–Alder/Schmidt reaction on basic model system 
 
 With the result shown in Scheme 77, we were confident about the tandem Diels–
Alder/Schmidt reaction on the fully functionalized system (Scheme 78). We used the 
same conditions as for the unfunctionalized system except we used a solution of 1,3-
butadiene instead of bubbling gaseous butadiene, which allowed for more control over 
the number of equivalents used in order to avoid any gelatin formation. From 218, we 
achieved the formation of 251 in 71% yield. An interesting outcome of the reaction was 
that two diastereomers of 218 went into the reaction and two diastereomers came out in a 
near 1:1 ratio. This confirms that the Diels–Alder reaction is facially selective, with 
addition to one side of the cyclopentenone as the other face is blocked by the allylic silyl 
ether. 
 
AlMeCl2, DCM
71%
N
TIPSO
OBn
O
O
TIPSO
OBn
N3
218
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Scheme 78. Diels–Alder/Schmidt reaction on functionalized system 
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4.5. Enantiomerically Pure Synthesis Toward (–)-Cylindricine C 
 
Our asymmetric synthesis begins with the starting material described in Chapter 
3, (R)-181, which was converted to iodide (R)-225 as shown in Scheme 69. The 
asymmetric alkene used in the Suzuki–Miyaura reaction was prepared from (R)-(+)-
glycidol (Scheme 79), which was treated with sodium hydride (NaH) and benzyl bromide 
(BnBr) to form (R)-252. Homologation of (R)-252 using a Corey-Chaykovsky reaction 
with trimethylsulfonium iodide and n-BuLi afforded (S)-234 in excellent yield.117 At this 
stage, analysis of the enantiopurity was >98% es determined by chiral GC analysis. 
Chiral GC separation: Astec Chiraldex B-DM fused silica capillary column, 30 m x 0.25 
mm x 0.12 µm, isothermal temperature of 115 ºC, tS = 42.39 min, tR = 43.60 min. Also, 
an optical rotation was determined of [α]
! 
24.7
D
 –3.3 (c 1.6, CHCl3), compared to the 
literature value of [α]D +6.2 (c 1.6, CHCl3) of the enantiomer.113 From (S)-234, 
protection with a TBS group formed (S)-238, the alkene synthon in the Suzuki–Miyaura 
coupling reaction. Although (R)-238 is a known compound in the literature, the optical 
rotation was not reported. We determined the optical rotation for (S)-238 to be [α]
! 
24.4
D
      
–17.0 (c 1.17, CHCl3). 
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Scheme 79. Preparation of (S)-238 
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 With the two synthons for the coupling reaction in hand and in enantiomerically-
pure form, we progressed with the coupling. Scheme 80 shows the results of the coupling 
reaction between (S)-238 and (R)-225 to afford (R,S)-245 in 88% yield. PPTS was used to 
remove the TBS group to form (R,S)-242. The hydroxyl group was quantitatively 
converted to the azide with inversion of configuration, (R,R)-218. The tandem Diels–
Alder/Schmidt reaction occurred in good yield to ultimately form a single diastereomer of 
251. From here, we envisioned only a couple more steps to complete the total synthesis. 
 
OTBS
OBn
+
O
I
TIPSO
88%
O
TIPSO
1. MsCl, TEA
2. NaN3, DMSO
70% 71% for 
2 steps
PPTS
AlMeCl2, DCM
67%
N
TIPSO
OBn
O
OBn
OTBS
O
TIPSO
OBn
OH O
TIPSO
OBn
N3
(S)-238 (R)-225 (R,S)-245
(R,R)-218(R,S)-242
(R,S,R,R)-251
a. 9-BBN
b. PdCl2(dppf)
    K3PO4, DMF/
    H2O/THF
 
Scheme 80. Asymmetric tricyclic lactam construction 
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4.6. Final Approach 
 
Our initial attempts to complete the synthesis of (–)-cylindricine C (3) are 
depicted in Scheme 81. From (4R,5R,10S,13R)-251, we intended to functionalize the 
lactam by hexylmagnesium bromide addition followed by a hydride to form tertiary 
amine (2S,4R,5R,10S,13R)-254. We envisioned the desired stereochemical outcome to 
result from a hydride delivery to the iminium 253 as shown because there seem to be less 
diaxial interactions from the face of the cyclohexene. From 254, removal of the TIPS 
group and oxidation of the unveiled hydroxyl group would complete the installation of 
the distal carbonyl, 255. The last step would be a global hydrogenation to saturate the 
alkene and hydrogenolysis to complete the total synthesis.  
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Scheme 81. Proposed end game 
 
 Scheme 82 shows the attempts at functionalizing the lactam. Scheme 82a 
represents the results of multiple reactions where hexylmagnesium bromide was added to 
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251 along with a hydride source. Although the order of addition was tried both ways 
between the Grignard and the hydride source, the results were either 256 or 257. These 
results are unsatisfactory because the hydroxyl was necessary for the installation of the 
carbonyl.  
 The addition of an alkynyl lithiate was then attempted (Scheme 82b), used 
because it is small and linear.23 However, only 256 was observed as before. Scheme 82c 
utilizes triflic anhydride (Tf2O) to first activate the amide for hydride addition followed 
by Grignard addition but again, only 256 was observed from the crude reaction 
mixture.118 In Scheme 82d we tried using Schwartz’s reagent following a precedent by 
Spletstoser et. al.,119 however, no reaction occurred. Scheme 82e represents what 
happened when LAH was added: complete reduction of the lactam and hydroxy group 
occurred to form 258.  
 Unfortunately, nothing we tried produced the outcome we were looking for. In 
order to complete this total synthesis, further investigation into the lactam 
functionalization will be necessary. 
 126 
N
TIPSO
OBn
O
(4R,5R,10S,13R)-251
a. C6H13MgBr
b. DIBAL N
OBn
O
or
N
OBn
256 257
(4R,5R,10S,13R)-251
C4H9Li
256
(4R,5R,10S,13R)-251 256
a. Tf2O, DTBMP
b. DIBAL
c. HexylMgBr
(4R,5R,10S,13R)-251 No Reaction
a. Cp2ZrCl(H)
b. HexylMgBr
(4R,5R,10S,13R)-251
LAH N
OBn
258
(a)
(b)
(c)
(d)
(e)
 
Scheme 82. Unsatisfactory attempts to functionalize the lactam 
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4.7. Conclusion 
 
We have developed a novel asymmetric route toward the ring system of (–)-
cylindricine C (3). Key steps were a Suzuki–Miyaura cross coupling and a key 
diastereoselective tandem Diels–Alder/Schmidt reaction, which quickly assembled the 
functionalized tricyclic core. Further investigation will be necessary to complete the total 
synthesis of (–)-cylindricine C (3). 
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Chapter 5 
 
Conclusions 
 
In this dissertation, the development of a tandem Prins/Schmidt reaction for the 
rapid construction of [5.6.6] tricyclic lactams containing four stereocenters has been 
described. Using this chemistry, we observed the formation of only three of eight 
possible diastereomers. The major diastereomer was purified and subsequently used in a 
formal synthesis of lepadiformine A and additionally completed the first total synthesis of 
lepadiformine C in ten total steps and 10% overall yield. Although the yields of the 
developed methodology were low, the high molecular complexity achieved was 
noteworthy and the stereochemical diversity was interesting and unexpected. The tandem 
Prins/Schmidt methodology is currently being used for library development. 
We also developed an approach to the versatile prostaglandin precursor, 4-
hydroxy-2-cyclopenten-1-one, which has been used in multiple prostaglandin syntheses. 
This concise route can afford either enantiomer in high enantiopurity (>98% es) in six 
steps instead of the standard seven or nine steps reported for the S- and R- enantiomers, 
respectively. The stereocenters were set with a Noyori reduction and the ring formed by 
ring closing metathesis. This short process involves inexpensive, readily available 
materials with the potential of being used in a process setting for large-scale production 
of prostaglandin therapeutics. 
Finally, we explored the use of a tandem Diels–Alder/Schmidt reaction toward the 
synthesis of (–)-cylindricine C. The enantiopure R-4-hydroxy-2-cyclopenten-1-one was 
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subjected to a Suzuki-Miyaura coupling reaction for the construction of the key 
precursor. The Diels–Alder reaction was highly diastereoselective. The lactam 
functionalization finishing strategy has not been successful. Efforts are currently 
underway to conclude the total synthesis of (–)-cylindricine C. 
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Chapter 6 
 
Experimental Procedures 
 
General Information:  All reactions were performed under an argon atmosphere in 
flame-dried glassware.  The stainless steel needles used for handling anhydrous solvents 
and reagents were oven dried and flushed with dry argon prior to use.  Plastic syringes 
were flushed with dry argon before use.  Methylene chloride and tetrahydrofuran were 
purified using a solvent purification system.120 Materials that were purchased from 
commercial sources were used without further purification.  All nuclear magnetic 
resonance spectra were recorded on Bruker spectrometers.  These spectrometers include 
Bruker AV 400, Bruker AV-III 500, Bruker DRX 400, and Bruker Avance 800.  All 
NMR samples were recorded in deuterochloroform.  Chemical shifts are reported in parts 
per million (ppm) and are referenced to the deuterosolvent centerline of 
deuterochloroform (δ 7.26 ppm 1H NMR, 77.0 ppm 13C NMR).  Structure elucidations 
were assigned based on DEPT, COSY, HSQC, HMQC, and NOESY spectra. Coupling 
constants are given in Hertz (Hz).  IR was taken with a Shimadzu FTIR-8400S.  Melting 
points were determined using a Staford Research Systems Optimelt Automated melting 
point system.  Low-resolution mass spectra (ESI) and high resolution mass spectra 
(HRMS) were taken using a Waters LCT Premier Micromass from MS Technologies.  
GC was performed on an Agilent Technologies 6850 Network GC System with a 5975C 
VL MSD triple-axis detector. 
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Chapter 2 Experimental Section 
 
N3
O
OMe
122a
N3
O
OMe
122b
N3
O
OMe
122c  
(3R*,4R*,5S*)-5-(3´-Azido-1´-methoxypropyl)spiro[3.5]nonan-1-one (122a), 
(3S* , 4R*,5S*)-5-(3´-azido-1´-methoxypropyl)spiro[3.5]nonan-1-one (122b), and 
(3S*,4S*,5S*)-5-(3´-azido-1´-methoxypropyl)spiro[3.5]nonan-1-one (122c). To a 
stirred solution of 3-azido-1,1-dimethoxypropane (220 mg, 1.5 mmol) and (1-
cyclohexenylcyclopropoxy)trimethylsilane79 (210 mg, 1.0 mmol) in DCM (10 mL) at –78 
°C was added 1.0 M TiCl4 in DCM (1.5 mL). Ether (10 mL) and brine (10 mL) were 
added to the reaction after 2 h, which was then allowed to warm to rt. The aqueous layer 
was extracted 3× with ether, dried with Na2SO4, filtered, and concentrated. The resulting 
yellow oil was purified by silica gel chromatography (10% EtOAc/hexanes), to afford a 
yellow oil (82%) that contained three diastereomers in a ca. 10:4:1 ratio (estimated by 13C 
NMR of the crude reaction mixture). For mixture: IR (neat) 2092, 1768 cm-1; MS (ES+) 
m/z 274 (M++H); HRMS calculated for C13H22N3O2 (M++H): 274.1531, found 274.1428. 
122a: Rf = 0.28 (20% EtOAc/hexanes); 1H NMR (400 MHz, CDCl3) δ 0.90 (distorted qd, 
J = 12.4, 3.2 Hz, 1H), 1.19 (m, 2H), 1.39 (distorted t, J = 12.8 Hz, 1H), 1.51-1.74 (m, 
6H), 1.80 (ddd, J = 12.8, 10.0, 3.6 Hz, 1H), 1.87-1.98 (m, 2H), 2.86 (m, 2H), 3.12 (m, 
1H), 3.20 (s, 3H), 3.31 (t, J = 7.2 Hz, 2H); 13C NMR (100.6 MHz, CDCl3) δ 18.2, 21.8, 
25.1, 26.1, 28.7, 33.8, 41.2, 44.2, 46.8, 55.9, 66.8, 80.0, 214.6. 122b (containing ca. 12% 
of 122c): Rf = 0.40 (20% EtOAc/hexanes); 1H NMR (400 MHz, CDCl3) δ 1.15-1.40 (m, 
3H), 1.46 (m, 1H), 1.60-1.80 (m, 9H), 2.34 (m, 1H), 2.87 (ddd, J = 16.0, 12.0, 4.0 Hz, 
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1H), 3.00 (ddd, J = 20.0, 12.0, 8.0 Hz, 1H), 3.16 (m, 2H), 3.28 (s, 3H), 3.31 (t, J = 6.8 
Hz, 2H); 13C NMR (100.6 MHz, CDCl3) δ 19.8, 22.0, 22.8, 25.7, 31.1, 34.6, 42.2, 43.2, 
48.3, 57.5, 69.2, 80.0, 216.6. 7c: Rf = 0.44 (20% EtOAc/hexanes); 1H NMR (400 MHz, 
CDCl3) δ 1.47−1.77 (m, 11H), 1.95 (m, 1H), 2.23 (ddd, J = 10.8, 9.2, 7.2 Hz, 1H), 2.89 
(ddd, J = 8.8, 7.2, 1.2 Hz, 2H), 3.29 (s, 3H), 3.37-3.42 (m, 3H); 13C NMR (100.6 MHz, 
CDCl3) δ 22.9, 23.3, 25.3, 25.8, 31.4, 35.5, 41.3, 46.2, 48.0, 57.7, 66.9, 79.4, 214.7. The 
stereochemical determination of compound 122a was determined via an SN2 
displacement reaction of the corresponding bromide (compound 117 reported by Cha and 
coworkers80) using NaN3 (structure of 117 proven by X-ray crystallography). 
 
N
O
OMe
123b  
(7S*,7aS*,111R*)-7-Methoxyoctahydro-1H-pyrrolo[1,2-j]quinolin-3(2H)-one 
(123b). To a stirred solution of cyclobutanone 122b (39 mg, 0.16 mmol) in DCM (1 mL) 
at 0 °C was added 1.0 M TiCl4 in DCM (0.8 mL). The reaction was stirred overnight at rt. 
The reaction was partitioned between ether (5 mL) and aqueous NH4Cl (5 mL). The 
aqueous layer was extracted with DCM (3×), washed with brine, dried with MgSO4, 
filtered, and concentrated. Purification by silica gel chromatography with 100% EtOAc 
afforded 36 mg (99%) of 123b (containing ca. 12% minor diastereomer 123c). Rf = 0.13 
(20% EtOAc/hexanes); IR (neat) 1687 cm-1; 1H NMR (500 MHz, CDCl3) δ 1.09 (qd, J = 
12.5, 3.5 Hz, 1H), 1.30 (m, 1H), 1.41 (m, 1H), 1.47 (m, 1H), 1.54 (m, 1H), 1.66 (m, 1H), 
1.71-1.80 (m, 4H), 1.95 (m, 1H), 2.04 (dd, J = 12.5, 7.5 Hz, 1H), 2.19 (dd, J = 16.5, 9.0 
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Hz, 1H), 2.32 (m, 1H), 2.49 (ddd, J = 16.5, 12.5, 8.0 Hz, 1H), 2.94 (ddd, J = 13.5, 11.0, 
6.5 Hz, 1H), 3.11 (ddd, J = 11.5, 8.0, 6.0 Hz, 1H), 3.27 (s, 3H), 3.95 (dd, J = 13.5, 8.0 
Hz, 1H); 13C NMR (126 MHz, CDCl3) δ 22.5, 23.6, 25.6, 26.2, 30.5, 31.0, 33.2, 34.2, 
47.4, 56.5, 63.3, 74.2, 175.6. MS (ES+) m/z 224 (M++H); HRMS calculated for 
C13H22NO2 (M++H): 224.1651, found 224.1468. 
 
Hi
N
O
He
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Hc
Hf
Hj
Hb
1
2 3
4
5
10
Hg
Hd
OMe
Hk Hh
 
  
Structure determination of 123b. The structure for compound 123b was 
determined beginning with the NOE between Hd and Hj. As the J values for Hd (11.5, 8.0, 
6.0 Hz) indicate an axial orientation, this NOE supports the trans-fused aza-decalin 
system. Further support includes NOEs observed between Hj with Hf and Hh, as well as 
Hd with Hf. The boat-like shape of the piperidine ring is supported by an NOE between 
Ha and He.  
 
N
O
OMe
123c  
(7S*,7aS*,111S*)-7-Methoxyoctahydro-1H-pyrrolo[1,2-j]quinolin-3(2H)-one 
(123c). To a stirred solution of 140 (33 mg, 0.16 mmol) in THF (3 mL) was added 60% 
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NaH in mineral oil (8.5 mg, 1.2 mmol). After 10 min, MeI (0.02 mL, 2.0 mmol) was 
added and the reaction was allowed to stir over night at ambient temperature. The 
reaction was quenched with water (3 mL) and the phases separated. The organic phase 
was washed with EtOAc (3×), dried with Na2SO4, filtered, and concentrated to afford a 
yellow oil (35 mg, 99%). Rf = 0.10 (25% EtOAc/hexanes); IR (neat) 1660 cm-1; 1H NMR 
(400 MHz, CDCl3) δ 0.88 (m, 1H), 1.17-1.53 (m, 8H), 1.75 (m, 2H), 2.18 (m, 2H), 2.38 
(m, 2H), 2.75 (distorted t, J = 13.6 Hz, 1H), 3.39 (s, 3H), 3.54 (td, J = 10.8, 4.0 Hz, 1H), 
4.14 (ddd, J = 13.6, 5.2, 2.0 Hz, 1H); 13C NMR (100.6 MHz, CDCl3) δ 19.6, 22.2, 23.1, 
29.1, 29.5, 29.6, 30.4, 34.7, 48.6, 56.7, 62.7, 74.9, 172.6; MS (ES+) m/z 224 (M++H); 
HRMS calculated for C13H22NO2 (M++H): 224.1610, found 224.1644.  
 
N3OMe
MeO
127  
3-Azido-1,1-dimethoxynonane (127). To a stirred solution of 3-azidononanal 
(975 mg, 5.33 mmol) and MeOH (6 mL) at 0 °C was added a spatula tip of p-
toluenesulfonic acid and trimethylorthoformate (1.27 mL, 11.6 mmol). The reaction was 
allowed to warm to rt overnight. MeOH was removed under rotary evaporation and the 
remaining residue was diluted in ether and NaHCO3. The aqueous layer was extracted 
with ether (3×), washed with brine, dried with Na2SO4, filtered and concentrated. A clear 
oil was obtained (94%). Rf = 0.80 (25% EtOAc/hex); IR (neat) 2104 cm-1; 1H NMR (400 
M Hz, CDCl3) δ 0.88 (distorted t, J = 7.2 Hz, 3H), 1.21-1.45 (m, 7H), 1.49-1.58 (m, 3H), 
1.75 (m, J = 14.4, 7.6, 4.0 Hz, 2H), 3.35 (s, 3H), 3.37 (s, 3H), 3.38 (m, 1H), 4.54 (dd, J = 
4.0, 7.6 Hz, 1H); 13C NMR (100.6 M Hz, CDCl3) δ 13.9, 22.5, 25.8, 28.9, 31.6, 34.7, 
 135 
37.6, 53.0, 53.4, 59.4, 102.2; MS (FAB+) m/z 230 (M++H); HRMS calculated for 
C11H24N3O2 (M++H) 230.1869, found 230.1858. 
 
O
N3
OMe C6H13
128  
5-(3´-Azido-1´-methoxynonyl)spiro[3.5]nonan-1-one (128; complex isomeric 
mixture). To a stirred solution of 3-azido-1,1-dimethoxynonane (244 mg, 1.5 mmol) and 
(1-cyclohexenylcyclopropoxy)trimethylsilane (210 mg, 1.0 mmol) in DCM (10 mL) at –
78 °C was added 1.0 M TiCl4 in DCM (1.5 mL). The reaction was allowed to stir for 2 h, 
at which time ether and brine were added and the solution was allowed to warm to rt. The 
aqueous layer was extracted 3× with DCM, dried with Na2SO4, filtered and concentrated. 
The resulting yellow oil was purified by silica gel chromatography (10% 
EtOAc/hexanes). After chromatography, two mixtures of otherwise inseparable 
diastereomers were isolated, comprising five diastereomers in total, and totaling 260 mg 
(78%). Mixture of 3 diastereomers: 96 mg (4:3:2.5 by 13C NMR); Rf = 0.42 (10% 
EtOAc/hexanes); IR (neat) 2098, 1770 cm-1. Major diastereomer (unambiguous peaks 
only): (400 MHz, CDCl3) δ 0.87 (distorted t, J = 6.0, 3H), 3.26 (s, 3H); 13C NMR (100.6 
M Hz, CDCl3) δ 14.0, 56.6, 60.0, 79.6, 216.7. Minor diastereomer (diagnostic peaks 
only): (400 MHz, CDCl3) δ 0.87 (distorted t, J = 6.0, 3H), 3.23 (s, 3H); 13C NMR (100.6 
M Hz, CDCl3) δ 14.0, 80.2, 216.2. Minor diastereomer (diagnostic peaks only): (400 
MHz, CDCl3) δ 0.87 (distorted t, J = 6.0, 3H), 3.29 (s, 3H); 13C NMR (100.6 M Hz, 
CDCl3) δ 14.0, 80.7, 214.3; MS (ES+) m/z 308 (M++H – N2); HRMS calculated for 
C19H34NO2 (M++H – N2): 308.2590, found 308.2718. Mixture of 2 diastereomers: 164 
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mg (1.1:1 mixture estimated by 13C NMR); Rf = 0.28 (10% EtOAc/hexanes); IR (neat) 
2098, 1770 cm-1. Major diastereomer (unambiguous peaks only): (400 MHz, CDCl3) δ 
0.84 (distorted t, J = 6.4 Hz, 3H), 3.24 (s, 3H), 3.43 (m, 1H); 13C NMR (100.6 M Hz, 
CDCl3) δ 14.0, 18.3, 45.2, 55.6, 59.3, 67.0, 80.4, 214.7. Minor diastereomer (diagnostic 
peaks only): (400 MHz, CDCl3) δ 0.84 (distorted t, J = 6.4 Hz, 3H), 3.26 (s, 3H), 3.35 
(m, 1H); 13C NMR (100.6 M Hz, CDCl3) δ 14.0, 18.7, 45.4, 56.5, 59.8, 67.2, 79.5, 215.0. 
MS (ES+) m/z 308 (M++H – N2); HRMS calculated for C19H34NO2 (M++H – N2): 
308.2590, found 308.2474.   
 
N
O
C6H13
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129  
5-Hexyl-7-methoxyoctahydro-1H-pyrrolo[1,2-j]quinolin-3(2H)-one (129). To 
a stirred solution of cyclobutanone 128 (mixture of 3 diastereomers as obtained above) 
(367 mg, 1.10 mmol) in DCM (1 mL) at 0 °C was added 1.0 M TiCl4 in DCM (5.5 mL). 
The reaction was allowed to stir overnight at rt, at which time it was partitioned between 
ether (10 mL) and aqueous NH4Cl (10 mL). The aqueous layer was extracted with DCM 
(3×), washed with brine, dried with MgSO4, filtered, and concentrated. Purification by 
silica gel chromatography with 20% EtOAc yielded 266 mg of 129 as a mixture of 
inseparable diastereomers in a ca. 4:3:2.9 mixture estimated by 13C NMR (79%). Mixture 
of diastereomers: Rf = 0.30 (20% EtOAc/hexanes); IR (neat) 1690 cm-1; MS (ES+) m/z 
308 (M++H – N2); HRMS calculated for C19H34NO2 (M++H – N2): 308.2590, found 
308.2579. Major diastereomer (unambiguous peaks only): 1H NMR (400 M Hz, CDCl3) δ 
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0.85 (distorted t, J = 6 Hz, 3H), 3.26 (s, 3H); 13C NMR (100.6 M Hz, CDCl3) δ 14.0, 
47.7, 51.1, 56.4, 64.8, 74.6, 175.8. Minor diastereomer (diagnostic peaks only): 1H NMR 
(400 M Hz, CDCl3) δ 0.85 (distorted t, J = 6 Hz, 3H), 3.28 (s, 3H); 13C NMR (100.6 M 
Hz, CDCl3) δ 14.0, 57.1, 65.3, 82.0, 174.8. Minor diastereomer (diagnostic peaks only): 
1H NMR (400 M Hz, CDCl3) δ 0.85 (distorted t, J = 6 Hz, 3H), 3.34 (s, 3H); 13C NMR 
(100.6 M Hz, CDCl3) δ 14.0, 56.5, 64.7, 75.4, 175.3. 
 
N
O
OH
O
N3
OH
140141  
(4S*,5R*)-5-(3′-Azido-1′-hydroxypropyl)spiro[3.5]nonan-1-one (141) and 
(7R*,7aR*,111R*)-7-hydroxyoctahydro-1H-pyrrolo[1,2-j]quinolin-3(2H)-one (140). 
To a stirred solution of 3-azido-1-propanal (120)(470 mg, 4.8 mmol) and (1-
cyclohexenylcyclopropoxy)trimethylsilane (112)(880 mg, 4.0 mmol) in DCM (20 mL) at 
0 °C was added 1.0 M TiCl4 in DCM (4.8 mL). After 2 h, a second amount of 1.0 M 
TiCl4 in DCM (4.8 mL) was added and the reaction was heated to reflux. After 2 h, the 
reaction was cooled to rt and partitioned between ether (20 mL) and water (20 mL). The 
aqueous layer was extracted with DCM (3×). The combined organic extracts were dried 
with MgSO4, filtered, and concentrated. The yellow oil was first purified by silica gel 
chromatography (0→10% MeOH/EtOAc) followed by subsequent chromatography of the 
fractions containing the cyclobutanone products using 10% EtOAc/hexanes. 
Cyclobutanone 141 (24%) was isolated as a yellow oil and lactam 140 (16%) as a white 
powder. Cyclobutanone 141: Rf = 0.19 (20% EtOAc/hexanes); IR (neat) 3468, 2097, 
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1761 cm-1; 1H NMR (400 MHz, CDCl3) δ 1.21-1.47 (m, 3H), 1.52 (m, 1H), 1.59-1.84 (m, 
9H), 2.60 (m, 1H), 2.87-3.12 (m, 2H), 3.42-3.55 (m, 2H), 3.79 (br d, J = 8.4 Hz); 13C 
NMR (100.6 MHz, CDCl3) δ 19.8, 21.8, 21.9, 25.5, 34.6, 35.5, 42.4, 45.3, 49.0, 69.6, 
70.5, 217.8; MS (ES+) m/z 260 (M++Na); HRMS calculated for C12H19N3O2Na (M++Na): 
260.1375, found 260.1390. Lactam 140: Rf = 0.11 (10% MeOH/EtOAc); mp = 210 °C 
(dec); IR (CH2Cl2) 1649 cm-1; 1H NMR (400 MHz, CDCl3) δ 1.24-1.54 (m, 7H), 1.69-
1.83 (m, 3H), 2.02 (m, 1H), 2.13-2.22 (m, 2H), 2.24 (br s, 1H), 2.31-2.49 (m, 2H), 2.79 
(m, 1H), 4.02 (dt, J =10.8, 4.4 Hz, 1H), 4.09 (ddd, J = 13.6, 5.2, 1.6 Hz, 1H); 13C NMR 
(100.6 MHz, CDCl3) d 19.3, 22.3, 23.0, 29.1, 29.6, 30.3, 34.3, 34.8, 50.3, 62.9, 65.9, 
172.7; MS (ES+) m/z 210 (M++H); HRMS calculated for C12H20NO2 (M++H): 210.1494, 
found 210.1315. Stereochemistry was confirmed by X-ray crystallography. 
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(1S*,4S*,5R*)-3-Azido-1-(1´-oxospiro[3.5]nonan-5´-yl)propyl acetate (142) 
and (2aS,4S,4aS,81R)-4-(2-azidoethyl)octahydro-1H-benzo[c]cyclobuta[b]furan-2a-yl 
acetate (143). A solution of alcohol 141 (285 mg, 1.2 mmol) dissolved in DCM (12 mL) 
was cooled to 0 °C and pyridine (1 mL, 10 mmol), glacial acetic acid (1.13 mL, 10 
mmol), and a single crystal of DMAP were added. The reaction was slowly warmed to rt 
and stirred overnight. The reaction was partitioned between DCM (20 mL) and water (20 
mL) and the aqueous layer was extracted with DCM (3×). The combined organic extracts 
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were washed with aqueous NaHCO3, 1M HCl, and then brine. The organic layer was 
dried with Na2SO4, filtered, and concentrated. The resulting yellow oil was further 
purified by silica gel chromatography (10% EtOAc/hexanes). Acetates 142 and 143 were 
separated by silica gel chromatography and obtained as yellow oils. Acetate 142 (89%): 
Rf = 0.20 (20% EtOAc/hexanes); IR (neat) 2098, 1770, 1735 cm-1; 1H NMR (400 MHz, 
CDCl3) δ 1.21 (m, 2H), 1.33 (m, 1H), 1.46 (br t, J = 12.8 Hz, 1H), 1.59-1.84 (m, 8H), 
2.05 (s, 3H), 2.05-2.13 (m, 1H), 2.80-3.06 (m, 2H), 3.16-3.30 (m, 2H), 4.99 (m, 1H); 13C 
NMR (100.6 MHz, CDCl3) δ 19.6, 21.0, 21.8, 23.0, 25.3, 33.1, 34.3, 42.3, 43.3, 47.9, 
68.9, 71.6, 170.5, 215.8; MS (ES+) m/z 297 (M++NH4); HRMS calculated for 
C14H22N3O3 (M++NH4): 297.1927, found 297.1790. Acetate 143 was isolated as a yellow 
oil (11%) and was accompanied by ca. 20% of an unidentified impurity. 143: Rf = 0.70 
(20% EtOAc/hexanes); IR (neat) 2096, 1747 cm-1; 1H NMR (400 MHz, CDCl3) δ 1.05-
1.36 (m, 4H), 1.43-1.57 (m, 2H), 1.60-1.81 (m, 7H), 1.81-1.98 (m, 2H), 2.04 (s, 3H), 
2.26-2.46 (m, 2H), 3.47 (ddd, J = 7.6, 6.0, 4.0 Hz, 2H), 3.96 (ddd, J = 10.0, 8.0, 3.6 Hz, 
1H); 13C NMR (101 MHz, CDCl3) δ 20.5, 21.4, 21.6, 23.0, 25.2, 30.7, 21.9, 33.1, 48.4, 
49.2, 56.6, 81.5, 106.6, 169.2; MS (ES+) m/z 302 (M++Na); HRMS calculated for 
C14H21N3O3 (M++Na): 302.1481, found 302.1382. Impurity (diagnostic peaks only): 1H 
NMR (400 MHz, CDCl3) δ 4.52 (ddd, J = 11.6, 9.2, 2.8 Hz, 1H); 13C NMR (101 MHz, 
CDCl3) δ 47.8, 49.2, 57.3, 82.2, 107.6. 
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(7R*,7aS*,111R*)-3-Oxodecahydro-1H-pyrrolo[1,2-j]quinolin-7-yl acetate 
(144). To a neat sample of acetate 142 (161 mg, 0.58 mmol) was added 1.0 M TiCl4 in 
DCM (2.9 mL). Gas evolution was immediately observed. The reaction was stirred at rt 
for 30 min and then partitioned between equivalent amounts of ether and water. The 
aqueous layer was extracted twice with ether and once with EtOAc. The combined 
organic layers were washed thrice with NaHCO3 and then with brine, then dried with 
MgSO4, filtered, and concentrated. Purification by silica gel chromatography (EtOAc) 
afforded 144 as a yellow oil (92%). Rf = 0.4 (EtOAc); IR (neat) 1735, 1693 cm-1; 1H 
NMR (400 MHz, CDCl3) δ 1.14 (qd, J = 12.4, 3.2, 1H), 1.32 (m, 1H), 1.43-1.65 (m, 3H), 
1.67-1.73 (m, 2H), 1.76-1.83 (m, 2H), 1.89 (br t, J = 12 Hz, 2H), 2.05 (s, 3H), 2.08 (m, 
1H), 2.25 (dd, J = 16.8, 8.8 Hz, 1H), 2.38-2.57 (m, 2H), 2.99 (ddd, J = 18.4, 11.6, 6.8 Hz, 
1H), 3.99 (dd, J = 10.8, 8.0 Hz, 1H), 4.75 (ddd, J = 12.4, 8.8, 6.0 Hz, 1H); 13C NMR 
(100.6 MHz, CDCl3) δ 20.9, 22.7, 23.5, 25.4, 26.1, 30.3, 31.3, 33.1, 34.2, 46.0, 63.3, 
68.4, 170.4, 175.5; MS (ES+) m/z 252 (M++H); HRMS calculated for C14H22NO3 
(M++H): 252.1600, found 252.1570. 
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Structure determination of 144. The structure of compound 144 is proposed 
beginning with the NOE observed between Ha and He. This NOE supports a boat 
conformation of the piperidine ring. This conformation is substantiated by He also 
exhibiting NOEs with Hc, Hg, and Hh. Since Hi has an observed NOE with Hf as well as 
 141 
Hd, this supports a trans-azadecalin ring structure. The axial orientation of Hd is 
supported by the J value of 12.4 Hz, indicating a trans-axial interaction. 
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(7S*,7aS*,111S*)-3-Oxodecahydro-1H-pyrrolo[1,2-j]quinolin-7-yl acetate 
(145). Lactam 140 was acetylated as described in the procedure for compound 142. 
Acetylated lactam 145 was isolated as a yellow oil (76%). Rf = 0.37 (EtOAc); IR (neat) 
1731, 1687 cm-1; 1H NMR (400 MHz, CDCl3) δ 1.25-1.52 (m, 6H), 1.59 (m, 1H), 1.72-
1.89 (m, 4H), 2.05 (m, 1H), 2.07 (s, 3H), 2.20 (m, 1H), 2.34-2.52 (m, 2H), 2.84 (br t, J = 
13.6 Hz, 1H), 4.12 (m, 1H), 5.27 (tdd, J = 11.2, 4.4, 1.2 Hz, 1H); 13C NMR (100.6 MHz, 
CDCl3) δ 19.3, 21.1, 22.6, 22.8, 29.0, 29.4, 30.3, 30.7, 34.4, 47.2, 62.8, 68.5, 170.6, 
172.6; MS (ES+) m/z 252 (M++H); HRMS calculated for C14H22NO3 (M++H): 252.1600, 
found 252.1521. 
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Structure determination of 145. This structure is proposed beginning with the J 
values of Hb, 11.2(t) and 4.4(d) Hz. The triplet J value indicates the presence of two trans 
relationships; hence, Hb must be axial. The observed NOE of Hb with Ha gave further 
support for the axial orientation of Hb. An observed NOE between He with Ha and Hb was 
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supportive of the cis ring fusion of the aza-decalin. This was further supported by the 
NOE present between Hg with Hc and Hd.  
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(1R*,3R*,4S*,5R*)-5´-(3´-Azido-1´-hydroxynonyl)spiro[3.5]nonan-1-one 
(149), (5R*,7R*,7aR*,111R*)-5-hexyl-7-hydroxyoctahydro-1H-pyrrolo[1,2-j] 
quinolin-3(2H)-one (150a), (5S*,7R*,7aR*,111R*)-5-hexyl-7-hydroxyoctahydro-1H-
pyrrolo[1,2-j]quinolin-3(2H)-one (150b) and (5S*,7S*,7aS*,111R*)-5-hexyl-7-
hydroxyoctahydro-1H-pyrrolo[1,2-j]quinolin-3(2H)-one (150c). Obtained as described 
in procedure for compounds 140 and 141. Examination of carbonyl region in the crude 
13C NMR spectrum indicated the formation of one diastereomeric cyclobutanone and 
three diastereomeric lactams in a ca. 3:1:1 ratio of a:b:c. Silica gel chromatography (50% 
EtOAc/hexanes→10% MeOH/EtOAc) afforded cyclobutanone 149 (30%) containing 
≤5% of a minor diastereomer (estimated by 1H NMR), plus three diastereomers of 
lactams (21%); all samples were obtained as yellow oils. Analytical samples of lactams 
150a–c were obtained by careful chromatography of the latter mixture. Cyclobutanone 
149: Rf = 0.20 (20% EtOAc/hexanes); IR (neat) 3456, 2100, 1766 cm-1; 1H NMR (400 
MHz, CDCl3) δ 0.90 (t, J = 6.4 Hz, 3H), 1.23-1.85 (complex, 21H), 2.40 (br s, 1H), 2.73 
(m, 1H), 2.85-3.07 (m, 3H), 3.46 (m, 1H), 3.80 (d, J = 8.8 Hz, 1H); 13C NMR (100.6 
MHz, CDCl3) δ 14.2, 20.2, 21.5, 22.1, 22.6, 25.8, 25.9, 29.3, 31.8, 34.8, 34.9, 41.0, 42.6, 
46.0, 62.1, 70.0, 71.9, 218.2; MS (ES+) m/z 344 (M++Na); HRMS calculated for 
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C18H31N3O2Na (M++Na): 344.2314, found 344.2287. Lactam 150a: Rf = 0.27 (EtOAc); 
IR (CH2Cl2) 3350, 1645 cm-1; 1H NMR (400 MHz, CDCl3) δ 0.87 (distorted t, J = 5.6 Hz, 
3H), 1.20-1.76 (complex, 21H), 2.02 (dd, J = 12.4, 3.2 Hz, 1H), 2.17 (m, 1H), 2.22-2.34 
(m, 2H), 2.45 (m, 1H), 4.16 (td, J = 11.2, 4.0 Hz, 1H), 4.28 (q, J = 7.2 Hz, 1H); 13C NMR 
(100.6 MHz, CDCl3) δ 14.1, 19.6, 22.3, 22.6, 23.8, 27.2, 29.3, 29.5, 31.4, 31.8, 32.0, 
36.0, 37.3, 48.5, 51.7, 62.8, 64.1, 173.6; MS (ES+) m/z 294 (M++H); HRMS calculated 
for C18H32NO2 (M++H): 294.2433, found 294.2417. Lactam 150b: Rf = 0.49 (EtOAc); IR 
(CH2Cl2) 3361, 1666 cm-1; 1H NMR (400 MHz, CDCl3) δ 0.89 (t, J = 5.4 Hz, 3H), 1.28-
1.52 (complex, 18H), 1.65-2.15 (complex, 6H), 2.32 (m, 1H), 2.54 (m, 1H), 3.24 (m, 1H), 
3.98 (td, J = 10.7, 4.8 Hz, 1H); 13C NMR (100.6 MHz, CDCl3) δ 14.0 (2C), 19.5, 22.6, 
22.9, 27.1, 29.2, 29.6, 30.6, 31.0, 31.8, 31.9, 40.8, 48.1, 52.0, 65.0, 66.5, 174.9; MS 
(ES+) m/z 294 (M++1); HRMS calculated for C18H32NO2 (M++H): 294.2433, found 
294.2299. The stereochemistry of 150b was confirmed by X-ray crystallography. Lactam 
150c: Rf = 0.43 (EtOAc); IR (neat) 3402, 1662 cm-1; 1H NMR (400 MHz, CDCl3) δ 0.89 
(distorted t, J = 6.8 Hz, 3H), 1.15 (qd, J = 12.4, 2.8 Hz, 1H), 1.24-1.37 (m, 8H), 1.42 (m, 
1H), 1.48-1.63 (m, 3H), 1.64-1.77 (m, 4H), 1.82 (m, 2H), 1.90-2.03 (m, 3H), 2.10 (dd, J 
= 16.4, 9.2 Hz, 1H), 2.29 (ddd, J = 13.6, 11.6, 8.8 Hz, 1H), 2.40-2.53 (m, 2H), 3.35 (m, 
1H), 3.69 (ddd, J = 12.0, 8.8, 6.0 Hz, 1H); 13C NMR (100.6 MHz, CDCl3) δ 14.1, 22.3,  
22.7, 23.7, 25.6, 25.7, 27.6, 29.1, 31.5, 31.7, 31.8, 33.5, 42.3, 48.9, 51.4, 65.1, 66.0, 175; 
MS (ES+) m/z 294 (M++H); HRMS calculated for C18H32NO2 (M++H): 294.2433, found 
294.2371.  
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(1S*,3S*,4R*,5S*)-3-Azido-1-(1´-oxospiro[3.5]nonan-5´-yl)nonyl acetate (151) 
and (2aS*,2′S*,4S*,4aS*,81R*)-4-(2′-azidooctyl)octahydro-1H-benzo[c]cyclobuta[b] 
furan-2a-yl acetate (152). The reaction was carried out as described in the procedure for 
compound 142. Starting with compound 149, acetate 151 was isolated as a yellow oil 
(74%). Rf = 0.41 (20% EtOAc/hexanes); IR (neat) 2100, 1770, 1737 cm-1; 1H NMR (400 
MHz, CDCl3) δ 0.88 (t, J = 6.8 Hz, 3H), 1.18-1.88 (m, 22H), 2.08 (s, 3H), 2.08 (m, 1H), 
2.83-3.06 (m, 2H), 3.19 (m, 1H), 5.07 (m, 1H); 13C NMR (100.6 MHz, CDCl3) δ 14.0, 
19.8, 21.2, 21.8, 22.5, 22.8, 25.4, 25.8, 29.0, 31.6, 34.2, 34.4, 38.3, 42.4, 43.5, 59.9, 69.2, 
71.7, 170.6, 215.9; MS (ES+) m/z 386 (M++Na); HRMS calculated for C20H33N3O3Na 
(M++Na): 386.2420, found 386.2391. Acetate 152 was isolated as a yellow oil (19%) 
containing ca. 10% of an unidentified impurity. Rf = 0.77 (20% EtOAc/hexanes); IR 
(neat) 2098, 1749 cm-1; 1H NMR (400 MHz, CDCl3) δ 0.91 (distorted t, J = 6.4 Hz, 3H), 
1.08-1.25 (m, 2H), 1.26-1.37 (m, 7H), 1.42-1.58 (m, 4H), 1.58-1.85 (m, 9H), 1.94 (m, 
1H), 2.04 (s, 3H), 2.29-2.44 (m, 2H), 3.49 (m, 1H), 3.99 (ddd, J = 11.6, 6.8, 4.4 Hz, 1H); 
13C NMR (101 MHz, CDCl3) δ 14.0, 20.6, 21.4, 21.5, 22.6, 23.4, 25.9, 29.1, 30.8, 31.7, 
31.9, 34.5, 38.4, 49.4, 56.7, 59.7, 81.6, 106.6, 169.2; MS (ES+) m/z 386 (M++Na); 
HRMS calculated for C20H33N3O3Na (M++Na): 386.2420, found 386.2279. Impurity 
(diagnostic peaks only): 1H NMR (400 MHz, CDCl3) δ 3.64 (m, 1H), 4.04 (m, 1H); 13C 
NMR (101 MHz, CDCl3) δ 14.0, 49.5, 60.2, 81.2.  
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(5R*,7R*,7aR*,111S*)-5-Hexyl-3-oxodecahydro-1H-pyrrolo[1,2-j]quinolin-7-
yl acetate (153). The reaction was carried out as described in the procedure for 
compound 144. Acetate 151 produced lactam 153 as a yellow oil (96%) containing a 
minor diastereomer in a ca. 12:1 ratio (1H NMR). Rf = 0.48 (EtOAc); IR (neat) 1735, 
1693 cm-1; MS (ES+) m/z 336 (M++H); HRMS calculated for C20H34NO3 (M++H): 
336.2539, found 336.2419. Major diastereomer: 1H NMR (400 MHz, CDCl3) δ 0.87 
(distorted t, J = 6.8 Hz, 3H), 1.21-1.38 (m, 8H), 1.45-1.62 (m, 4H), 1.63-1.72 (m, 4H), 
1.75-1.89 (m, 4H), 2.0 (m, 1H), 2.04 (s, 3H), 2.12 (dd, J = 16.4, 8.8 Hz, 1H), 2.34 (m, 
1H), 2.41-2.53 (m, 2H), 3.34 (m, 1H), 4.77 (ddd, J = 14.8, 9.2, 6.0 Hz, 1H); 13C NMR 
(100.6 MHz, CDCl3) δ 14.1, 21.1, 22.6, 22.7, 23.5, 25.5, 25.6, 27.6, 29.1, 31.4, 31.5, 
31.8, 33.6, 39.3, 46.4, 51.2, 64.8, 68.9, 170.5, 175.8. Minor diastereomer (diagnostic 
peaks only): 1H NMR (400 MHz, CDCl3) δ 0.87 (distorted t, J = 6.8 Hz, 3H), 2.90-3.11 
(m, 2H), 3.16 (m, 1H), 5.10 (m, 1H); 13C NMR (100.6 MHz, CDCl3) δ 14.1, 38.7, 42.3, 
47.3, 59.7, 71.5.  
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Structure determination of 153. The proposed structure of 153 is supported 
beginning with the NOE between Ha and Hc. This correlation supports a boat-like 
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conformation of the piperidine ring as well as well as suggesting that the hexyl side chain 
is equatorial. Unfortunately, the complex proton signal of Ha does not allow for proper J 
value calculations in order to further confirm it as being axial. The trans-azadecalin 
system was supported by the NOE between Hb and both Hd and He. The axial orientation 
of Hb is further substantiated by the J value of 14.8 Hz, indicating a diaxial relationship. 
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(5R*,7R*,7aR*,111R*)-5-Hexyl-3-oxodecahydro-1H-pyrrolo[1,2-j]quinolin-7-
yl acetate (Ac-150a). The reaction was carried out as described in the procedure for 
compound 142. Acetate Ac-150a was isolated as a yellow oil (84%). Rf  = 0.53 (EtOAc); 
IR (neat) 1737, 1681 cm-1; 1H NMR (400 MHz, CDCl3) δ 0.87 (distorted t, J = 6.4 Hz, 
3H), 1.26 (m, 8H), 1.42 (m, 5H), 1.52-1.68 (m, 5H), 1.71-1.82 (m, 3H), 2.01 (m, 1H), 
2.07 (s, 3H), 2.23-2.36 (m, 2H), 2.47 (m, 1H), 4.32 (q, J = 7.6 Hz, 1H), 5.42 (td, J = 11.2, 
4.0 Hz, 1H); 13C NMR (100.6 MHz, CDCl3) δ 14.1, 19.6, 21.2, 22.5, 22.6, 23.6, 27.1, 
29.2, 29.4, 31.4, 31.7, 31.9, 33.9, 35.8, 48.0, 48.8, 63.8, 66.2, 170.6, 173.4; MS (ES+) 
m/z 336 (M++H); HRMS calculated for C20H34NO3 (M++H): 336.2539, found 336.2498. 
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Structure determination of Ac-150a. The structure was proposed based on 
NOEs between Hc and Ha as well as between Hc and He. These NOEs support the axial 
position of the hexyl sidechain as Hc is axial by the calculated J value of 11.2 Hz for the 
triplet, indicative of two diaxial couplings. The two trans-trans couplings also support an 
axial orientation of Hd as there must be an axial proton on each side of Hc. The NOE 
between Hc and He along with the axial position of Hd leads to the assignment of the cis-
fused azadecalin ring system. 
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154  
3-Azidoheptanal (154). To a stirred solution of sodium azide (2.92 g, 45 mmol) 
in water (8 mL) at 0 °C was added glacial AcOH (3.45 mL, 60 mmol). After 1 h, 2-
heptenal (2.0 mL, 15 mmol) was added and the reaction mixture allowed to slowly warm 
to rt overnight. The reaction was cooled to 0 °C and DCM (10 mL) and aqueous NaHCO3 
(10 mL) were added. Upon warming to rt, the aqueous layer was extracted with DCM 
(3×), washed with NaHCO3 (3×) then brine, dried with Na2SO4, filtered and concentrated. 
The resulting yellow oil was purified by silica gel chromatography (10% EtOAc/hexanes) 
to yield 2.27 g (99%) of 154 as a yellow oil. Rf = 0.54 (20% EtOAc/hexanes); IR (neat) 
2100, 1726 cm-1; 1H NMR (400 M Hz, CDCl3) δ 0.91 (distorted t, J = 6.8 Hz, 3H), 1.28-
1.47 (m, 4H), 1.50-1.63 (m, 2H), 2.62 (m, 2H), 3.87 (ddd, J = 13.2, 7.6, 5.2 Hz, 1H), 9.78 
(br t, J = 1.6 Hz, 1H); 13C NMR (100.6 M Hz, CDCl3) δ 13.8, 22.3, 27.9, 34.1, 48.1, 57.0, 
199.4; MS (ES–) m/z 127 (M+ – N2); HRMS calculated for C7H13NO (M+ – N2): 
127.0997, found 127.0777. 
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(1S*,3S*,4R*,5S*)-5-(3-Azido-1-hydroxyheptyl)spiro[3.5]nonan-1-one (155), 
(5S*,7S*,7aS*,111S*)-5-butyl-7-hydroxyoctahydro-1H-pyrrolo[1,2-j]quinolin-3(2H)-
one (156a), (5R*,7S*,7aS*,111S*)-5-butyl-7-hydroxyoctahydro-1H-pyrrolo[1,2-
j]quinolin-3(2H)-one (156b), (5S*,7S*,7aS*,111R*)-5-butyl-7-hydroxyoctahydro-1H-
pyrrolo[1,2-j]quinolin-3(2H)-one (156c). Obtained as described in procedure for 
compounds 140 and 141. Examination of carbonyl region in the crude 13C NMR 
spectrum indicated the formation of one diastereomeric cyclobutanone and three 
diastereomeric lactams in ca. 3:1:1 ratio of a:b:c. Chromatography (5% EtOAc/hexanes 
→10% MeOH/EtOAc) afforded cyclobutanone 155 (22%) plus a mixture containing 
three diastereomers of lactams (30%) as yellow oils. Analytical samples of lactams 156a–
c were obtained by careful chromatography of the latter mixture. Cyclobutanone 155: Rf 
= 0.51 (20% EtOAc/hexanes); IR (neat) 3498, 2100, 1759 cm-1; 1H NMR (400 MHz, 
CDCl3) δ 0.90 (distorted t, J = 6.8 Hz, 3H), 1.22 (dd, J = 10.7, 14.2 Hz, 1H), 1.27-1.43 
(m, 7H), 1.45-1.53 (m, 3H), 1.54-1.66 (m, 5H), 1.67-1.88 (m, 4H), 2.39 (d, J = 3.6 Hz, 
1H), 2.69 (dd, J = 10.4, 17.4 Hz, 1H), 2.79-3.07 (m, 2H), 3.43 (dd, J = 4.0, 9.7 Hz, 1H), 
3.77 (d, J = 9.0 Hz, 1H); 13C NMR (101 MHz, CDCl3) δ 13.9, 19.9, 21.3, 21.9, 22.5, 
25.7, 27.8, 34.3, 34.7, 40.9, 42.5, 45.8, 61.9, 69.9, 71.6, 217.9; MS (ES+) m/z 316 
(M++Na); HRMS calculated for C16H27N3O2Na (M++Na): 316.2001, found 316.1916. 
Lactam 156a: Rf = 0.43 (10%MeOH/EtOAc); IR (neat) 3380, 1654 cm-1; 1H NMR (500 
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MHz, CDCl3) δ 0.84 (distorted t, J = 7.1 Hz, 3H), 1.14-1.32 (m, 6H), 1.33-1.39 (m, 3H), 
1.42-1.53 (m, 5H), 1.57 (dd, J = 9.9, 20.0 Hz, 1H), 1.63-1.71 (m, 2H), 1.99 (dd, J = 3.0, 
12.7 Hz, 1H), 2.09-2.16 (m, 1H), 2.17-2.30 (m, 2H), 2.42 (ddd, J = 9.3, 11.1, 17.0 Hz, 
1H), 4.12 (td, J = 4.0, 11.1 Hz, 1H), 4.25 (q, J = 7.3 Hz, 1H); 13C NMR (126 MHz, 
CDCl3) δ 14.0, 19.5, 22.2, 22.6, 23.7, 29.3, 29.4, 31.3, 32.0, 35.6, 37.3, 48.3, 51.7, 62.8, 
63.9, 173.4; MS (ES+) m/z 266 (M++H); HRMS calculated for C16H28NO2 (M++H): 
266.2120, found 266.2087. Lactam 156b: Rf = 0.45 (EtOAc); IR (neat) 3367, 1666 cm-1; 
1H NMR (500 MHz, CDCl3) δ 0.87 (distorted t, J = 6.9, 3H), 1.19-1.39 (m, 9H), 1.45-
1.55 (m, 3H), 1.72 (d, J = 13.4 Hz, 1H), 1.76-1.88 (m, 3H), 1.91 (m, 1H), 1.96-2.03 (m, 
1H), 2.08 (d, J = 14.8 Hz, 1H), 2.22-2.36 (m, 2H), 2.50 (m, 1H), 3.20 (d, J = 9.9 Hz, 1H), 
3.94 (td, J = 4.7, 10.8 Hz, 1H); 13C NMR (126 MHz, CDCl3) δ 14.1, 19.5, 22.6 (2), 22.9, 
29.4, 29.6, 30.6, 31.0, 31.7, 40.8, 48.0, 52.0, 65.1, 66.5, 175.1; MS (ES+) m/z 266 
(M++H); HRMS calculated for C16H28NO2 (M++H): 266.2120, found 266.1846. Lactam 
156c: Rf = 0.24 (60% EtOAc/hexanes); IR (neat) 3384, 1654 cm-1; 1H NMR (500 MHz, 
CDCl3) δ 0.88 (distorted t, J = 7.1 Hz, 3H), 1.11 (ddd, J = 3.3, 12.6, 25.2 Hz, 1H), 1.21-
1.40 (m, 6H), 1.42-1.58 (m, 3H), 1.61-1.73 (m, 5H), 1.79 (d, J = 11.9 Hz, 2H), 1.89 (d, J 
= 10.5 Hz, 1H), 1.96 (dd, J = 8.1, 12.6 Hz, 1H), 2.07 (m, 1H), 2.27 (ddd, J = 8.8, 11.8, 
13.6 Hz, 1H), 2.35-2.55 (m, 2H), 3.31 (dt, J = 6.1, 11.9 Hz, 1H), 3.66 (ddd, J = 5.8, 8.7, 
11.8 Hz, 1H); 13C NMR (126 MHz, CDCl3) δ 14.1, 22.3, 22.5, 23.7, 25.6, 25.7, 29.8, 
31.33, 31.5, 33.5, 42.3, 48.9, 51.3, 65.0, 66.0, 175.79; MS (ES+) m/z 266 (M++H); 
HRMS calculated for C16H28NO2 (M++H): 266.2120, found 266.1917. 
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Structure determination of 156a. The structure of 156a is proposed based on the 
observed NOE between Ha and Hd. This NOE suggests an axial orientation of the butyl 
side chain. An axial orientation of the butyl chain is also supported by the coupling 
constant of Hb, J = 7.3 Hz, which suggests no possible trans-axial couplings. The 
coupling constants of Hd, however, are indicative of trans-axial coupling with a triplet J 
value of 11.1 Hz, thus supporting the diaxial interaction with the butyl sidechain. Next, 
the observed NOE between He and Hf supports the cis-azadecalin geometry. Also, the 
NOE between Hg and Hd supports the facial orientation of the cyclohexane ring being on 
the same face as the butyl group. 
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Structure determination of 156b. The proposed structure for 156b is supported 
by observation of an NOE between Ha and Hd. This NOE supports a chair conformation 
of the piperidine ring as well as the orientation of the butyl side chain and hydroxy side 
chain. The chair conformation is also upheld by the splitting pattern of a triplet of 
doublets and coupling constants, 11.0 and 5.0 Hz, of Hd. The cis-azadecalin moiety is 
backed by the NOEs between Hf and Hi as well as He and Hh. The orientation of the cis-
azadecalin ring is supported by the NOE between Ha and Hg. 
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Structure determination of 156c. The proposed structure of compound 156c was 
assigned by beginning with the NOE between Ha and Hc. This correlation supports a boat-
like conformation of the piperidine ring as well as well as suggesting that the butyl side 
chain is equatorial. Unfortunately, the complex proton signal of Ha does not allow for 
proper J value calculations in order to further confirm it as being axial. The trans-
azadecalin system was supported by the observed NOEs between Hb with Hf, Hd with Hf 
as well as He with Hf. The axial orientation of Hb is further substantiated by an observed J 
value of 12.0 Hz, indicating a diaxial relationship.  
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(1S*,3S*,4R*,5S*)-3-Azido-1-(-1-oxospiro[3.5]nonan-5-yl)heptyl acetate 
(157). The reaction was carried out as described in the procedure for compound 142. 
Starting with cyclobutanone 155, Acetate 157 was isolated as a yellow oil (88%). Rf = 
0.60 (20% EtOAc/hexanes); IR (neat) 2098, 1770, 1735 cm-1; 1H NMR (400 MHz, 
CDCl3) δ 0.88 (distorted t, J = 6.8 Hz), 1.19-1.39 (m, 7H), 1.48-1.56 (m, 3H), 1.58-1.86 
(m, 8H), 2.05 (s, 3H), 2.08 (m, 1H), 2.86 (ddd, J = 16.4, 10.4, 6.4 Hz, 1H), 2.99 (ddd, J = 
17.2, 10.0, 6.8 Hz, 1H), 3.17 (ddd, J = 13.2, 8.0, 5.6 Hz, 1H), 5.05 (ddd, J = 7.6, 4.4, 2.8 
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Hz, 1H); 13C NMR (100.6 MHz, CDCl3) δ 13.8, 19.7, 21.1, 21.8, 22.3, 22.7, 25.3, 27.9, 
33.8, 34.3, 38.3, 42.3, 43.5, 59.8, 69.1, 71.6, 170.5, 215.7; MS (ES+) m/z 358 (M++Na); 
HRMS calculated for C18H29N3O3Na (M++Na): 358.2107, found 358.1805. 
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158  
5-Butyl-3-oxodecahydro-1H-pyrrolo[1,2-j]quinolin-7-yl acetate (158). The 
reaction was carried out as described in the procedure for compound 144. Acetate 157 
afforded lactam 158 as a yellow oil (99%). Rf = 0.50 (60% EtOAc/hexanes); IR (neat) 
1737, 1693 cm-1; 1H NMR (500 MHz, CDCl3) δ 0.87 (distorted t, J = 8.5 Hz, 3H), 1.10 
(qd, J = 15.5, 4.0 Hz, 1H), 1.20-1.42 (m, 6H), 1.45-1.59 (m, 3H), 1.60-1.69 (m, 3H), 
1.72-1.87 (m, 3H), 1.97 (dd, J = 15.5, 9.5 Hz, 1H), 2.02 (s, 3H), 2.10 (dd, J = 20.5, 11.5 
Hz, 1H), 2.32 (ddd, J = 17.0, 14.5, 11.0 Hz, 1H), 2.38-2.51 (m, 2H), 3.32 (m, 1H), 4.74 
(ddd, J = 15.5, 11.0, 7.0 Hz, 1H); 13C NMR (100.6 MHz, CDCl3) 
δ 14.0, 20.9, 22.4, 22.6, 23.4, 25.4, 25.5, 29.7, 31.1, 31.2, 33.5, 39.2, 46.3, 51.1, 64.7,  
68.8, 170.4, 175.7; MS (ES+) m/z 308 (M++H); HRMS calculated for C18H30NO3 
(M++H): 308.2226, found 308.2031. 
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160 161a 161b  
(1S*,2R*,4S*,5R*)-3-Azido-1-(1´-hydroxy-2-methylpropyl)spiro[3.5]nonan-1-
one (160), (6R*,7R*,7aR*,111R*)-7-hydroxy-6-methyloctahydro-1H-pyrrolo[1,2-
j]quinolin-3(2H)-one (161a) and (6S*,7R*,7aR*,111R*)-7-hydroxy-6-
methyloctahydro-1H-pyrrolo[1,2-j]quinolin-3(2H)-one (161b). The reaction was 
carried out as described for compounds 140 and 141. Examination of the carbonyl region 
in the crude 13C NMR indicated the formation of two diastereomeric cyclobutanones in 
ca. 4:1 ratio and four diastereomeric amide peaks in ca. 4:2:2:1 ratio. An inseparable 
mixture of four diastereomers along with a mixture of two diastereomers in ca. 2:1 ratio 
was afforded from column chromatography. This resulted in a yield of 12% of a mixture 
of all four diastereomers. Both mixtures were isolated as yellow oils. Lactam 161a 
(major): Rf = 0.28 (10% MeOH/EtOAc); IR (CH2Cl2) 3336, 1666 cm-1; 1H NMR (400 
MHz, CDCl3) δ 0.92 (d, J = 6.8 Hz, 3H), 1.25 (m, 1H), 1.36-1.50 (m, 3H), 1.62 (d, J = 
12.0 Hz, 1H), 1.71-1.83 (m, 3H), 2.06 (m, 1H), 2.12-2.25 (m, 2H), 2.40-2.51 (m, 3H), 
2.59 (br s, 1H), 2.96 (d, J = 13.6 Hz, 1H), 3.88 (dd, J = 13.6, 1.6 Hz, 1H), 4.12 (dd, J = 
11.2, 4.4 Hz, 1H); 13C NMR (100.6 MHz, CDCl3) 
δ 9.9, 19.2, 22.2, 23.1, 28.6, 29.6, 30.6, 34.5, 40.7, 43.1, 63.1, 67.6, 173.6. Minor 
diastereomer 161b (diagnostic peaks only):  1H NMR (400 MHz, CDCl3) δ 1.04 (d, J = 
6.8 Hz, 3H), 3.98 (dd, J = 13.6, 5.2 Hz, 1H); 13C NMR (100.6 MHz, CDCl3) 
δ 49.8, 51.6, 71.5, 172.6. MS (ES+) m/z 224 (M++1); HRMS calculated for C13H22NO2 
(M++H): 224.1650, found 224.1557. Cyclobutanone 160 was isolated as a yellow oil 
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(NMR showed the presence of an unknown diastereomer, ca. 10:1) (14%). Rf = 0.20 
(20% EtOAc/hexanes); IR (neat) 3492, 2096, 1759 cm-1; 1H NMR (400 MHz, CDCl3) 
δ 0.94 (d, J = 5.2 Hz, 3H), 1.22-1.44 (m, 3H), 1.51 (m, 1H), 1.57 (m, 1H), 1.65-1.83 (m, 
7H), 1.97 (d, J = 5.6 Hz, 1H), 2.65 (ddd, J = 14.8, 5.6, 1.2 Hz, 1H), 2.86 (ddd, J = 14.8, 
8.4, 4.8 Hz, 1H), 3.05 (m, 1H), 3.42 (m, 2H); 13C NMR (100.6 MHz, CDCl3) 
δ 15.2, 19.8, 21.3, 22.0, 25.6, 34.6, 37.7, 41.7, 42.5, 55.4, 69.9, 75.4, 217.6; MS (ES+) 
m/z 274 (M + Na); HRMS calculated for C13H21N3O2Na (M + Na): 274.1531, found 
274.1511.  
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162  
(1S*,2R*,4S*,5R*)-3-Azido-2-methyl-1-(1´-oxospiro[3.5]nonan-5´-yl)propyl 
acetate (162). The reaction was carried out as described in the general procedure. The 
diastereomeric mixture of alcohol 160 produced acetate 162 as a mixture with an 
unknown diastereomer in ca. 10:1 ratio as a yellow oil (76%). Major: Rf = 0.70 (20% 
EtOAc/hexanes); IR (neat) 2100, 1770, 1731 cm-1; 1H NMR (400 MHz, CDCl3) δ 0.92 
(d, J = 6.8 Hz, 3H), 1.15-1.38 (m, 3H), 1.46 (br t, J = 12.8 Hz, 1H), 1.58-1.76 (m, 5H), 
1.81-1.88 (m, 2H), 1.95 (m, 1H), 2.06 (s, 3H), 2.83 (m, 1H), 2.98 (m, 2H), 3.30 (dd, J = 
12.0, 4.4 Hz, 1H), 4.79 (dd, J = 6.8, 3.2 Hz, 1H); 13C NMR (100.6 MHz, CDCl3) δ 15.1, 
19.3, 21.0, 21.8, 23.1, 25.4, 34.3, 36.8, 41.0, 42.3, 53.5, 69.2, 75.4, 170.6, 215.9. Minor 
diastereomer (diagnostic peaks only): 1H NMR (400 MHz, CDCl3) δ 0.87 (d, J = 6.8 Hz, 
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3H), 2.05 (s, 3H), 3.11 (t, J = 7.2 Hz, 2H), 4.95 (dd, J = 5.2, 4.0 Hz, 1H); MS (ES+) m/z 
316 (M + Na); HRMS calculated for C15H23N3O3 (M + Na): 316.1637, found 316.2632. 
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Ac-161a Ac-161b  
(6R*,7R*,7aR*,111R*)-6-Methyl-3-oxodecahydro-1H-pyrrolo[1,2-j]quinolin-
7-yl acetate (Ac-161a) and (6S*,7R*,7aR*,111R*)-6-methyl-3-oxodecahydro-1H-
pyrrolo[1,2-j]quinolin-7-yl acetate (Ac-161b). The reaction was carried out as 
described for compound142. Lactams Ac-161a and Ac-161b were isolated as an 
inseparable mixture of diastereomers in ca. 3:1 ratio estimated by 1H NMR as a yellow 
oil (83%). Acetate-161a: Rf = 0.22 (EtOAc); IR (neat) 1735, 1689 cm-1; 1H NMR (400 
MHz, CDCl3) δ 0.92 (distorted d, J = 6.8 Hz, 3H), 1.22-1.51 (m, 5H), 1.53-1.96 (m, 5H), 
2.08 (s, 3H), 2.16-2.33 (m, 2H), 2.34-2.55 (m, 2H), 3.01 (m, 1H), 3.88 (d, J = 14.0 Hz, 
1H), 5.33 (dd, J = 12.0, 4.8 Hz, 1H); 13C NMR (100.6 MHz, CDCl3) 
δ 10.8, 19.2, 21.0, 22.4, 22.9, 28.5, 29.4, 30.5, 31.6, 40.3, 40.6, 62.8, 70.4, 170.4, 173.3. 
Acetate-161b (diagnostic peaks only): 1H NMR (400 MHz, CDCl3) δ 2.10 (s, 3H), 4.10 
(m, 1H), 5.10 (distorted t, J = 10.8 Hz, 1H); 13C NMR (400 MHz, CDCl3) 
δ 15.1, 36.6, 47.4, 73.5, 172.4. For mixture: MS (ES+) m/z 266 (M + 1); HRMS 
calculated for C15H23NO3 (M + H): 266.1756, found 266.1682. 
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Structure determination for Ac-161a and Ac-161b. The structure of the major 
diastereomer of compound Ac-161a was proposed starting with Ha being in the axial 
position based on chemical shift compared to the other C-1 proton (3.01 ppm vs. 3.89 
ppm). The existing NOE between Ha and Hc gave evidence for the chair-like 
conformation of the piperidine ring. The J coupling values for Hc of 12.0 and 4.8 Hz 
indicate one axial and one equatorial proton on adjacent carbons. Since an NOE was 
observed between the methyl group and Hd indicating a 1,3-diaxial orientation, then Hb 
must be equatorial to leave the methyl axial and therefore Hd is axial. These proposed 
orientations are supported by the observed J values for Hc. The cis ring fusion was 
supported by the observed NOEs between both Ha and Hc with He, the axial proton on C-
8.  
 The minor diastereomer Ac-161b was inseparable from the major diastereomer 
but the structure shown could be proposed due to differences in prominent protons. It was 
determined that the minor diastereomer was epimeric at C-2 due to the difference J 
values of Hj relative to Hc. Hj has two equivalent J values of 10.8 Hz, which it having 
relations with both Hi and Hk. Although NOE’s were not clearly observed due to 
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diminished signals, the shift of Hi is significantly lower than Hb, which also supports the 
proposed epimer. 
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163  
(6R*,7R*,7aR*,111S*)-6-Methyl-3-oxodecahydro-1H-pyrrolo[1,2-j]quinolin-
7-yl acetate (163). The reaction was carried out as described for compound 144. Acetate 
162 produced lactam 163 as a 10:1 diastereomeric mixture with an unknown 
diastereomer isolated as a yellow oil and characterized without further purification  
(80%). Rf = 0.47 (EtOAc); IR (neat) 1737, 1693 cm-1; 1H NMR (400 MHz, CDCl3) δ 0.79 
(d, J = 6.8 Hz, 3H), 1.11 (m, 1H), 1.32 (m, 1H), 1.45-1.61 (m, 2H), 1.62-1.73 (m, 2H), 
1.76-1.85 (m, 3H), 1.93 (m, 1H), 2.04 (m, 1H), 2.08 (s, 3H), 2.25 (dd, J = 16.4, 8.8 Hz, 
1H), 2.44-2.63 (m, 3H), 4.05 (dd, J = 12.8, 6.8 Hz, 1H), 4.77 (dd, J = 12.4, 8.0 Hz, 1H); 
13C NMR (100.6 MHz, CDCl3) δ 12.2, 20.6, 22.4, 23.3, 25.4, 25.9, 30.2, 32.6, 33.9, 41.1, 
43.0, 63.9, 70.0, 170.5, 175.0; MS (ES+) m/z 266 (M++1); HRMS calculated for 
C15H24NO3 (M++H): 266.1756, found 266.1620. 
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Structure determination for 163. The structure of compound 163 was proposed 
starting with Ha that was assigned the axial proton of C-1 based on the more upfield shift 
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(2.54 ppm vs. 4.04 ppm). He was assigned as axial due to the more upfield shift relative to 
the juxtapositional proton on C-5. Based on a present NOE between Hc and He, Hc must 
be axial, placing the acetoxy group equatorial. The J values for Hc of 12.4 and 8.0 Hz 
indicate one trans-diaxial and one axial-equatorial coupling. This suggests that Hb is 
equatorial since Hd must be axial based on the ring orientation. Thus, the methyl group is 
assigned axial. An NOE present between Ha and Hd supports the boat conformation of the 
piperidine ring, which is further supported by an NOE between the methyl group and Hd. 
The trans-fused ring system was supported by the NOE between Hc and He as well as the 
NOE between Hc and Hf.   
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150c  
(5S*,7S*,7aS*,111R*)-5-Hexyl-7-hydroxyoctahydro-1H-pyrrolo[1,2-
j]quinolin-3(2H)-one (150c). To a stirred solution of acetate 153 (135 mg, 0.40 mmol) in 
5 mL of a 1:1 MeOH/H2O mixture was added K2CO3 (165 mg, 1.2 mmol) at rt. After 1 h, 
TLC analysis indicated no remaining starting material, at which point the reaction was 
filtered and concentrated by rotary evaporation. The residue was redissolved in EtOAc 
and filtered to remove the remaining salts. The resulting yellow oil was purified by silica 
gel chromatography (EtOAc) to afford 107 mg (91%) of 150c as a yellow oil. Rf = 0.43 
(EtOAc); IR (neat) 3402, 1662 cm-1; 1H NMR (400 MHz, CDCl3) δ 0.89 (distorted t, J = 
6.8 Hz, 3H), 1.15 (qd, J = 12.4, 2.8 Hz, 1H), 1.24-1.37 (m, 8H), 1.42 (m, 1H), 1.48-1.63 
(m, 3H), 1.64-1.77 (m, 4H), 1.82 (m, 2H), 1.90-2.03 (m, 3H), 2.10 (dd, J = 16.4, 9.2 Hz, 
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1H), 2.29 (ddd, J = 13.6, 11.6, 8.8 Hz, 1H), 2.40-2.53 (m, 2H), 3.35 (m, 1H), 3.69 (ddd, J 
= 12.0, 8.8, 6.0 Hz, 1H); 13C NMR (100.6 MHz, CDCl3) d 144.1, 22.3, 22.7, 23.7, 25.6, 
25.7, 27.6, 29.1, 31.5, 31.7, 31.8, 33.5, 42.3, 48.9, 51.4, 65.1, 66.0, 175.8;  MS (ES+) m/z 
294 (M++H); HRMS calculated for C18H32NO2 (M++H): 294.2433, found 294.2371. 
 
N
O
O
C6H13
SMe
S
164  
O-(5S*,7S*,7aS*,111R*)-5-Hexyl-3-oxodecahydro-1H-pyrrolo[1,2-j]quinolin-
7-yl S-methyl carbonodithioate (164). The alcohol 150c (16 mg, 0.05 mmol) in THF (1 
mL) was added to a suspension of NaH (95% NaH, 12 mg, 0.5 mmol) in THF (1 mL) at –
78 °C. The solution was slowly warmed to 0 °C over 30 min when CS2 (0.1 mL, 1 mmol) 
was added along with a few flakes of imidazole. The reaction was warmed to rt for 15 
min and heated to reflux for 45 min. MeI (0.06 mL, 1 mmol) was added and refluxing 
was allowed to continue for 30 min. The reaction was cooled to rt and poured into a 
separatory funnel containing DCM and water (10 mL each). The aqueous layer was 
extracted twice with DCM (10 mL). The combined organic layers were dried over 
MgSO4, filtered, and concentrated. The residual oil was purified by preparative thin layer 
chromatography (10% EtOAc/hexanes), which afforded 164 as a yellow oil (89%). Rf = 
0.22 (20% EtOAc/hexanes); IR (neat) 1692, 1341, 1230, 1057 cm-1; 1H NMR (400 MHz, 
CDCl3) δ 0.89 (distorted t, J = 6.4 Hz, 3H), 1.17-1.38 (m, 10H), 1.48-1.63 (m, 2H), 1.64-
1.76 (m, 4H), 1.77-1.92 (m, 3H), 2.07 (m, 2H), 2.18 (dd, J = 16.4, 8.8 Hz, 1H), 2.43-2.55 
(m, 3H), 2.58 (s, 3H), 3.42 (m, 1H), 5.62 (ddd, J = 12.4, 8.8, 5.2 Hz, 1H); 13C NMR 
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(100.6 MHz, CDCl3) δ 14.1, 19.2, 22.6, 22.9, 23.5, 25.5, 25.8, 27.6, 29.1, 31.4, 31.5, 
31.8, 33.6, 38.7, 46.9, 51.4, 64.9, 78.7, 175.9, 215.6; MS (ES+) m/z 384 (M++H); HRMS 
calculated for C20H34NO2S2 (M++H): 384.2031, found 384.2023. 
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165  
(5S*,7aR*,111R*)-5-Hexyloctahydro-1H-pyrrolo[1,2-j]quinolin-3(2H)-one 
(165). To a stirred solution of 164 (13 mg, 0.03 mmol) in benzene (1 mL) was added a 
spatula tip of 2,2′-azobis(2-methylpropionitrile) followed by tributyltin hydride (0.03 mL, 
0.09 mmol) at rt. The reaction was allowed to reflux for 6 h before being cooled to rt and 
concentrated by rotary evaporation. The resulting yellow oil was purified by silica gel 
chromatography (20% → 40% EtOAc/hexanes). The fractions containing the lactam 
were passed through a short pad of silica impregnated with 10% KF using EtOAc. 
Lactam 165 was isolated as a yellow oil (99%). Rf = 0.10 (20% EtOAc/hexanes); IR 
(neat) 1689 cm-1; 1H NMR (400 MHz, CDCl3) δ 0.87 (distorted t, J = 6.4 Hz, 3H), 1.16 
(qd, J = 12.4, 3.2 Hz, 1H), 1.23-1.39 (m, 10H), 1.40-1.48 (m, 2H), 1.48-1.58 (m, 2H), 
1.59-1.81 (m, 8H), 1.88 (dd, J = 12.4, 8.0 Hz, 1H), 2.11 (dd, J = 16.0, 8.8 Hz, 1H), 2.40-
2.54 (m, 2H), 3.17 (m, 1H); 13C NMR (101 MHz, CDCl3) δ 14.1, 22.2, 22.7, 23.6, 24.5, 
26.2, 27.3, 27.8, 29.2, 30.5, 31.7, 31.9, 31.9, 33.3, 42.5, 51.7, 66.2, 176.3; MS (ES+) m/z 
278 (M++H); HRMS calculated for C18H32NO (M++H): 278.2484, found 278.2267. 
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Lactam 165 is equivalent to the a late-stage intermediate reported in Renaud’s total 
synthesis of lepadiformine A.44 
Renaud's Intermediate Observed shifts Difference 
14.3 14.1 0.2 
22.3 22.2 0.1 
22.8 22.7 0.1 
23.7 23.6 0.1 
24.6 24.5 0.1 
26.3 26.2 0.1 
27.4 27.2 0.2 
28 27.8 0.2 
29.3 29.2 0.1 
30.6 30.5 0.1 
31.8 31.7 0.1 
32 31.9 0.1 
32 31.9 0.1 
33.4 33.3 0.1 
42.7 42.5 0.2 
51.8 51.7 0.1 
66.3 66.2 0.1 
176.5 176.3 0.2 
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156c  
(5S*,7S*,7aS*,111R*)-5-Butyl-7-hydroxyoctahydro-1H-pyrrolo[1,2-j] 
quinolin-3(2H)-one (156c). The reaction was carried out as described in the procedure 
for compound 150c. Acetate 158 afforded lactam 156c as a yellow oil (75%). Rf = 0.24 
(60% EtOAc/hexanes); IR (neat) 3384, 1654 cm-1; 1H NMR (500 MHz, CDCl3) δ 0.88 
(distorted t, J = 7.1 Hz, 3H), 1.11 (ddd, J = 3.3, 12.6, 25.2 Hz, 1H), 1.21-1.40 (m, 6H), 
1.42-1.58 (m, 3H), 1.61-1.73 (m, 5H), 1.79 (d, J = 11.9 Hz, 2H), 1.89 (d, J = 10.5 Hz, 
1H), 1.96 (dd, J = 8.1, 12.6 Hz, 1H), 2.07 (m, 1H), 2.27 (ddd, J = 8.8, 11.8, 13.6 Hz, 1H), 
2.35-2.55 (m, 2H), 3.31 (dt, J = 6.1, 11.9 Hz, 1H), 3.66 (ddd, J = 5.8, 8.7, 11.8 Hz, 1H); 
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13C NMR (126 MHz, CDCl3) δ 14.1, 22.3, 22.5, 23.7, 25.6, 25.7, 29.8, 31.33, 31.5, 33.5, 
42.3, 48.9, 51.3, 65.0, 66.0, 175.79; MS (ES+) m/z 266 (M++H); HRMS calculated for 
C16H28NO2 (M++H): 266.2120, found 266.1917. 
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168  
O-(5S*,7S*,7aS*,111R*)-5-Butyl-3-oxodecahydro-1H-pyrrolo[1,2-j]quinolin-
7-yl S-methyl carbonodithioate (168). The reaction was carried out as described in the 
procedure for 164. Lactam 156c was used to afford xanthate 168 (81%) as a yellow oil 
after purification by preparative TLC (15% EtOAc/hexanes). Rf = 0.28 (20% 
EtOAc/hexanes); IR (neat) 1695, 1228, 1209, 1056 cm-1; 1H NMR (400 MHz, CDCl3) δ 
0.90 (distorted t, J = 7.0 Hz, 3H), 1.14-1.45 (m, 6H), 1.46-1.91 (m, 9H), 1.98-2.10 (m, 
2H), 2.15 (ddd, J = 8.9, 16.3 Hz, 1H), 2.56 (s, 3H), 2.53 – 2.40 (m, 3H), 3.37 (m, 1H), 
5.61 (ddd, J = 14.4, 8.8, 5.6 Hz, 1H); 13C NMR (101 MHz, CDCl3) δ 14.1, 19.2, 22.5, 
22.9, 23.5, 25.5, 25.8, 29.8, 31.2, 31.4, 33.6, 38.7, 46.9, 51.4, 64.9, 78.7, 175.8, 215.6; 
MS (ES+) m/z 356 (M++H); HRMS calculated for C18H30NO2S2 (M++H): 356.1718, 
found 356.1369. 
 
N
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 163 
(5S*,7aR*,111R*)-5-Butyloctahydro-1H-pyrrolo[1,2-j]quinolin-3(2H)-one 
(169). Lactam 169 was prepared following the procedure of compound 165 starting from 
168. Purification provided 169 as a yellow oil (88%). Rf = 0.27 (20% EtOAc/hexanes); IR 
(neat) 1689 cm-1; 1H NMR (400 MHz, CDCl3) δ 0.89 (distorted t, J = 7.1 Hz, 3H), 1.15 
(ddd, J = 3.4, 12.4, 24.8 Hz, 1H), 1.39 – 1.23 (m, 7H), 1.40 – 1.55 (m, 4H), 1.80 – 1.58 
(m, 9H), 1.86 (m, 1H), 2.10 (dd, J = 8.9, 16.1 Hz, 1H), 2.58 – 2.35 (m, 2H), 3.20 (m, 
1H); 13C NMR (101 MHz, CDCl3) δ 14.1, 22.1, 22.5, 23.5, 24.4, 26.1, 27.2, 30.0, 30.4, 
31.6 (2), 33.2, 42.5, 51.6, 66.1, 176.3; MS (ES+) m/z 250 (M++1); HRMS calculated for 
C16H28NO (M++H): 250.2171, found 250.2036. 
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14-HCl  
(5S*,7aR*,111R*)-5-butyldodecahydropyrrolo[1,2-j]quinolinium chloride 
(Lepadiformine C hydrochloride, 14). To a stirred solution of 169 (20 mg, 0.08 mmol) 
in THF (2 mL) at 0 °C was added 1M lithium aluminum hydride in ether (0.4 mL, 0.4 
mmol). The solution was heated to 60 °C for 5 h and then cooled to 0 °C. The reaction 
was diluted with ether followed by the addition of ca. 1 mL of H2O, then 1 mL of 10% 
NaOH/H2O, and subsequently Na2SO4. The reaction was stirred and warmed to rt. The 
phases were separated and the aqueous phase was extracted twice with DCM (10 mL), 
washed with brine (10 mL), dried with MgSO4, filtered and concentrated. Compound 14 
was dissolved in a minimum amount of DCM and about 1 mL of HCl/dioxane (4.0 M) 
was added dropwise. The solution was allowed to stir at rt for 30 min followed by 
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concentration. Purification with silica gel chromatography (5% MeOH/DCM) yielded 14-
HCl as a yellow oil (20 mg, 95%). IR (neat) 3392, 2927, 1645, 1464 cm-1; 1H NMR (400 
MHz, CDCl3) δ 0.89 (distorted t, J = 5.6 Hz, 3H), 1.06 (dq, J = 10.0, 2.8 Hz, 1H), 1.18-
1.42 (m, 7H), 1.46-1.55 (m, 2H), 1.60 (m, 1H), 1.68-1.75 (m, 3H), 1.83-1.87 (m, 2H), 
1.90-2.15 (m, 6H), 2.18 (m, 1H), 2.35 (m, 1H), 2.86 (m, 1H), 3.53 (m, 1H), 3.67 (dd, J = 
7.6, 4.8 Hz, 1H); 13C NMR (101 MHz, CDCl3) δ 13.9, 19.8, 20.8, 22.3, 22.4, 23.7, 25.1, 
27.6, 28.2, 29.8, 30.8, 35.3, 37.7, 46.9, 55.3, 74.8; MS (ES+) m/z 236 (M++H); HRMS 
calculated for C16H30N (M++H): 236.2378, found 236.2303. 
The data for amine 14-HCl are equivalent to those reported for the isolated natural 
product.10 
Reported Observed Difference 
13.9 13.9 0 
20 19.8 0.2 
21 20.8 0.2 
22.4 22.3 0.1 
22.4 22.4 0 
23.7 23.7 0 
25.1 25.1 0 
27.6 27.6 0 
28.3 28.2 0.1 
29.9 29.8 0.1 
30.8 30.8 0 
35.5 35.3 0.2 
37.8 37.7 0.1 
46.9 46.9 0 
55.3 55.3 0 
74.6 74.8 -0.2 
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Chapter 3 Experimental Section 
 
 
OTIPSOH
 
193 
(3R,5R)-5-((Triisopropylsilyl)oxy)hepta-1,6-dien-3-ol (193). To a stirred 
solution of (3R,5R)-hepta-1,6-diene-3,5-diol (2.7 g, 21.1 mmol) in THF (200 mL) at –78 
°C, was added n-BuLi (9.3 mL, 2.5 M in hexanes, 23.2 mmol) dropwise. The solution 
was allowed to stir for 20 min at –78 °C followed by the slow addition of TIPSCl (4.9 
mL, 23.2 mmol). After 2 hrs, the reaction was allowed to slowly warm to rt over night 
and was quenched with NH4Cl(aq) (100 mL) and the phases separated. The organic phase 
was washed with NH4Cl(aq) (3×), brine, dried with MgSO4, filtered, and concentrated. The 
crude extract was purified by silica gel chromatography (0→10% EtOAc/hexanes) to 
afford a yellow oil (6 g, 99%). Rf = 0.73 (20% EtOAc/hexanes); IR (neat) 3423, 1645, 
1463, 1064 cm-1; 1H NMR (400 MHz, CDCl3) δ 1.03-1.10 (m, 21H), 1.68 (ddd, J = 14.4, 
4.4, 2.8 Hz,1H), 1.87 (ddd, J = 14.0, 9.6, 4.4 Hz, 1H), 3.59 (s, 1H), 4.43 (m, 1H), 4.62 
(m, 1H), 5.06 (dt, J = 10.8, 1.2 Hz, 1H), 5.17 (dt, J = 10.4, 1.2 Hz, 1H), 5.26 (ddt, J = 
17.2, 12.0, 1.6 Hz, 2H), 5.83 (ddd, J = 16.0, 10.4, 5.6 Hz, 1H), 5.94 (ddd, J = 6.0, 10.4, 
16.4 Hz, 1H); 13C NMR (100.6 MHz, CDCl3) δ 12.2, 18.0 (2), 43.2, 69.6, 73.2, 114.0, 
114.9, 140.0, 140.9; MS (ES+) m/z 285 (M++H); HRMS calculated for C16H32O2Si 
(M++H): 285.2272, found 285.2255; [α]
! 
23.6
D
 –5.4 (c 1.02, DCM).  
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195 
(1R,4R)-4-((Triisopropylsilyl)oxy)cyclopent-2-enol (195). To a stirred solution 
of Grubbs I catalyst (362 mg, 0.44 mmol) in DCM (1200 mL) was added 193 (2.5 g, 8.8 
mmol) at rt. The reaction was allowed to stir over night followed by concentration under 
rotary evaporation. The crude material was purified by column chromatography (0→20% 
EtOAc/hexanes) to yield a yellow oil (1.5 g, 68%). Rf = 0.41 (20% EtOAc/hexanes); IR 
(neat) 3322, 1463, 1062 cm-1; 1H NMR (400 MHz, CDCl3) δ 1.03-1.07 (m, 21H), 2.03-
2.08 (m, 2H), 2.10 (s, 1H), 4.98 (m, 1H), 5.15 (m, 1H), 5.91-5.98 (m, 2H); 13C NMR 
(100.6 MHz, CDCl3) δ 12.0, 17.9 (2), 44.7, 76.0, 76.5, 135.4, 138.4; MS (ES+) m/z 239 
(M+-H2O); HRMS calculated for C14H27OSi (M+-H2O): 239.1826, found 239.1834; 
[α]
! 
23.7
D
 +107.9 (c 2.15, DCM) 
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(R)-181 
(R)-4-((Triisopropylsilyl)oxy)cyclopent-2-enone (181). To a stirred solution of 
195 (2.0 g, 7.8 mmol) in DCM (40 mL) was added pyridinium dichlorochromate (4.4 g, 
11.7 mmol). The reaction stirred at rt for 24 hr followed by filtration through filter paper 
with Et2O two sequential times. The solution was concentrated under rotary evaporation 
and the concentrate was purified by silica gel column chromatography (0→10% 
EtOAc/hexanes) to afford a yellow oil (1.8 g, 92%). Rf = 0.30 (10% EtOAc/hexanes); IR 
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(neat) 1725, 1463, 1111 cm-1; 1H NMR (400 MHz, CDCl3) δ 1.02-1.12 (m, 21H), 2.28 
(dd, J = 18.0, 2.0 Hz,1H), 2.73 (dd, J = 18.0, 6.0 Hz, 1H), 5.06 (m, 1H), 6.16 (d, J = 5.6 
Hz, 1H), 7.48 (dd, J = 5.2, 2.0 Hz, 1H), 13C NMR (100.6 MHz, CDCl3) δ 12.0, 17.8 (2), 
45.3, 70.9, 134.3, 163.8, 206.4; MS (ES+) m/z 255 (M++H); HRMS calculated for 
C14H27O2Si (M++H): 255.1780, found 255.1735; [α]
! 
25.2
D
 +53.3 (c 1.05, MeOH). Lit. value 
for enantiomer is [α]D –58.8 (c 1.05, MeOH).121 Chiral GC separation: Astec Chiraldex 
B-DM fused silica capillary column, 30 m x 0.25 mm x 0.12 µm, temperature gradient 
from 120 ºC–140 ºC ramping up at 0.25 ºC/min, tR = 44.13 min, tS = 45.26 min. 
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231 
2-(3-((tert-Butyldimethylsilyl)oxy)propyl)cyclopent-2-enone (231). Following a 
procedure by Johnson and coworkers,110 to neat allyl tert-butyldimethylsilyl ether (340 
mg, 2.0 mmol) was added 4.8 mL of 9-BBN (0.5 M, 2.4 mmol) and stirred at 40 ºC for 
two hours and cooled to rt. In a separate flask, PdCl2(dppf) (82 mg, 0.1 mmol) was added 
to a solution of 230 (620 mg, 1.5 mmol) in 4 mL of DMF (0.5 M based on allyl ether). 
Immediately following the catalyst addition, the solution of allyl ether and 9-BBN was 
added followed by 3 M K3PO4 (2.0 mL, 6.0 mmol). The combined solution was stirred at 
60 ºC for four hours. Equal parts of DCM (20 mL) and NH4Cl(aq) (20 mL) were added to 
the reaction and the layers were separated. The aqueous phase was extracted with DCM 
(3×), brine, dried with Na2SO4 and celite, filtered and concentrated. The resulting oil was 
purified by silica gel column chromatography (0→10% EtOAc/hexanes) to afford a 
yellow oil (295 mg, 58%). Rf = 0.40 (10% EtOAc/hexanes); IR (neat) 1705, 1252, 1104 
cm-1; 1H NMR (400 MHz, CDCl3) δ 0.01 (s, 6H), 0.85 (s, 9H), 1.67 (p, J = 8.0 Hz, 2H), 
2.19 (t, J = 7.2 Hz, 2H), 2.32-2.39 (m, 2H), 2.49-2.56 (m, 2H), 3.58 (t, J = 6.4 Hz, 2H), 
7.29 (s, 1H), 13C NMR (100.6 MHz, CDCl3) δ 5.4, 18.2, 21.2, 25.9, 26.3, 30.7, 34.5, 
62.5, 145.9, 157.4, 209.8; MS (ES+) m/z 255 (M++H); HRMS calculated for C14H27O2Si 
(M++H): 255.1780, found 255.1776. 
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233 
2-(3-((tert-butyldimethylsilyl)oxy)propyl)-4-((triisopropylsilyl)oxy)cyclopent-
2-enone (233). Obtained according to the procedure for the formation of 231 starting 
with allyl tert-butyldimethylsilylether and 225. The crude mixture was purified by silica 
gel column chromatography (5% EtOAc/hexanes) to afford a yellow oil (470 mg, 55%). 
Rf = 0.63 (10% EtOAc/hexanes); IR (neat) 1706, 1463, 1100 cm-1; 1H NMR (400 MHz, 
CDCl3) δ 0.04 (s, 6H), 0.89 (s, 9H), 1.04-1.10 (m, 21H), 1.71 (p, J = 6.4 Hz, 2H), 2.24 (t, 
J = 7.6 Hz, 2H), 2.32 (dd, J = 18.4, 2.0 Hz, 1H), 2.77 (dd, J = 18.0, 5.6 Hz, 1H), 3.62 (t, J 
= 6.4 Hz, 2H), 7.10 (s, 1H); 13C NMR (100.6 MHz, CDCl3) δ 5.3, 12.0, 17.9, 17.7, 20.9, 
25.9, 30.3, 45.9, 62.4, 69.0, 146.7, 156.9, 206.2; MS (ES+) m/z 427 (M++H); HRMS 
calculated for C23H47O3Si2 (M++H): 427.3064, found 427.3047.  
 
O
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245 
2-(4-(Benzyloxy)-3-((tert-butyldimethylsilyl)oxy)butyl)-4-((triisopropylsilyl)-
oxy)cyclopent-2-enone (245). Obtained according to the procedure for the formation of 
231 starting from 238 and 225. The crude mixture was purified by silica gel column 
chromatography (0→10% EtOAc/hexanes) to afford a yellow oil (190 mg, 70%) as an 
inseparable mixture of two diastereomers. Rf = 0.77 (20% EtOAc/hexanes); IR (neat) 
1716, 1462, 1251, 1088 cm-1; 1H NMR (400 MHz, CDCl3) δ 0.07 (s, 6H), 0.08 (s, 6H), 
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0.91 (s, 18H), 1.06-1.12 (m, 42H), 1.61-1.74 (m, 2H), 1.74-1.87 (m, 4H), 2.16-2.39 (m, 
6H), 2.79 (dd, J = 18.4, 6.0 Hz, 2H), 3.42 (ddd, J = 19.2, 9.6, 5.6 Hz, 4H), 3.88 (p, J = 
5.2 Hz, 2H), 4.54 (s, 4H),4.96-5.00 (m, 2H), 7.11 (s, 2H), 7.25-7.38 (m, 10H); 13C NMR 
(100.6 MHz, CDCl3) δ -4.9, -4.5, 12.0, 12.2, 17.6, 17.8, 17.9, 18.1, 20.2, 25.8, 32.1, 32.2, 
45.9, 69.0, 70.8, 70.9, 73.2, 74.2, 74.3, 127.4, 127.5, 128.0, 128.2, 138.2, 146.9, 147.0, 
156.5, 156.6, 206.0, 206.1; MS (ES+) m/z 564 (M++NH4); HRMS calculated for 
C31H55O4Si2 (M++H): 547.3639, found 547.3725. 
 
O
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242 
2-(4-(Benzyloxy)-3-hydroxybutyl)-4-((triisopropylsilyl)oxy)cyclopent-2-enone 
(242). To a stirred solution of 1% HCl in EtOH (140 mL) was added 245 (750 mg, 1.4 
mmol) at rt. After 2 hr, NaHCO3 (100 mL) and DCM (100 mL) were added and the 
layers separated. The aqueous layer was extracted 3× with DCM and the combined 
organic layers were washed with brine, dried with Na2SO4, filtered and concentrated. The 
crude oil was purified by silica gel column chromatography (20% EtOAc/hexanes) to 
afford 242 as a yellow oil (415 mg, 70%) as an inseparable mixture of two diastereomers. 
Rf = 0.25 (20% EtOAc/hexanes); IR (neat) 3432, 1710, 1463, 1088 cm-1; 1H NMR (400 
MHz, CDCl3) δ 1.04-1.13 (m, 42H), 1.60-1.69 (m, 4H), 1.74-1.87 (m, 4H), 2.16-2.39 (m, 
6H), 2.50 (dd, J = 24.8, 4.0 Hz, 2H), 2.78 (ddd, J = 18.0, 6.0, 1.2 Hz, 4H), 3.36 (ddd, J = 
10.0, 7.6, 2.8 Hz, 2H), 3.50 (dt, J = 9.2, 2.4 Hz, 2H), 3.74-3.82 (m, 2H), 4.55 (s, 4H), 
4.95-4.99 (m, 2H), 7.11-7.15 (m, 2H), 7.27-7.38 (m, 10H); 13C NMR (100.6 MHz, 
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CDCl3) δ 12.0, 17.8, 17.8, 20.5, 20. 6, 30.9, 31.2, 45.8, 68.9, 68.9, 69.5, 69.6, 73.2, 73.3, 
74.2, 74.2, 127.6, 127.6, 127.7, 127.7, 128.3, 137.8, 137.9, 146.3, 146.4, 157.3, 157.4, 
206.3, 206.4; MS (ES+) m/z 450 (M++NH4); HRMS calculated for C25H41O4Si (M++H): 
433.2774, found 433.2790. 
 
O
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247 
1-(Benzyloxy)-4-(5-oxo-3-((triisopropylsilyl)oxy)cyclopent-1-en-1-yl)butan-2-
yl methanesulfonate (247). Following a procedure by Molander and coworkers,26 to a 
stirred solution of 242 (100 mg, 0.23 mmol) in DCM (2 mL) was sequentially added TEA 
(0.06 mL, 0.46 mmol), a spatula tip of DMAP, and MsCl (0.02 mL, 0.28 mmol) at rt. 
After no more than 20 min, the reaction was concentrated under rotary evaporation and 
passed through a plug of silica with 30% EtOAc/hexanes to afford 247 as a yellow oil 
(117 mg, 99%) as an inseparable mixture of two diastereomers. Rf = 0.21 (20% 
EtOAc/hexanes); IR (neat) 1713, 1463, 1350, 1173, 1095 cm-1; 1H NMR (400 MHz, 
CDCl3) δ 1.04-1.14 (m, 42H), 1.85-1.94 (m, 4H), 2.26-2.39 (m, 6H), 2.77 (dd, J = 18.4, 
6.0 Hz, 2H), 3.02 (s, 6H), 3.56-3.67 (m, 4H), 4.54 (dd, J = 18.0, 12.0 Hz, 4H), 4.75-4.86 
(m, 2H), 4.94-4.99 (m, 2H), 7.17-7.21 (m, 2H), 7.27-7.38 (m, 10H); 13C NMR (100.6 
MHz, CDCl3) δ 12.0, 17.8, 17.9, 20.3, 20. 4, 29.2, 29.4, 38.6, 38.6, 45.8, 45.9, 68.9, 68.9, 
71.3, 71.4, 73.4, 73.4, 81.4, 127.7, 127.8, 127.9, 128.5, 137.2, 137.2, 144.9, 145.1, 157.9, 
158.3, 205.9, 206.0; MS (ES+) m/z 528 (M++NH4); HRMS calculated for C26H46O6SNSi 
(M++NH)4: 528.2816, found 528.2781. 
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218 
2-(3-Azido-4-(benzyloxy)butyl)-4-((triisopropylsilyl)oxy)cyclopent-2-enone 
(218). Following a procedure from Molander and coworkers,26 to a stirred solution of 247 
(780 mg, 1.5 mmol) in DMSO (6 mL) was added NaN3 (487 mg, 7.5 mmol) at rt. The 
reaction was heated to 60 ºC for 2 hr. At rt, DCM (20 mL) and H2O (20 mL) were added 
and the layers were separated. The aqueous layer was extracted 3× with DCM and the 
combined organic layers were washed with brine, dried with Na2SO4, filtered and 
concentrated. The crude oil was purified by silica gel column chromatography (10% 
EtOAc/hexanes) to afford 218 as a yellow oil (640 mg, 94%) as an inseparable mixture of 
two diastereomers. Rf = 0.36 (20% EtOAc/hexanes); IR (neat) 2095, 1713, 1091 cm-1; 1H 
NMR (400 MHz, CDCl3) δ 0.97-1.09 (m, 42H), 1.48-1.59 (m, 2H), 1.60-1.72 (m, 2H), 
2.11-2.33 (m, 6H), 2.70 (dd, J = 18.0, 6.0 Hz, 2H), 3.36-3.55 (m, 6H), 4.49 (s, 4H), 4.87-
4.91 (m, 2H), 7.03-7.05 (m, 2H), 7.18-7.30 (m, 10H); 13C NMR (100.6 MHz, CDCl3) 
δ 12.0, 17.9, 17.9, 21.3, 21.3, 28.6, 28.7, 45.9, 61.3, 61.3, 68.9, 72.6, 73.3, 73.4,127.6, 
127.8, 128.4, 137.7, 145.6, 157.5, 206.0; MS (ES+) m/z 430 (M+-N2+H); HRMS 
calculated for C25H40NO3Si (M+-N2+H): 430.2783, found 430.2766 
  
O
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248 
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2-(3-Hydroxypropyl)cyclopent-2-enone (248). To a stirred solution of 231 (1.3 
g, 5.1 mmol) in THF (3 mL) was slowly added a 1M solution of TBAF (10.2 mL, 10.2 
mmol) in THF at 0 ºC. The reaction was allowed to slowly warm to rt. After 12 h the 
reaction was concentrated and purified by silica gel column chromatography (50→100% 
EtOAc/hexanes) to afford 248 as a yellow oil (230 mg, 33%). Spectral data matched the 
literature values.116 
 
O
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249 
2-(3-Azidopropyl)cyclopent-2-enone (249). To a stirred solution of 248 (90 mg, 
0.64 mmol) in THF (1.5 mL) was added PPh3 (340 mg, 1.3 mmol) at 0 ºC. DIAD (0.25 
mL, 1.3 mmol) was added after 5 minutes and DPPA (0.31 mL, 1.4 mmol) was added 10 
minutes later. The reaction was allowed to slowly warm up to room temperature over 1 hr 
and DCM (5 mL) and NaHCO3 (5 mL) were added. The layers were separated and the 
aqueous layer was extracted 3× with DCM. The combined organic extracts were washed 
with brine, dried with Na2SO4, filtered, and concentrated. The resulting yellow oil was 
further purified by silica gel chromatography (10% EtOAc/hexanes) to afford a yellow oil 
(70 mg, 67%). The spectral data matched that in the literature.122 
 
N
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(7aR*,11aS*)-2,3,6,7,7a,8-Hexahydro-1H-pyrrolo[2,1-j]quinolin-5(11H)-one 
(250). To a stirred solution of 249 (16 mg, 0.10 mmol) in DCM (4 mL) was bubbled 1,3-
butadiene gas for 5 min at 0 ºC. A 1M solution of MeAlCl2 in hexanes (0.3 mL, 0.3 
mmol) was added after 5 min and a temperature of 0 ºC was maintained for 1 hr and then 
allowed to warm to rt. The reaction media was gelatin so DCM (10 mL) was added to 
loosen up the mixture.  NaHCO3 (10 mL) was subsequently added and the layers were 
separated. The aqueous layer was extracted with DCM (2×). The combined organic layers 
were washed with NaHCO3 followed by brine, dried with MgSO4, filtered and 
concentrated. The resulting oil was purified by silica gel column chromatography 
(EtOAc) to afford a yellow oil (12 mg, 63%). Rf = 0.33 (EtOAc); IR (neat) 1638, 1439 
cm-1; MS (ES+) m/z 192 (M++H); HRMS calculated for C12H18NO (M++H): 192.1390, 
found 192.1371. 
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251 
(7R*,7aR*,11aS*)-3-((Benzyloxy)methyl)-7-((triisopropylsilyl)oxy)-
2,3,6,7,7a,8-hexahydro-1H-pyrrolo[2,1-j]quinolin-5(11H)-one (251). To a stirred 
solution of the diastereomeric mixture of 218 (40 mg, 0.08 mmol) in DCM (1 mL) was 
added 20% wt 1,3-butadiene in toluene (0.94 mL, 2.8 mmol) at 0 ºC. After 5 min, 1M 
MeAlCl2 in hexanes (0.16 mL, 0.16 mmol) was added and the temperature of 0 ºC was 
maintained for 2 hr and allowed to warm to rt. After 2 hr, NaHCO3 (5 mL) and EtOAc (5 
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mL) were added and the layers were separated and the aqueous layer was extracted with 
EtOAc (2×). The combined organic layers were washed with brine, dried with MgSO4, 
filtered and concentrated. Analysis of the crude NMR mixture indicated ca. 1:1 mixture 
of two diastereomers. The resulting oil was purified by silica gel preparative TLC (30% 
EtOAc/hexanes) to afford a yellow oil (30 mg, 71%) as a 5:1 mixture of diastereomers. Rf 
= 0.41 (30% EtOAc/hexanes); IR (neat) 1645, 1429, 1100 cm-1; 1H NMR (400 MHz, 
CDCl3) δ 1.05 (s, 21H), 1.64-1.85 (m, 3H), 1.88-1.97 (m, 2H), 1.99-2.15 (m, 2H), 2.29-
2.42 (m, 2H), 2.55(dd, J = 18.0, 3.2, 1H), 2.81 (dd, J = 18.0, 7.6 Hz, 1H), 3.60-3.76 (m, 
2H), 4.28 (m, 1H), 4.38 (m, 1H), 4.43-4.55 (m, 2H), 5.53 (m, 1H), 5.61 (m, 1H), 7.23-
7.36 (m, 5H); Major diastereomer: 13C NMR (100.6 MHz, CDCl3) δ 12.7, 18.2, 25.0, 
26.9, 33.9, 36.7, 41.8, 43.7, 57.3, 63.3, 69.2, 69.8, 73.1, 124.9, 126.3, 127.4, 127.5, 128.3, 
138.6, 168.0; ); Minor diastereomer (diagnostic peaks only): 13C NMR (100.6 MHz, 
CDCl3) δ 42.4, 46.1, 56.8, 62.4, 66.6, 69.0, 124.0, 125.4, 138.5, 168.1; MS (ES+) m/z 
484 (M++H); HRMS calculated for C29H46NO3Si (M++H): 484.3247, found 484.3238. 
 
OTBS
OBn  
(S)-238 
(S)-((1-(Benzyloxy)but-3-en-2-yl)oxy)(tert-butyl)dimethylsilane (238). To a 
stirred solution of (S)-1-(benzyloxy)but-3-en-2-ol117 (1.0 g, 5.6 mmol) in DMF (6 mL) 
was added TBSCl (2.5 g, 17 mmol) and imidazole (1.5 g, 23 mmol) at rt. Ether (10 mL) 
and water (10 mL) were added to the reaction after 24 h, which was then allowed to 
warm to rt. The aqueous layer was extracted 3× with ether. The combined organic 
extracts were washed with aqueous 1M HCl, NaHCO3, and then brine. The organic layer 
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was dried with Na2SO4, filtered, and concentrated. The resulting yellow oil was further 
purified by silica gel chromatography (0 → 5% EtOAc/hexanes) to afford a yellow oil 
(1.3 g, 81%), %). Rf = 0.81 (10% EtOAc/hexanes); Spectral data matched literature;113 
[α]
! 
23.7
D –17.0 (c 1.17, CHCl3). 
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(R)-225 
(R)-2-Iodo-4-((triisopropylsilyl)oxy)cyclopent-2-enone (225). To a stirred 
solution of I2 (10.7 g, 42 mmol) in Et2O (70 mL) was added pyridine (2.0 mL, 25 mmol) 
followed by dropwise addition of (R)-181 (8.9 g, 35 mmol) at rt. The reaction flask was 
covered completely with aluminum foil. After 24 hr, the reaction was quenched with 
Na2S2O3(aq) (50 mL) and allowed to stir until the solution changed from dark in color to 
clear and light yellow. Subsequently, the layers were partitioned and the organic layer 
was washed with Na2S2O3(aq) (3×), 1 M HCl (3×), again with Na2S2O3(aq) (3×), and brine. 
The organic layer was then dried with MgSO4, filtered and concentrated under rotary 
evaporation and the resulting oil was purified using silica gel column chromatography 
(0→10% Et2O/hexanes) to afford a yellow oil (11 g, 85%). Rf = 0.45 (10% 
EtOAc/hexanes); IR (neat) 1726, 1463, 1093 cm-1; 1H NMR (400 MHz, CDCl3) δ 1.03-
1.10 (m, 21H), 2.38 (dd, J = 18.0, 2.0 Hz,1H), 2.89 (dd, J = 18.0, 5.6 Hz, 1H), 5.03 (dt, J 
= 6.0, 2.0 Hz, 1H), 7.82 (d, J = 2.8 Hz, 1H), 13C NMR (100.6 MHz, CDCl3) δ 11.9, 17.8 
(2), 42.8, 72.2, 104.8, 169.2, 200.1; MS (ES+) m/z 398 (M++NH4); HRMS calculated for 
C14H26O2Si (M++NH4): 398.1012, found 398.0972; [α]
! 
23.7
D
 +25.5 (c 4.3, DCM). 
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(R,S)-245 
(R)-2-((S)-4-(Benzyloxy)-3-((tert-butyldimethylsilyl)oxy)butyl)-4-
((triisopropylsilyl) oxy)cyclopent-2-enone (245). Obtained according to the procedure 
for the formation of 231 starting from (S)-238 and (R)-225. The crude mixture was 
purified by silica gel column chromatography (0→10% EtOAc/hexanes) to afford a 
yellow oil (3.6 g, 88%). Rf = 0.77 (20% EtOAc/hexanes); IR (neat) 1716, 1462, 1251, 
1088 cm-1; 1H NMR (400 MHz, CDCl3) δ 0.05 (s, 3H), 0.06 (s, 3H), 0.89 (s, 9H), 1.06-
1.12 (m, 21H), 1.65 (m, 1H), 1.78 (m, 1H), 2.14-2.39 (m, 3H), 2.77 (dd, J = 18.4, 6.0 Hz, 
2H), 3.41 (ddd, J = 19.2, 9.6, 5.6 Hz, 4H), 3.86 (m, 1H), 4.52 (s, 2H),4.96 (m, 1H), 7.09 
(m, 1H), 7.25-7.38 (m, 5H); 13C NMR (100.6 MHz, CDCl3) δ -4.8, -4.4, 12.0, 17.7, 17.8, 
17.9, 20.2, 25.8, 32.2, 45.9, 69.0, 70.8, 73.2, 74.3, 127.4, 127.5, 128.2, 138.3, 147.0, 
156.5, 205.9; MS (ES+) m/z 564 (M++NH4); HRMS calculated for C31H55O4Si2 (M++H): 
547.3639, found 547.3725; ; [α]
! 
23.7
D
 +4.91 (c 3.8, DCM). 
 
O
TIPSO
OBn
OH
 
(R,S)-242 
(R)-2-((S)-4-(Benzyloxy)-3-hydroxybutyl)-4-((triisopropylsilyl)oxy)cyclopent-
2-enone (242). To a stirred solution of (R,S)-245 (1.0 g, 1.8 mmol) in MeOH (4 mL) was 
added PPTS (900 mg, 3.6 mmol) at rt. After 12 hr, DCM (20 mL) and H2O (20 mL) were 
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added and the layers were partitioned and the aqueous layer was extracted with DCM 
(3×). The combined organic layers were washed with 1 M HCl (3×) followed by brine. 
The organic layer was then dried with MgSO4, filtered and concentrated under rotary 
evaporation and the resulting oil was purified using silica gel column chromatography 
(0→10% Et2O/hexanes) to afford a yellow oil (540 mg, 70%). Rf = 0.25 (20% 
EtOAc/hexanes); IR (neat) 3432, 1710, 1463, 1088 cm-1; 1H NMR (400 MHz, 
CDCl3) δ 0.98-1.18 (m, 21H), 1.63 (q, J = 6.8 Hz, 2H), 2.22-2.42 (m, 3H), 2.64 (br s,1H), 
2.78 (dd, J = 18.0, 6.0 Hz, 1H), 3.36 (t, J = 8.0 Hz, 1H), 3.49 (dd, J = 9.6, 3.2 Hz, 1H), 
3.78 (m, 1H), 4.54 (s, 2H), 4.95 (m, 1H), 7.13 (s, 1H), 7.25-7.37 (m, 5H); 13C NMR 
(100.6 MHz, CDCl3) δ 12.0, 17.8, 17.9, 20.5, 31.2, 45.9, 69.0, 69.6, 73.3, 74.2, 127.7, 
127.7, 128.4, 137.9, 146.4, 157.5, 206.4; MS (ES+) m/z 450 (M++NH4); HRMS 
calculated for C25H41O4Si (M++H): 433.2774, found 433.2790; [α]
! 
23.7
D
 +8.1 (c 1.0, DCM). 
 
O
TIPSO
OBn
OMs
 
(R,S)-247 
(S)-1-(Benzyloxy)-4-((R)-5-oxo-3-((triisopropylsilyl)oxy)cyclopent-1-en-1-
yl)butan-2-yl methanesulfonate (247). Obtained according to the procedure for the 
formation of 247 starting from (R,S)-242 to afford (R,S)-247 (340 mg, 99%) as a yellow 
oil. Rf = 0.21 (20% EtOAc/hexanes); IR (neat) 1713, 1463, 1350, 1173, 1095 cm-1; 1H 
NMR (400 MHz, CDCl3) δ 1.03-1.12 (m, 21H), 1.89 (q, J = 7.6 Hz, 2H), 2.27-2.35 (m, 
3H), 2.77 (dd, J = 18.4, 6.0 Hz, 1H), 3.01 (s, 3H), 3.61 (ddd, J = 22.8, 10.8, 7.2 Hz, 2H), 
4.54 (dd, J = 17.6, 12.0 Hz, 2H), 4.81 (ddd, J = 10.0, 6.4, 3.6 Hz, 1H), 4.96 (m, 1H), 7.18 
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(s, 1H), 7.25-7.37 (m, 5H); 13C NMR (100.6 MHz, CDCl3) δ 12.0, 17.8, 17.8, 20.2, 29.3, 
38.6, 45.8, 68.9, 71.2, 73.3, 81.3, 127.7, 127.9, 128.4, 137.2, 145.1, 157.9, 205.9; MS 
(ES+) m/z 528 (M++NH4); HRMS calculated for C26H46O6NSSi (M++NH)4: 528.2816, 
found 528.2781; ; [α]
! 
23.7
D
 +17.2 (c 4.3, DCM). 
 
O
TIPSO
OBn
N3
 
(R,R)-218 
(R)-2-((R)-3-Azido-4-(benzyloxy)butyl)-4-((triisopropylsilyl)oxy)cyclopent-2-
enone (218). Obtained according to the procedure for the formation of 218 starting from 
(R,S)-247 to afford (R,S)-218 (160 mg, 72%) as a yellow oil. Rf = 0.36 (20% 
EtOAc/hexanes); IR (neat) 2095, 1713, 1091 cm-1; 1H NMR (400 MHz, CDCl3) δ 1.03-
1.16 (m, 21H), 1.62 (m, 1H), 1.74 (m, 1H), 2.19-2.40 (m, 3H), 2.78 (dd, J = 18.4, 6.0 Hz, 
1H), 3.47-3.55 (m, 2H), 3.59 (m, 1H), 4.56 (s, 2H), 4.97 (m, 1H), 7.12 (m, 1H), 7.25-7.38 
(m, 5H); 13C NMR (100.6 MHz, CDCl3) δ 12.0, 17.8, 17.9, 21.3, 28.5, 45.8, 61.3, 68.9, 
72.6, 73.3,127.5, 127.7, 128.4, 137.6, 145.6, 157.4, 205.9; MS (ES+) m/z 430 (M+-
N2+H); HRMS calculated for C25H40NO3Si (M+-N2+H): 430.2783, found 430.2766; ; 
[α]
! 
23.7
D
 +31.5 (c 1.00, DCM). 
 
N
TIPSO
OBn
O
 
(R,S,R,R)-251 
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(3R,7R,7aR,11aS)-3-((Benzyloxy)methyl)-7-((triisopropylsilyl)oxy)-
2,3,6,7,7a,8-hexahydro-1H-pyrrolo[2,1-j]quinolin-5(11H)-one (251). Obtained 
according to the procedure for the formation of 251 starting from (R,S)-218 to afford 
(R,S,R,R)-251 (32 mg, 67%) as a yellow oil. NMR analysis of the crude reaction mixture 
indicated a single diastereomer. Rf = 0.41 (30% EtOAc/hexanes); IR (neat) 1645, 1429, 
1100 cm-1; 1H NMR (400 MHz, CDCl3) δ 1.06 (s, 21H), 1.70-1.85 (m, 3H), 1.92-1.99 (m, 
2H), 2.00-2.15 (m, 2H), 2.29-2.42 (m, 2H), 2.57 (dd, J = 18.0, 3.2, 1H), 2.83 (dd, J = 
18.0, 7.6 Hz, 1H), 3.62-3.78 (m, 2H), 4.30 (m, 1H), 4.40 (ddd, J = 7.6, 5.6, 3.6 Hz, 1H), 
4.51 (dd, J = 21.6, 11.6 Hz, 2H), 5.55 (m, 1H), 5.64 (m, 1H), 7.26-7.38 (m, 5H); 13C 
NMR (100.6 MHz, CDCl3) δ 12.7, 18.2, 25.0, 26.9, 33.9, 36.7, 41.8, 43.7, 57.3, 63.3, 
69.2, 69.8, 73.1, 124.9, 126.3, 127.4, 127.5, 128.3, 138.6, 168.0; MS (ES+) m/z 484 
(M++H); HRMS calculated for C29H46NO3Si (M++H): 484.3247, found 484.3238; ; [α]
! 
23.7
D
 
–16.5 (c 2.2, DCM). 
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Appendix I 
 
 General Methods. X-ray crystal structure determination was performed by Victor 
Day, Ph.D. at the University of Kansas. Intensity data were collected using a Bruker APEX 
CCD area detector mounded on a Bruker D8 geniometer with graphite-monochromated MoK 
radiation.  
 
N
O
OH
140  
 
Specific methods for structure determination and refinement of compound 140. 
The compound was recrystallized from DCM. Colorless plate-shaped crystals of C12H19NO2 
are, at 100(2) K, monoclinic, space group Cc – Cs4 (No. 9) [1] with a = 15.052(2) Å, b = 
7.812(1) Å, c = 10.978(1) Å,   = 127.009(2), V = 1030.8(2) Å3 and Z =  4 molecules {dcalcd = 
1.348 g/cm3; a(MoK) = 0.091 mm-1}.   A full hemisphere of diffracted intensities (1850 20-
second frames with a scan width of 0.30) was measured for a single-domain specimen using 
graphite-monochromated MoK radiation (= 0.71073 Å) on a Bruker SMART APEX CCD 
Single Crystal Diffraction System [2].  X-rays were provided by a fine-focus sealed x-ray 
tube operated at 50kV and 30mA.  Lattice constants were determined with the Bruker 
SAINT software package using peak centers for 1580 reflections.  A total of 5843 integrated 
reflection intensities having 2((MoK)< 61.00 were produced using the Bruker program 
SAINT[3]; 2882 of these were unique and gave Rint = 0.042 with a coverage which was 
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98.0% complete. The data were corrected empirically for variable absorption effects using 
equivalent reflections; the relative transmission factors ranged from 0.906 to 1.000.  The 
Bruker software package SHELXTL was used to solve the structure using “direct methods” 
techniques.  All stages of weighted full-matrix least-squares refinement were conducted 
using Fo2 data with the SHELXTL Version 6.10 software package[4].  
 The final structural model incorporated anisotropic thermal parameters for all 
nonhydrogen atoms and isotropic thermal parameters for all hydrogen atoms.  All 
hydrogen atoms were located in a difference Fourier and included in the structural 
model as independent isotropic atoms whose parameters were allowed to vary in 
least-squares refinement cycles.  When a couple isotropic thermal parameters for 
these hydrogen atoms refined to non-positive-definite values, the isotropic thermal 
parameters for all hydrogen atoms except the hydroxyl hydrogen were fixed at values 
1.2 times the equivalent isotropic thermal parameter of the carbon atom to which they 
were covalently bonded.  A total of 194 parameters were refined using 2 restraints, 
2882 data and weights of w = 1/ [
2
(F
2
) + (0.0932 P)
2
], where P = [Fo
2
 + 2Fc
2
] / 3.  
Final agreement factors at convergence are:  R1(unweighted, based on F) = 0.069 for 
2542 independent absorption-corrected “observed” reflections having 2(MoK)<  
61.00 and I>2(I);  R1(unweighted, based on F) = 0.078 and wR2(weighted, based on 
F2) = 0.162 for all 2882 independent absorption-corrected reflections having 
2(MoK)< 61.00.  The largest shift/s.u. was 0.000 in the final refinement cycle.  The 
final difference map had maxima and minima of 0.40 and -0.25 e-/Å
3
, respectively. 
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Figure 7. Ellipsoid drawing of 140 
   
Table 6.  Crystal data and structure refinement for C12H19NO2. 
Empirical formula  C12H19NO2 
Formula weight  209.28 
Temperature  100(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  Cc – Cs4 (No. 9) 
Unit cell dimensions a = 15.052(2) Å  = 90.000° 
 b = 7.812(1) Å  = 127.009(2)°. 
 c = 10.978(1) Å  = 90.000° 
Volume 1030.8(2) Å
3
 
Z 4 
Density (calculated) 1.348 Mg/m
3 
Absorption coefficient 0.091 mm
-1 
F(000) 456 
Crystal size 0.20 x 0.16 x 0.05 mm
3
 
Theta range for data collection 3.11° to 30.50° 
Index ranges -21  h  20, -10  k  10, -15  l  15 
Reflections collected 5843 
Independent reflections 2882 [Rint = 0.042] 
Completeness to theta = 30.50° 98.0 %  
Absorption correction Multi-scans 
Max. and min. transmission 1.000 and 0.906 
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Refinement method Full-matrix least-squares on F
2
 
Data / restraints / parameters 2882 / 2 / 194 
Goodness-of-fit on F
2
 1.054 
Final R indices [I>2sigma(I)] R1 = 0.069, wR2 = 0.156 
R indices (all data) R1 = 0.078, wR2 = 0.162 
Absolute structure parameter 0.0(18) 
Largest diff. peak and hole 0.40 and -0.25 e-/Å
3
 
---------------------------------------------------------------------------------------------------------------- 
R1 =  ||Fo| - |Fc|| /  |Fo|  
wR2 = {  [w(Fo
2
 - Fc
2
)
2
] /  [w(Fo
2
)
2
] }
1/2
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Table 7.  Atomic coordinates  ( x 10
4
) and equivalent  isotropic displacement parameters 
(Å
2
x 10
3
) for C12H19NO2.  U(eq) is defined as one third of  the trace of the orthogonalized Uij 
tensor. 
__________________________________________________________________________  
 x y z U(eq) 
__________________________________________________________________________  
O(1) 6219(2) 3137(3) 4625(2) 19(1) 
O(2) 2827(2) 7766(3) 4174(3) 24(1) 
N 4922(2) 3762(3) 5020(2) 11(1) 
C(1) 5346(2) 2834(4) 4441(3) 13(1) 
C(2) 4569(2) 1338(4) 3568(3) 16(1) 
C(3) 3507(2) 1773(4) 3393(3) 17(1) 
C(4) 3834(2) 3194(3) 4581(3) 11(1) 
C(5) 3037(2) 4725(3) 3887(3) 12(1) 
C(6) 3528(2) 6324(4) 4905(3) 15(1) 
C(7) 4634(2) 6781(4) 5237(3) 18(1) 
C(8) 5453(2) 5290(4) 5947(3) 14(1) 
C(9) 1897(2) 4196(4) 3465(3) 13(1) 
C(10) 1984(2) 3484(4) 4824(3) 13(1) 
C(11) 2813(2) 2015(4) 5584(3) 15(1) 
C(12) 3951(2) 2488(4) 5977(3) 14(1) 
  
Table 8.   Bond lengths [Å] and angles [°] for  C12H19NO2. 
__________________________________________________________________________  
O(1)-C(1)  1.227(3) 
O(2)-C(6)  1.417(4) 
O(2)-H(2O)  0.73(6) 
N-C(1)  1.350(3) 
N-C(8)  1.456(3) 
N-C(4)  1.471(3) 
C(1)-C(2)  1.518(4) 
C(2)-C(3)  1.528(4) 
C(2)-H(2A)  0.96(4) 
C(2)-H(2B)  0.91(4) 
C(3)-C(4)  1.550(4) 
C(3)-H(3B)  0.99(4) 
C(3)-H(3A)  0.95(4) 
C(4)-C(5)  1.533(3) 
C(4)-C(12)  1.535(4) 
C(5)-C(6)  1.536(4) 
C(5)-C(9)  1.540(3) 
C(5)-H(5)  1.01(3) 
C(6)-C(7)  1.517(4) 
C(6)-H(6)  0.89(4) 
C(7)-C(8)  1.526(4) 
C(7)-H(7A)  0.96(4) 
 195 
C(7)-H(7B)  0.95(4) 
C(8)-H(8A)  0.98(4) 
C(8)-H(8B)  0.98(3) 
C(9)-C(10)  1.522(4) 
C(9)-H(9A)  0.98(4) 
C(9)-H(9B)  1.00(3) 
C(10)-C(11)  1.522(4) 
C(10)-H(10A)  0.90(4) 
C(10)-H(10B)  0.92(4) 
C(11)-C(12)  1.538(4) 
C(11)-H(11A)  0.92(4) 
C(11)-H(11B)  0.98(4) 
C(12)-H(12A)  0.98(4) 
C(12)-H(12B)  0.96(4) 
__________________________________________________________________________ 
 
Table 9.   Bond angles [°] for  C12H19NO2. 
__________________________________________________________________________ 
C(6)-O(2)-H(2O) 105(5) 
C(1)-N-C(8) 123.6(2) 
C(1)-N-C(4) 115.6(2) 
C(8)-N-C(4) 120.7(2) 
O(1)-C(1)-N 125.6(3) 
O(1)-C(1)-C(2) 126.4(2) 
N-C(1)-C(2) 107.9(2) 
C(1)-C(2)-C(3) 104.9(2) 
C(1)-C(2)-H(2A) 102(2) 
C(3)-C(2)-H(2A) 114(2) 
C(1)-C(2)-H(2B) 115(2) 
C(3)-C(2)-H(2B) 114(2) 
H(2A)-C(2)-H(2B) 107(3) 
C(2)-C(3)-C(4) 106.0(2) 
C(2)-C(3)-H(3B) 111(2) 
C(4)-C(3)-H(3B) 112(2) 
C(2)-C(3)-H(3A) 105(2) 
C(4)-C(3)-H(3A) 109(2) 
H(3B)-C(3)-H(3A) 113(3) 
N-C(4)-C(5) 108.2(2) 
N-C(4)-C(12) 110.20(2) 
C(5)-C(4)-C(12) 111.2(2) 
N-C(4)-C(3) 102.6(2) 
C(5)-C(4)-C(3) 112.6(2) 
C(12)-C(4)-C(3) 111.7(2) 
C(4)-C(5)-C(6) 112.5(2) 
C(4)-C(5)-C(9) 109.7(2) 
C(6)-C(5)-C(9) 113.5(2) 
C(4)-C(5)-H(5) 107(2) 
C(6)-C(5)-H(5) 106(2) 
C(9)-C(5)-H(5) 108(2) 
O(2)-C(6)-C(7) 106.5(2) 
O(2)-C(6)-C(5) 111.5(2) 
C(7)-C(6)-C(5) 110.1(2) 
O(2)-C(6)-H(6) 114(2) 
C(7)-C(6)-H(6) 110(2) 
C(5)-C(6)-H(6) 105(2) 
C(6)-C(7)-C(8) 112.1(2) 
C(6)-C(7)-H(7A) 104(2) 
C(8)-C(7)-H(7A) 113(2) 
C(6)-C(7)-H(7B) 114(2) 
C(8)-C(7)-H(7B) 109(2) 
H(7A)-C(7)-H(7B) 105(3) 
N-C(8)-C(7) 109.5(2) 
N-C(8)-H(8A) 105(2) 
C(7)-C(8)-H(8A) 110(2) 
N-C(8)-H(8B) 108(2) 
C(7)-C(8)-H(8B) 109(2) 
H(8A)-C(8)-H(8B) 116(3) 
C(10)-C(9)-C(5) 112.3(2) 
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C(10)-C(9)-H(9A) 113(2) 
C(5)-C(9)-H(9A) 113(2) 
C(10)-C(9)-H(9B) 110(2) 
C(5)-C(9)-H(9B) 109(2) 
H(9A)-C(9)-H(9B) 100(3) 
C(11)-C(10)-C(9) 111.8(2) 
C(11)-C(10)-H(10A) 116(2) 
C(9)-C(10)-H(10A) 108(2) 
C(11)-C(10)-H(10B) 104(2) 
C(9)-C(10)-H(10B) 113(2) 
H(10A)-C(10)-H(10B) 105(3) 
C(10)-C(11)-C(12) 112.3(2) 
C(10)-C(11)-H(11A) 111(2) 
C(12)-C(11)-H(11A) 109(2) 
C(10)-C(11)-H(11B) 112(2) 
C(12)-C(11)-H(11B) 106(2) 
H(11A)-C(11)-H(11B) 105(3) 
C(4)-C(12)-C(11) 111.5(2) 
C(4)-C(12)-H(12A) 109(2) 
C(11)-C(12)-H(12A) 105(2) 
C(4)-C(12)-H(12B) 110(2) 
C(11)-C(12)-H(12B) 111(2) 
H(12A)-C(12)-H(12B) 111(3) 
__________________________________________________________________________  
 
Table 10.   Anisotropic displacement parameters  (Å
2
x 10
3
) for C12H19NO2.  The anisotropic 
displacement factor exponent takes the form:  -2
2
[ h
2
 a*
2
U11 + ...  + 2 h k a* b* U12 ] 
__________________________________________________________________________  
 U11 U22  U33 U23 U13 U12 
__________________________________________________________________________ 
O(1) 13(1)  26(1) 25(1)  -2(1) 15(1)  1(1) 
O(2) 25(1)  15(1) 45(1)  9(1) 29(1)  8(1) 
N 6(1)  14(1) 14(1)  -1(1) 6(1)  -1(1) 
C(1) 9(1)  15(1) 14(1)  2(1) 6(1)  1(1) 
C(2) 15(1)  15(1) 21(1)  -5(1) 12(1)  2(1) 
C(3) 14(1)  19(1) 23(1)  -6(1) 14(1)  -2(1) 
C(4) 7(1)  13(1) 14(1)  -3(1) 6(1)  -2(1) 
C(5) 10(1)  17(1) 13(1)  1(1) 9(1)  2(1) 
C(6) 20(1)  14(1) 23(1)  -2(1) 19(1)  -1(1) 
C(7) 20(1)  14(1) 27(2)  -3(1) 19(1)  -3(1) 
C(8) 8(1)  18(1) 18(1)  -4(1) 8(1)  -4(1) 
C(9) 7(1)  21(1) 11(1)  2(1) 5(1)  2(1) 
C(10) 11(1)  18(1) 15(1)  -1(1) 10(1)  1(1) 
C(11) 11(1)  18(1) 19(1)  7(1) 10(1)  3(1) 
C(12) 6(1)  15(1) 17(1)  7(1) 5(1)  2(1) 
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Table 11.   Hydrogen coordinates ( x 10
4
) and isotropic  displacement parameters (Å
2
x 10
3
) 
for C12H19NO2. 
__________________________________________________________________________ 
 x  y  z  U(eq) 
__________________________________________________________________________  
 H(2O) 2400(50) 7680(80) 4300(60) 68(19) 
H(2A) 4980(30) 400(50) 4240(40) 19 
H(2B) 4450(30) 1100(50) 2670(40) 19 
H(3B) 3200(30) 750(50) 3550(40) 20 
H(3A) 3020(30) 2250(50) 2400(40) 20 
H(5) 2930(30) 5030(50) 2910(40) 15 
H(6) 3630(30) 6030(50) 5770(40) 19 
H(7A) 4450(30) 7110(50) 4270(40) 21 
H(7B) 4980(30) 7760(50) 5860(40) 21 
H(8A) 5630(30) 5000(50) 6940(40) 17 
H(8B) 6090(30) 5560(50) 5960(40) 17 
H(9A) 1340(30) 5110(50) 2940(40) 16 
H(9B) 1550(30) 3330(40) 2630(40) 16 
H(10A) 2110(30) 4370(50) 5430(40) 16 
H(10B) 1330(30) 3010(40) 4560(40) 16 
H(11A) 2910(30) 1650(50) 6450(40) 18 
H(11B) 2550(30) 1000(50) 4920(40) 18 
H(12A) 4240(30) 3400(50) 6740(40) 16 
H(12B) 4440(30) 1510(50) 6380(40) 16 
 
Table 12.  Torsion angles [°] for C12H19NO2. 
__________________________________________________________________________  
C(8)-N-C(1)-O(1) 0.7(4) 
C(4)-N-C(1)-O(1) 177.2(2) 
C(8)-N-C(1)-C(2) 179.2(2) 
C(4)-N-C(1)-C(2) -4.4(3) 
O(1)-C(1)-C(2)-C(3) -168.0(3) 
N-C(1)-C(2)-C(3) 13.5(3) 
C(1)-C(2)-C(3)-C(4) -17.2(3) 
C(1)-N-C(4)-C(5) -125.7(2) 
C(8)-N-C(4)-C(5) 50.9(3) 
C(1)-N-C(4)-C(12) 112.5(2) 
C(8)-N-C(4)-C(12) -70.9(3) 
C(1)-N-C(4)-C(3) -6.6(3) 
C(8)-N-C(4)-C(3) 170.0(2) 
C(2)-C(3)-C(4)-N 14.5(3) 
C(2)-C(3)-C(4)-C(5) 130.5(2) 
C(2)-C(3)-C(4)-C(12) -103.5(2) 
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N-C(4)-C(5)-C(6) -50.7(3) 
C(12)-C(4)-C(5)-C(6) 70.4(3) 
C(3)-C(4)-C(5)-C(6) -163.3(2) 
N-C(4)-C(5)-C(9) -178.0(2) 
C(12)-C(4)-C(5)-C(9) -56.9(3) 
C(3)-C(4)-C(5)-C(9) 69.4(3) 
C(4)-C(5)-C(6)-O(2) 174.0(2) 
C(9)-C(5)-C(6)-O(2) -60.7(3) 
C(4)-C(5)-C(6)-C(7) 56.0(3) 
C(9)-C(5)-C(6)-C(7) -178.7(2) 
O(2)-C(6)-C(7)-C(8) -176.6(2) 
C(5)-C(6)-C(7)-C(8) -55.6(3) 
C(1)-N-C(8)-C(7) 124.9(3) 
C(4)-N-C(8)-C(7) -51.3(3) 
C(6)-C(7)-C(8)-N 51.2(3) 
C(4)-C(5)-C(9)-C(10) 56.6(3) 
C(6)-C(5)-C(9)-C(10) -70.2(3) 
C(5)-C(9)-C(10)-C(11) -54.3(3) 
C(9)-C(10)-C(11)-C(12)52.0(3) 
N-C(4)-C(12)-C(11) 175.5(2) 
C(5)-C(4)-C(12)-C(11) 55.6(3) 
C(3)-C(4)-C(12)-C(11) -71.2(3) 
C(10)-C(11)-C(12)-C(4)-52.8(3) 
__________________________________________________________________________  
 
Table 13.  Hydrogen bonds for C12H19NO2 [Å and °]. 
__________________________________________________________________________  
D-H...A d(D-H) d(H...A) d(D...A) <(DHA) 
__________________________________________________________________________  
 O(2)-H(2O)...O(1)#1 0.73(6) 2.05(6) 2.762(3) 165(7) 
__________________________________________________________________________  
Symmetry transformations used to generate equivalent atoms:  #1:  x-1/2, y+1/2, z.       
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